[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Alung Technologies Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":401},{"warningLetters":4,"total":400},[5,32,53,74,93,113,133,154,174,193,211,223,242,263,284,307,328,345,363,381],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},2000,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-07-11T13:20:00Z\">07\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-21T04:00:00Z\">06\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyto-technologies-inc-652316-06212023\">ZYTO Technologies, Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations West","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Vaughn R. Cook\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and Owner\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ZYTO Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1172 W. 700 N., Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lindon\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84042\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 652316\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 21, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Cook,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Lindon, UT on December 5 through 13, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ZYTO Hand Cradle Galvanic Skin Response (GSR) device and associated proprietary software used to scan a patient to identify “stressors” and “balancers.” Your website refers to using the ZYTO as part of a “journey to wellness.\" However, some of the “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s disease, human immunodeficiency virus (HIV), Parkinson’s disease and melanoma, and some of the “balancers” recommended by the software represent specific treatments or mitigations for a given “stressor.” Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the ZYTO Hand Cradle GSR and associated proprietary software is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>The ZYTO Hand Cradle was cleared under K111308 with the following intended use: “the measurement of galvanic skin response (GSR).” However, your firm’s promotion of the device represents a major change or modification to its intended use, for which your firm lacks clearance or approval. Thus, although originally classified as Class II under 21 CFR 882.1540, the device does not qualify for the exemption from 510(k) granted in 2019 for that generic type of device (see 84 FR 71794 (December 30, 2019)) because, among other things, the device “is intended for a use different from the intended use of a legally marketed device in that generic type of device.” See 21 CFR 882.9(a).\u003C\u002Fp>\n\n\u003Cp>Further, as we informed you previously, the ZYTO associated proprietary software is a component of the ZYTO Hand Cradle and shares its classification.\u003C\u002Fp>\n\n\u003Cp>In our June 11, 2015, correspondence after the Warning Letter, we stated that per 21 CFR, part 820.3(c), the definition of a component includes software intended to be included as part of a finished, packaged, labeled device. Components of a device are defined as the device itself. The letter further states “…The software, downloaded by end users for the intention of use with your device is considered a component.”\u003C\u002Fp>\n\n\u003Cp>Per our Regulatory Meeting, held August 28, 2015, you were informed again that our review found that your associated proprietary software was intended to be used with the ZYTO Hand Cradle GSR device. You were informed that because the ZYTO Hand Cradle GSR and the software did not function alone but must be used together, the software was a component of the device.\u003C\u002Fp>\n\n\u003Cp>This continues to be the case. For example, your website explains how the ZYTO Hand Cradle GSR and the associated proprietary software function together as follows:\u003C\u002Fp>\n\n\u003Cp>“The ZYTO Hand Cradle measures the user’s galvanic skin response and sends that data directly to the ZYTO software for analysis. The [galvanic skin responses] GSR data is correlated and compared with Virtual Items in the software database.”\u003C\u002Fp>\n\n\u003Cp>“Each Virtual Item represents a different physical item. Every time the software introduces a Virtual Item, a corresponding GSR reading is taken by the Hand Cradle. Each new response is measured and tracked in comparison to the GSR baseline reading.”\u003C\u002Fp>\n\n\u003Cp>Our investigator documented that the virtual items are added to the library in-house using a machine referred to as the “Tower”. Your representative explained that to create a library item, your firm places the item in front of the Tower and the Tower then scans and identifies the item with a generated code from the system which it associates with the energy of that item. This becomes a virtual library item. In addition, your firm’s promotional materials indicate that the hand cradle can now perform this function as well, so that users can add their own virtual items.\u003C\u002Fp>\n\n\u003Cp>Your website further states:\u003C\u002Fp>\n\n\u003Cp>“ZYTO’s proprietary software analyzes GSR data for patterns of coherence—looking for the ways your GSR readings fluctuate or shift in response to each Virtual Item.”\u003C\u002Fp>\n\n\u003Cp>Your proprietary software is a component of the ZYTO Hand Cradle GSR.\u003C\u002Fp>\n\n\u003Cp>Your firm is promoting the ZYTO Hand Cradle GSR and associated proprietary software outside its cleared intended use.\u003C\u002Fp>\n\n\u003Cp>The ZYTO Hand Cradle Galvanic Skin Response System was cleared under K111308 only to measure galvanic skin responses. Despite prior notice from FDA in your 2015 Warning Letter and some corrections made around that time, your firm has added back promotion of the ZYTO Hand Cradle GSR for use in diagnosing diseases or conditions, including determining whether someone responds to a specific allergen, and continues to predict biological responses to a wide range of virtual stimuli including homeopathic nosodes and nutritional supplements.\u003C\u002Fp>\n\n\u003Cp>For example, your current website explains that first the system scans for general categories of “Biomarkers” which might be specific locations or anatomy of the body such as organs, muscles, or bones. Next, there is a subset of “Stressor” virtual items which are scanned for, including heavy metals, bacteria, parasites, viruses, electromagnetic fields, chemicals, allergens, lifestyle choices, and foods.\u003C\u002Fp>\n\n\u003Cp>While a scan may consist of only a stressor Virtual Item scan to reveal which items may warrant further attention, a balancer Virtual Item scan often follows to determine which items bring the stressors into range. The website further states ZYTO software contains thousands of “Balancer” Virtual Items from over 250 health and wellness companies in these categories: supplements, essential oils, homeopathics, herbs, flower essences, or topicals.\u003C\u002Fp>\n\n\u003Cp>Most importantly, your virtual item library identifies items which you describe could be stressors or balancers including, but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Alzheimer’s\u003Cbr>\n• E. coli\u003Cbr>\n• Ebola\u003Cbr>\n• Fibromyalgia\u003Cbr>\n• Flu\u003Cbr>\n• Hepatitis (A, B, C, D, and E)\u003Cbr>\n• Herpes, various forms\u003Cbr>\n• Human immunodeficiency virus (HIV)\u003Cbr>\n• Leukemia, various forms and related nosodes\u003Cbr>\n• Lupus, various forms\u003Cbr>\n• Lymphoma, Melanoma\u003Cbr>\n• Parkinson’s disease\u003Cbr>\n• Staphylococcus aureus\u003Cbr>\n• Zika viruses\u003Cbr>\n• Food allergen’s including but not limited to soy, milk, eggs, peanuts, flaxseed, and fish\u003Cbr>\n• Environmental allergens including but not limited to “Bee Pollen”\u003Cbr>\n• Homeopathic nosodes to above listed disease states, such as but not limited to: asthma, cholera, hepatitis, lupus, infant botulism, scarlet fever, malignant rectal polyps, uterine polyps, leukemia, polio, rabies, and Parkinson’s disease.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. You have added disease claims back to your software library.\u003C\u002Fstrong> The “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s, HIV, Parkinson’s disease and melanoma, and the identification of these by the device amount to diagnoses. These uses fall outside the device’s cleared intended use to measure galvanic skin response and constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm continues to market the ZYTO Hand Cradle GSR to predict biological responses to a range of virtual stimuli, as discussed in your 2015 Warning Letter. \u003C\u002Fstrong>The “balancers” recommended by the software for the “stressors” represent specific treatments, mitigations, or suggestions to prevent such diseases and conditions. You’ve been notified this represents a major change or modification to the device’s intended use for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>The promotion of the ZYTO Hand Cradle GSR and associated proprietary software in examples 1 - 2 above for use in diagnosing a disease or condition, including determining whether someone responds to a specific allergen, and predicting biological responses to a wide range of virtual stimuli, including homeopathic nosodes or nutritional supplements, fall outside the device’s cleared intended use to measure galvanic skin response and constitute major changes or modifications to the device’s intended use.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Observations Pertaining to Quality System Regulations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The December 2022 inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. As noted above, your proprietary software which works with the ZYTO Hand Cradle GSR is a component of the ZYTO Hand Cradle GSR. Thus, it is subject to all applicable regulatory requirements, including design controls.\u003C\u002Fp>\n\n\u003Cp>We received a response from Mr. Ford dated January 5, 2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. While reviewing this letter, be aware FDA defines “establish” to include actions to define, document, and implement. The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately establish procedures for design controls, as required by 21 CFR 820.30.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. You have not conducted design verification and validation testing per the requirements of 21 CFR 820.30(f) and 820.30(g), and your SOP-00302 Design Verification and Validation, rev D, eff 12\u002F14\u002F2020, for the ZYTO Hand Cradle GSR and associated proprietary software, or the device library development processes used in house and by customers.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>SOP-00302 requires you to perform design \u003Cem>verification\u003C\u002Fem> to provide objective evidence that specified requirements have been fulfilled, to confirm that the design output meets the design input requirements, and to document results in the design history file (DHF). It also requires you to perform design \u003Cem>validation\u003C\u002Fem> to establish objective evidence that device specifications conform to user needs and intended use(s). The procedure states you shall include software validation and risk analysis, where appropriate, and activities shall be documented in the DHF.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>i. You failed to verify or validate the ZYTO Hand Cradle GSR and associated proprietary software.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, you provided the Hardware Verification and Validation (TR-00370, Rev. A, eff 06\u002F03\u002F2021) noted in DHF-00664 for the ZYTO Hand Cradle GSR. TR-00370 states these “procedures are not intended to test the engineering of the hand cradle. Instead, they focus on the software’s interactions with the hardware.” TR-00370 defines the testing procedures used to verify the hardware software user interface requirements, as specified in SRS-00288. SRS-00288 includes a \u003Cstrong>(b)(4)\u003C\u002Fstrong> protocol to test the \u003Cstrong>(b)(4)\u003C\u002Fstrong> between the software and ZYTO Hand Cradle GSR. However, your Quality Supervisor stated your firm has no documented evidence to provide to demonstrate this testing was actually performed. She further stated you have no evidence to verify that design outputs meet design inputs. Despite no evidence of conducting this testing, the DHF shows TR-00370 as “Approved” on 6\u002F3\u002F2021.\u003C\u002Fp>\n\n\u003Cp>Your firm’s attorney stated that you have no documented validation of the virtual items in the ZYTO software.\u003C\u002Fp>\n\n\u003Cp>Your firm also received a complaint of an “abnormal” or “empty” scan “where no stressors were found out of range, but many products were recommended for use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response regarding observation 1 and the completion of the DHF activities and understand that you will review TR-00370 and SRS-00288 to confirm verification and validation that design outputs meet the design inputs to be completed by 6\u002F30\u002F23, subject to “Development availability”. We reviewed your response and determined your response is inadequate, as evidence of corrective actions to this observation were not provided. Additionally, corrective actions were not planned for completion until over six months after the inspection concluded, yet you were notified of this violation both during our August 2015 Regulatory Meeting and again during your 2019 inspection, and at that time you promised corrections.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>ii. You failed to validate the ZYTO Tower or Hand Cradle GSR for addition of virtual library items.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Tower is used in-house for the transmission, interpretation, and creation of virtual library items. This has not been validated. Currently, your firm has directed customers to use the ZYTO Hand Cradle GSR to add new virtual library items for biological preference prediction. We observed your firm’s promotional materials indicate you have replicated the prior functionality of the Tower with what you describe as an antenna inside the ZYTO Hand Cradle GSR. Your website contains videos with instructions (in both the Immunity Biosurvey and the Digestive Biosurvey) on how to use the ZYTO Hand Cradle GSR to perform the same function as the Tower by your clients. This use of the ZYTO Hand Cradle GSR for the transmission, interpretation, and creation of virtual library items has also not been validated.\u003C\u002Fp>\n\n\u003Cp>During our inspection, your firm’s attorney stated you have no documented validation of use of the Tower to identify and add virtual items to the library. He further stated there would be no way to test the process used to input these virtual items.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response specific to the validation of “ZYTO 5 Software and the EVOX phrases” and documentation of virtual items (currently done in house by the Tower) and determined it is inadequate as your recent response states “Documentation for the virtual items in the ZYTO 5 Software and the EVOX phrases is not necessary as the process of creating them is definitional—the unique identifier virtual item name is created \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” We do not agree that documentation demonstrating validation for the virtual items in the ZYTO 5 Software is unnecessary. Medical devices and software controlling them require design validation under 21 CFR Part 820.30.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. You have not conducted design reviews as required by 21 CFR 820.30(e), and your procedure, SOP-00301 Design Control and Project Management, rev K, eff 12\u002F21\u002F2020.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your procedure describes design reviews as a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements and to identify problems at appropriate stages of the process. Your procedure also states that these should be documented in the DHF.\u003C\u002Fp>\n\n\u003Cp>The DHF for the ZYTO Hand Cradle GSR, DHF-00664, shows the Design Review is “in process” with no associated file or date. The DHF is signed as approved as of 6\u002F8\u002F2021; however, you do not have a documented design review as required by 21 CFR 820.30(e). You have been marketing this product since at least 2019 with no evidence that this design review requirement has been met.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response and determined your response is inadequate as it does not address why the design review was not completed, why the DHF was signed and approved when the design reviews showed as “In Progress”, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. You failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Corrective and Preventive Actions (CAPA) procedure, SOP-01002, requires assignees to investigate the identified issue(s) to uncover and eliminate potential causes as identified in the CAPA and document their activities. You failed to implement the requirements of your procedure. For example, CAPA records 091719001 and 052720001 were opened based on customer complaints. The related ZYTO Hand Cradle GSRs were replaced, and the records state NCR testing was conducted but neither record shows the cause of the ZYTO Hand Cradle GSR shocking the patient \u002F user or what action should be taken to prevent recurrence. In your uncontrolled testing record titled “Subject Hand Cradle: \u003Cstrong>(b)(4)\u003C\u002Fstrong> Hand Cradle Tested” tied to a related complaint serial number, you confirmed a user was shocked during your own internal testing. Yet still no investigation was performed to see what caused the ZYTO Hand Cradle GSR to shock patients \u002F users. Instead, the record states the customer account was terminated, and therefore no follow up is needed. The other CAPA associated complaint record says the customer was happy with their replacement; however, replacing one ZYTO Hand Cradle GSR with another does not address the need to identify the nonconformity or underlying quality problem causing the ZYTO Hand Cradle GSR to shock patients \u002F users, or the need to identify the action(s) needed to correct and prevent recurrence, which are required by 21 CFR 820.100(a)(2) and (3), respectively.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. You failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, SOP-01002 requires CAPA investigations to address and monitor the effectiveness of the actions taken. You failed to implement the requirements of your procedure. For example, six CAPA records were opened as a result of past FDA observations in 2019. Despite having dates and initials documented, all six of these are blank or show “ongoing work” in the verification of effectiveness column regarding \u003Cem>what action\u003C\u002Fem> needs to be taken to ensure effectiveness and no adverse effect of corrective action, in accordance with the SOP and 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response and we cannot determine its adequacy as your corrective actions, including root cause analysis and verification of effectiveness, are in progress and not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately establish procedures for complaint handling per the requirements of 21 CFR Part 820.198, including an evaluation to determine reportability under 21 CFR Part 803 (Medical Device Reporting), and to document complaint investigations or a record including the reason when no investigation is performed.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your SOP-01980, Complaint and MDR System, rev G, eff 8\u002F19\u002F2021, in accordance with 21 CFR 820.198(a)(3), requires an evaluation of complaints to determine whether a medical device report (MDR) is required. Additionally, 21 CFR Part 820.198(b) requires evaluation of complaints to determine whether an investigation is necessary and a record of justification if a complaint does not require investigation.\u003C\u002Fp>\n\n\u003Cp>At least four complaints reviewed during our inspection which were handled using your current complaint handling software and under the current SOP did not include either a documented investigation or a justification for lack thereof and did not include any documented MDR determination. These were complaints of the ZYTO Hand Cradle GSR not scanning, hardware connectivity issues causing the device not to perform scans, and the hand cradle not connecting with some clients which meet both FDA’s definition of a complaint under 21 CFR Part 820.3(b) as well as your procedure’s definition. Additionally, complaints under your previous complaint handling software system related to shocking of patients and users were observed without documented investigations or a written justification.\u003C\u002Fp>\n\n\u003Cp>Section 8.2.2 of the current SOP specifically excludes libraries and biosurveys from the complaint handling process. Since these are functions of the software that controls the ZYTO Hand Cradle GSR, related complaints should be documented, reviewed, and evaluated and, if necessary, investigated per the regulatory requirements set forth in 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response which states you will update procedures to ensure all complaints for the ZYTO Hand Cradle GSR hardware and software will undergo root cause analysis, define types of complaints that should require an MDR Questionnaire, and define instructions on how to do so in your new system. We have concluded that your response is inadequate because your corrective actions do not include a retrospective review of cases outside those identified by our Investigator, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to adequately establish a procedure to ensure DHRs are maintained to demonstrate the device is manufactured in accordance with the DMR, per the requirements of 21 CFR Part 820.184.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your SOP-01840, Device History Record (DHR) Procedure, rev L, eff 6\u002F15\u002F2020, states that samples of labels and labeling will be verified in the approved folder of the Document Management System, but does not require inclusion in the DHR of the primary identification label and labeling used for each production unit or the unique device identifier (UDI), or the location of the label, labeling or UDI. 21 CFR 820.184 requires that the DHR include or refer to the location of these items. All 11 DHRs reviewed during our recent inspection were missing this information.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time as no evidence of corrective actions has been provided.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to develop, maintain, and implement written labeling procedures to control UDI labeling activities pursuant to 21 CFR 820.120.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your primary label includes an UDI, yet your firm has not established and maintained procedures to control labeling activities to include performing a labeling inspection to ensure the \u003Cem>correct\u003C\u002Fem> UDI is present. Your Quality Supervisor told our investigator that you do not have any UDI procedures and your SOP-01201 Labeling and Packaging Controls, Rev D, eff 12\u002F21\u002F2020, does not include UDI.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to oradevices3firmresponse@fda.hhs.gov on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device quality systems (QS) regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – 12\u002F21\u002F2023\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – 12\u002F23\u002F2024 and 12\u002F22\u002F2025\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. The ZYTO Hand Cradle GSR is adulterated and misbranded, and we request that you immediately cease any marketing of this product and its accessories. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action (which must address systemic problems) you have taken. If your planned corrections will occur over time, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response. This letter notifies you of our findings and provides you an opportunity to address the above deficiencies.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS 652316\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violation(s) at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violation(s) noted in this letter and in the Inspectional Observations, FDA 483, issued at the closeout of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality assurance systems. Your firm should investigate and determine the causes of the violation(s) and take prompt actions to correct the violation(s) and to bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nina Mezu‐Nwaba, Deputy Director\u003Cbr>\nOffice of Health Technology 5 – Office of\u003Cbr>\nNeurological and Physical Medical Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh, Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\n\u003Cbr>\nCc: Ms. Kami J. Howard, President and CEO\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Vaughn R. Cook\n\nRecipient Title\n\nChairman and Owner\u002FFounder\n\nZYTO Technologies, Inc.\n\n1172 W. 700 N., Suite 300\n\nLindon, UT 84042\n\nUnited States\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS 652316\n\nJune 21, 2023\n\nDear Dr. Cook,\n\nDuring an inspection of your firm located in Lindon, UT on December 5 through 13, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ZYTO Hand Cradle Galvanic Skin Response (GSR) device and associated proprietary software used to scan a patient to identify “stressors” and “balancers.” Your website refers to using the ZYTO as part of a “journey to wellness.\" However, some of the “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s disease, human immunodeficiency virus (HIV), Parkinson’s disease and melanoma, and some of the “balancers” recommended by the software represent specific treatments or mitigations for a given “stressor.” Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\n\nOur inspection revealed that the ZYTO Hand Cradle GSR and associated proprietary software is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), because you did not notify the agency of your intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\n\nThe ZYTO Hand Cradle was cleared under K111308 with the following intended use: “the measurement of galvanic skin response (GSR).” However, your firm’s promotion of the device represents a major change or modification to its intended use, for which your firm lacks clearance or approval. Thus, although originally classified as Class II under 21 CFR 882.1540, the device does not qualify for the exemption from 510(k) granted in 2019 for that generic type of device (see 84 FR 71794 (December 30, 2019)) because, among other things, the device “is intended for a use different from the intended use of a legally marketed device in that generic type of device.” See 21 CFR 882.9(a).\n\nFurther, as we informed you previously, the ZYTO associated proprietary software is a component of the ZYTO Hand Cradle and shares its classification.\n\nIn our June 11, 2015, correspondence after the Warning Letter, we stated that per 21 CFR, part 820.3(c), the definition of a component includes software intended to be included as part of a finished, packaged, labeled device. Components of a device are defined as the device itself. The letter further states “…The software, downloaded by end users for the intention of use with your device is considered a component.”\n\nPer our Regulatory Meeting, held August 28, 2015, you were informed again that our review found that your associated proprietary software was intended to be used with the ZYTO Hand Cradle GSR device. You were informed that because the ZYTO Hand Cradle GSR and the software did not function alone but must be used together, the software was a component of the device.\n\nThis continues to be the case. For example, your website explains how the ZYTO Hand Cradle GSR and the associated proprietary software function together as follows:\n\n“The ZYTO Hand Cradle measures the user’s galvanic skin response and sends that data directly to the ZYTO software for analysis. The [galvanic skin responses] GSR data is correlated and compared with Virtual Items in the software database.”\n\n“Each Virtual Item represents a different physical item. Every time the software introduces a Virtual Item, a corresponding GSR reading is taken by the Hand Cradle. Each new response is measured and tracked in comparison to the GSR baseline reading.”\n\nOur investigator documented that the virtual items are added to the library in-house using a machine referred to as the “Tower”. Your representative explained that to create a library item, your firm places the item in front of the Tower and the Tower then scans and identifies the item with a generated code from the system which it associates with the energy of that item. This becomes a virtual library item. In addition, your firm’s promotional materials indicate that the hand cradle can now perform this function as well, so that users can add their own virtual items.\n\nYour website further states:\n\n“ZYTO’s proprietary software analyzes GSR data for patterns of coherence—looking for the ways your GSR readings fluctuate or shift in response to each Virtual Item.”\n\nYour proprietary software is a component of the ZYTO Hand Cradle GSR.\n\nYour firm is promoting the ZYTO Hand Cradle GSR and associated proprietary software outside its cleared intended use.\n\nThe ZYTO Hand Cradle Galvanic Skin Response System was cleared under K111308 only to measure galvanic skin responses. Despite prior notice from FDA in your 2015 Warning Letter and some corrections made around that time, your firm has added back promotion of the ZYTO Hand Cradle GSR for use in diagnosing diseases or conditions, including determining whether someone responds to a specific allergen, and continues to predict biological responses to a wide range of virtual stimuli including homeopathic nosodes and nutritional supplements.\n\nFor example, your current website explains that first the system scans for general categories of “Biomarkers” which might be specific locations or anatomy of the body such as organs, muscles, or bones. Next, there is a subset of “Stressor” virtual items which are scanned for, including heavy metals, bacteria, parasites, viruses, electromagnetic fields, chemicals, allergens, lifestyle choices, and foods.\n\nWhile a scan may consist of only a stressor Virtual Item scan to reveal which items may warrant further attention, a balancer Virtual Item scan often follows to determine which items bring the stressors into range. The website further states ZYTO software contains thousands of “Balancer” Virtual Items from over 250 health and wellness companies in these categories: supplements, essential oils, homeopathics, herbs, flower essences, or topicals.\n\nMost importantly, your virtual item library identifies items which you describe could be stressors or balancers including, but not limited to:\n\n• Alzheimer’s\n\n• E. coli\n\n• Ebola\n\n• Fibromyalgia\n\n• Flu\n\n• Hepatitis (A, B, C, D, and E)\n\n• Herpes, various forms\n\n• Human immunodeficiency virus (HIV)\n\n• Leukemia, various forms and related nosodes\n\n• Lupus, various forms\n\n• Lymphoma, Melanoma\n\n• Parkinson’s disease\n\n• Staphylococcus aureus\n\n• Zika viruses\n\n• Food allergen’s including but not limited to soy, milk, eggs, peanuts, flaxseed, and fish\n\n• Environmental allergens including but not limited to “Bee Pollen”\n\n• Homeopathic nosodes to above listed disease states, such as but not limited to: asthma, cholera, hepatitis, lupus, infant botulism, scarlet fever, malignant rectal polyps, uterine polyps, leukemia, polio, rabies, and Parkinson’s disease.\n\n1. You have added disease claims back to your software library. The “stressors” identified or diagnosed by the ZYTO Hand cradle and associated proprietary software include diseases and conditions such as Alzheimer’s, HIV, Parkinson’s disease and melanoma, and the identification of these by the device amount to diagnoses. These uses fall outside the device’s cleared intended use to measure galvanic skin response and constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval.\n\n2. Your firm continues to market the ZYTO Hand Cradle GSR to predict biological responses to a range of virtual stimuli, as discussed in your 2015 Warning Letter. The “balancers” recommended by the software for the “stressors” represent specific treatments, mitigations, or suggestions to prevent such diseases and conditions. You’ve been notified this represents a major change or modification to the device’s intended use for which your firm lacks clearance or approval.\n\nThe promotion of the ZYTO Hand Cradle GSR and associated proprietary software in examples 1 - 2 above for use in diagnosing a disease or condition, including determining whether someone responds to a specific allergen, and predicting biological responses to a wide range of virtual stimuli, including homeopathic nosodes or nutritional supplements, fall outside the device’s cleared intended use to measure galvanic skin response and constitute major changes or modifications to the device’s intended use.\n\nObservations Pertaining to Quality System Regulations\n\nThe December 2022 inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. As noted above, your proprietary software which works with the ZYTO Hand Cradle GSR is a component of the ZYTO Hand Cradle GSR. Thus, it is subject to all applicable regulatory requirements, including design controls.\n\nWe received a response from Mr. Ford dated January 5, 2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. While reviewing this letter, be aware FDA defines “establish” to include actions to define, document, and implement. The violations include, but are not limited to, the following:\n\n1. Failure to adequately establish procedures for design controls, as required by 21 CFR 820.30.\n\nA. You have not conducted design verification and validation testing per the requirements of 21 CFR 820.30(f) and 820.30(g), and your SOP-00302 Design Verification and Validation, rev D, eff 12\u002F14\u002F2020, for the ZYTO Hand Cradle GSR and associated proprietary software, or the device library development processes used in house and by customers.\n\nSOP-00302 requires you to perform design verification to provide objective evidence that specified requirements have been fulfilled, to confirm that the design output meets the design input requirements, and to document results in the design history file (DHF). It also requires you to perform design validation to establish objective evidence that device specifications conform to user needs and intended use(s). The procedure states you shall include software validation and risk analysis, where appropriate, and activities shall be documented in the DHF.\n\ni. You failed to verify or validate the ZYTO Hand Cradle GSR and associated proprietary software.\n\nDuring our inspection, you provided the Hardware Verification and Validation (TR-00370, Rev. A, eff 06\u002F03\u002F2021) noted in DHF-00664 for the ZYTO Hand Cradle GSR. TR-00370 states these “procedures are not intended to test the engineering of the hand cradle. Instead, they focus on the software’s interactions with the hardware.” TR-00370 defines the testing procedures used to verify the hardware software user interface requirements, as specified in SRS-00288. SRS-00288 includes a (b)(4) protocol to test the (b)(4) between the software and ZYTO Hand Cradle GSR. However, your Quality Supervisor stated your firm has no documented evidence to provide to demonstrate this testing was actually performed. She further stated you have no evidence to verify that design outputs meet design inputs. Despite no evidence of conducting this testing, the DHF shows TR-00370 as “Approved” on 6\u002F3\u002F2021.\n\nYour firm’s attorney stated that you have no documented validation of the virtual items in the ZYTO software.\n\nYour firm also received a complaint of an “abnormal” or “empty” scan “where no stressors were found out of range, but many products were recommended for use.\n\nWe reviewed your response regarding observation 1 and the completion of the DHF activities and understand that you will review TR-00370 and SRS-00288 to confirm verification and validation that design outputs meet the design inputs to be completed by 6\u002F30\u002F23, subject to “Development availability”. We reviewed your response and determined your response is inadequate, as evidence of corrective actions to this observation were not provided. Additionally, corrective actions were not planned for completion until over six months after the inspection concluded, yet you were notified of this violation both during our August 2015 Regulatory Meeting and again during your 2019 inspection, and at that time you promised corrections.\n\nii. You failed to validate the ZYTO Tower or Hand Cradle GSR for addition of virtual library items.\n\nThe Tower is used in-house for the transmission, interpretation, and creation of virtual library items. This has not been validated. Currently, your firm has directed customers to use the ZYTO Hand Cradle GSR to add new virtual library items for biological preference prediction. We observed your firm’s promotional materials indicate you have replicated the prior functionality of the Tower with what you describe as an antenna inside the ZYTO Hand Cradle GSR. Your website contains videos with instructions (in both the Immunity Biosurvey and the Digestive Biosurvey) on how to use the ZYTO Hand Cradle GSR to perform the same function as the Tower by your clients. This use of the ZYTO Hand Cradle GSR for the transmission, interpretation, and creation of virtual library items has also not been validated.\n\nDuring our inspection, your firm’s attorney stated you have no documented validation of use of the Tower to identify and add virtual items to the library. He further stated there would be no way to test the process used to input these virtual items.\n\nWe reviewed your response specific to the validation of “ZYTO 5 Software and the EVOX phrases” and documentation of virtual items (currently done in house by the Tower) and determined it is inadequate as your recent response states “Documentation for the virtual items in the ZYTO 5 Software and the EVOX phrases is not necessary as the process of creating them is definitional—the unique identifier virtual item name is created (b)(4).” We do not agree that documentation demonstrating validation for the virtual items in the ZYTO 5 Software is unnecessary. Medical devices and software controlling them require design validation under 21 CFR Part 820.30.\n\nB. You have not conducted design reviews as required by 21 CFR 820.30(e), and your procedure, SOP-00301 Design Control and Project Management, rev K, eff 12\u002F21\u002F2020.\n\nYour procedure describes design reviews as a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements and to identify problems at appropriate stages of the process. Your procedure also states that these should be documented in the DHF.\n\nThe DHF for the ZYTO Hand Cradle GSR, DHF-00664, shows the Design Review is “in process” with no associated file or date. The DHF is signed as approved as of 6\u002F8\u002F2021; however, you do not have a documented design review as required by 21 CFR 820.30(e). You have been marketing this product since at least 2019 with no evidence that this design review requirement has been met.\n\nWe reviewed your response and determined your response is inadequate as it does not address why the design review was not completed, why the DHF was signed and approved when the design reviews showed as “In Progress”, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\n\n2. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\n\nA. You failed to identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems.\n\nSpecifically, your Corrective and Preventive Actions (CAPA) procedure, SOP-01002, requires assignees to investigate the identified issue(s) to uncover and eliminate potential causes as identified in the CAPA and document their activities. You failed to implement the requirements of your procedure. For example, CAPA records 091719001 and 052720001 were opened based on customer complaints. The related ZYTO Hand Cradle GSRs were replaced, and the records state NCR testing was conducted but neither record shows the cause of the ZYTO Hand Cradle GSR shocking the patient \u002F user or what action should be taken to prevent recurrence. In your uncontrolled testing record titled “Subject Hand Cradle: (b)(4) Hand Cradle Tested” tied to a related complaint serial number, you confirmed a user was shocked during your own internal testing. Yet still no investigation was performed to see what caused the ZYTO Hand Cradle GSR to shock patients \u002F users. Instead, the record states the customer account was terminated, and therefore no follow up is needed. The other CAPA associated complaint record says the customer was happy with their replacement; however, replacing one ZYTO Hand Cradle GSR with another does not address the need to identify the nonconformity or underlying quality problem causing the ZYTO Hand Cradle GSR to shock patients \u002F users, or the need to identify the action(s) needed to correct and prevent recurrence, which are required by 21 CFR 820.100(a)(2) and (3), respectively.\n\nB. You failed to verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device.\n\nAdditionally, SOP-01002 requires CAPA investigations to address and monitor the effectiveness of the actions taken. You failed to implement the requirements of your procedure. For example, six CAPA records were opened as a result of past FDA observations in 2019. Despite having dates and initials documented, all six of these are blank or show “ongoing work” in the verification of effectiveness column regarding what action needs to be taken to ensure effectiveness and no adverse effect of corrective action, in accordance with the SOP and 21 CFR 820.100(a)(4).\n\nWe reviewed your response and we cannot determine its adequacy as your corrective actions, including root cause analysis and verification of effectiveness, are in progress and not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019.\n\n3. Failure to adequately establish procedures for complaint handling per the requirements of 21 CFR Part 820.198, including an evaluation to determine reportability under 21 CFR Part 803 (Medical Device Reporting), and to document complaint investigations or a record including the reason when no investigation is performed.\n\nSpecifically, your SOP-01980, Complaint and MDR System, rev G, eff 8\u002F19\u002F2021, in accordance with 21 CFR 820.198(a)(3), requires an evaluation of complaints to determine whether a medical device report (MDR) is required. Additionally, 21 CFR Part 820.198(b) requires evaluation of complaints to determine whether an investigation is necessary and a record of justification if a complaint does not require investigation.\n\nAt least four complaints reviewed during our inspection which were handled using your current complaint handling software and under the current SOP did not include either a documented investigation or a justification for lack thereof and did not include any documented MDR determination. These were complaints of the ZYTO Hand Cradle GSR not scanning, hardware connectivity issues causing the device not to perform scans, and the hand cradle not connecting with some clients which meet both FDA’s definition of a complaint under 21 CFR Part 820.3(b) as well as your procedure’s definition. Additionally, complaints under your previous complaint handling software system related to shocking of patients and users were observed without documented investigations or a written justification.\n\nSection 8.2.2 of the current SOP specifically excludes libraries and biosurveys from the complaint handling process. Since these are functions of the software that controls the ZYTO Hand Cradle GSR, related complaints should be documented, reviewed, and evaluated and, if necessary, investigated per the regulatory requirements set forth in 21 CFR 820.198.\n\nWe have reviewed your response which states you will update procedures to ensure all complaints for the ZYTO Hand Cradle GSR hardware and software will undergo root cause analysis, define types of complaints that should require an MDR Questionnaire, and define instructions on how to do so in your new system. We have concluded that your response is inadequate because your corrective actions do not include a retrospective review of cases outside those identified by our Investigator, and corrective actions are not planned for completion until 6\u002F30\u002F2023, yet you were notified of this violation in 2019 and promised corrections at that time.\n\n4. Failure to adequately establish a procedure to ensure DHRs are maintained to demonstrate the device is manufactured in accordance with the DMR, per the requirements of 21 CFR Part 820.184.\n\nSpecifically, your SOP-01840, Device History Record (DHR) Procedure, rev L, eff 6\u002F15\u002F2020, states that samples of labels and labeling will be verified in the approved folder of the Document Management System, but does not require inclusion in the DHR of the primary identification label and labeling used for each production unit or the unique device identifier (UDI), or the location of the label, labeling or UDI. 21 CFR 820.184 requires that the DHR include or refer to the location of these items. All 11 DHRs reviewed during our recent inspection were missing this information.\n\nThe adequacy of your firm’s response cannot be determined at this time as no evidence of corrective actions has been provided.\n\n5. Failure to develop, maintain, and implement written labeling procedures to control UDI labeling activities pursuant to 21 CFR 820.120.\n\nSpecifically, your primary label includes an UDI, yet your firm has not established and maintained procedures to control labeling activities to include performing a labeling inspection to ensure the correct UDI is present. Your Quality Supervisor told our investigator that you do not have any UDI procedures and your SOP-01201 Labeling and Packaging Controls, Rev D, eff 12\u002F21\u002F2020, does not include UDI.\n\nWe are requesting that you submit to oradevices3firmresponse@fda.hhs.gov on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device quality systems (QS) regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – 12\u002F21\u002F2023\n\nSubsequent certifications – 12\u002F23\u002F2024 and 12\u002F22\u002F2025\n\nYour firm should take prompt action to address any violations identified in this letter. The ZYTO Hand Cradle GSR is adulterated and misbranded, and we request that you immediately cease any marketing of this product and its accessories. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen (15) working days from the date you receive this letter of the specific steps you have taken to correct the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrective action (which must address systemic problems) you have taken. If your planned corrections will occur over time, please include a timetable for implementation of those corrections. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response. This letter notifies you of our findings and provides you an opportunity to address the above deficiencies.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 652316 when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violation(s) at your facility. It is your responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violation(s) noted in this letter and in the Inspectional Observations, FDA 483, issued at the closeout of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality assurance systems. Your firm should investigate and determine the causes of the violation(s) and take prompt actions to correct the violation(s) and to bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Nina Mezu‐Nwaba, Deputy Director\n\nOffice of Health Technology 5 – Office of\n\nNeurological and Physical Medical Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh, Program Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc: Ms. Kami J. Howard, President and CEO","ZYTO Technologies, Inc.","zyto-technologies-inc-652316-06212023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzyto-technologies-inc-652316-06212023","2026-10-26T08:10:40.338776+00:00","Warning Letter","Issued","2023-07-11","652316","Medical Devices","Division of Medical Device and Radiological Health Operations West","Dr. Vaughn R. Cook","2026-08-20T00:55:45.601+00:00","VIA UNITED PARCEL SERVICE","2023-06-21",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},7,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoven-technologies-inc-734643-07212026\">Koven Technologies, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Heather S. Bell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Koven Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>477 N. Lindbergh Blvd. Ste. 220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63141\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 734643\u003C\u002Fp>\u003Cp>July 21, 2026\u003C\u002Fp>\u003Cp>Dear Ms. Bell:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Saint Louis, MO, conducted from February 2, 2026, through February 6, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and\u002For markets the Bidop 3 Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Management System Regulation Violation(s)\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Heather Bell, President, on February 27, 2026; April 17, 2026; and May 28, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to document procedures to control design and development changes, and determine the significance of these changes to function, performance, usability, safety and regulatory requirements for the medical device and its intended use, as required by ISO 13485:2016 Clause 7.3.9.&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow procedure 1-SOP-014, Design Control, which states, “All design changes must be identified, documented, where appropriate validated, reviewed and approved before the changes may be implemented.” Additionally, your firm failed to follow procedure 2-SOP-010, Device Registration, Submission and Notification, which requires that once a device or process is changed, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not document design and development changes related to expanding the indications for use of the Bidop 3 (K954397) to include a fetal application which was not cleared as an intended use. During the inspection, the Bidop 3 operations manual noted the indications for use include detection of fetal heart sounds. Your firm has not provided documentation of:\u003C\u002Fp>\u003Cp>A. The review and approval of design change documentation, including:\u003Cbr>i. Specific modifications made to the device (hardware, software, or performance specifications) to support fetal use.\u003Cbr>ii. Validation data demonstrating the device's safety and effectiveness for fetal applications.\u003C\u002Fp>\u003Cp>B. An evaluation to determine whether the change in indications for use (from non-fetal to fetal application) required a new 510(k) submission.\u003C\u002Fp>\u003Cp>C. The date when distribution was initiated for the Bidop 3 as a Fetal Doppler.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your responses mention that your firm notified customers via certified mail to suspend the use of fetal probes with Bidop 3 doppler units and that you conducted a 21 CFR 806 reportability assessment. FDA received your 806 report on 03\u002F06\u002F2026 and it is being processed under RES ID: 98556. The recall is on-going.\u003C\u002Fp>\u003Cp>2. Failure to document one or more processes for risk management in product realization and determine, as appropriate, quality objectives and requirements for the product, as required by ISO 13485:2016 Clause 7.1.\u003C\u002Fp>\u003Cp>Specifically, your firm’s risk management analysis for your devices revealed inadequate hazard identification and risk analysis as evidenced by the two (2) fetal dopplers below:\u003C\u002Fp>\u003Cp>A. Product ES-100V3 (Bidop 3), 510(k) K954397, cleared March 29, 1996: The risk management report (Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated September 3, 2025) was revised to include an indication for use as a fetal heart rate doppler, according to management. However, this report fails to evaluate risks to the fetus, despite the device being labeled for determining fetal heart rate and sounds.\u003C\u002Fp>\u003Cp>B. Product Bidop 7, 510(k) K201114, cleared January 5, 2021: The risk management report (Document \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated February 5, 2020) contains no evaluation of risks to the fetus, despite the device's indication for use, which includes displaying bi-directional velocity waveforms, numerical data, and fetal heart rate with a heartbeat indicator.\u003C\u002Fp>\u003Cp>The fetus is directly exposed to ultrasound energy and is the primary patient population for these devices. Failure to evaluate fetal-specific hazards (e.g., thermal effects, acoustic exposure, diagnostic accuracy affecting clinical decisions) represents inadequate risk analysis for the devices' intended use. Use of doppler ultrasound devices for fetal monitoring entails additional risks as compared to their use for blood flow monitoring. Fetal tissue is more vulnerable to prolonged or inappropriate ultrasound exposure than adult tissue. Additionally, improper use of the doppler for fetal monitoring may cause misinterpretation of maternal heartbeats or placental blood flow as fetal heartbeat, creating false reassurance. This can result in missed fetal distress signals, delayed care, and severe outcomes including fetal death. Conversely, failure to correctly detect a fetal heartbeat may cause anxiety and unnecessary clinical interventions.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, the risk analysis of the fetal doppler ultrasound device should clearly assess these specific risks associated with use of the device for fetal monitoring as discussed above and specific hazards including fetal distress or death due to misinterpretation, and delayed care.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm completed a review of the risk management files for the Bidop 7 to address hazards consistent with the cleared intended use. However, your firm did not provide supporting documentation.\u003C\u002Fp>\u003Cp>3. Failure to establish criteria for the evaluation and selection of suppliers, as required by ISO 13485:2016 Clause 7.4.1.&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm has not established adequate criteria for the evaluation and selection of your approved suppliers based on their ability to provide product that meets requirements, the performance of the supplier, and the effect of the purchased product on the quality of the device. For example,\u003C\u002Fp>\u003Cp>A. Your firm holds 25 510(k) clearances for devices designed and manufactured by a contract manufacturer. During the inspection the Bidop 3 Doppler was found to have indications for use that differ from those in the cleared 510(k). The indications for use were changed from non-fetal to fetal application. This design change was implemented by your contract manufacturer and your firm does not have documentation of this change nor could your firm identify when this change occurred. The quality agreement between your firm and your contract manufacturer (Section 5.5, Labeling) requires that any changes to labeling \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This undocumented change represents a failure to ensure that \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling changes as is established in your quality agreement. Furthermore, the quality agreement fails to \u003Cstrong>(b)(4)\u003C\u002Fstrong> design changes beyond labeling.\u003C\u002Fp>\u003Cp>B. Per procedure 1-SOP-020, \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier approval criteria include requirements that must be met such as having a quality agreement, product inspection, and site assessment. There is no documentation that a site assessment (supplier audit) has been conducted for the contract manufacturer, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> supplier which your firm’s procedure defines as “Highest\u002FCritical Impact.”\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. We acknowledge that one of your corrective actions is that your firm amended the quality agreement with your contract manufacturer to include comprehensive design change notifications, access to change logs, and audit rights commensurate with the planned transfer of the 510(k)’s to your supplier. You mention that CAPA CA2026-3 is complete; however, it is in the effectiveness stage and your firm mentioned open corrective actions. As such, please ensure to keep the CAPA open and documented while you are completing all the steps of a CAPA.\u003C\u002Fp>\u003Cp>4. Failure to maintain records of the review, evaluation, and investigation for any complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.35(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your firm failed to evaluate returned devices related to device failures affecting performance and reliability as complaints. Between January 1, 2024, and December 31, 2025, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> Returned Goods Authorizations (RGAs) were issued for device returns. The investigator reviewed 29 completed RGA forms coded as \"\u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and found that 13 of these forms reported device failures but were not evaluated as complaints. Your firm did not consider these reports as complaints and did not initiate or complete a complaint form as required by your complaint procedure, SOP 4-SOP-050 (Customer Complaint). This procedure defines a complaint as \"Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization's control or related to a service that affects the performance of such medical devices.” For example:\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>RGA\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Number\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Date\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Device\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Code\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Failure\u002FInspection\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>10923\u003C\u002Ftd>\u003Ctd>6\u002F26\u002F2024\u003C\u002Ftd>\u003Ctd>Bidop 7\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>The doppler memory has been cleared and when it is turned off and on, it comes up memory store #11 or memory store #1. The doppler should go straight to the LCD screen.\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11061\u003C\u002Ftd>\u003Ctd>9\u002F18\u002F2024\u003C\u002Ftd>\u003Ctd>Bidop 3\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>No consistent waveform with toe pressure sensor\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11211\u003C\u002Ftd>\u003Ctd>1\u002F8\u002F2025\u003C\u002Ftd>\u003Ctd>Bidop 3\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Out of box failure\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11509\u003C\u002Ftd>\u003Ctd>6\u002F27\u002F2025\u003C\u002Ftd>\u003Ctd>CRP-20H, cardiovascular probe\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Not picking up vascular flow\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>11402\u003C\u002Ftd>\u003Ctd>4\u002F22\u002F2025\u003C\u002Ftd>\u003Ctd>Aneroid Sphygmomanometer\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Doesn’t measure correctly on toe\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm provided the training records showing the employees trained to the updated procedures; however, you did not provide specifics on the evaluation conducted for the employees to confirm they understood the updates. Please provide this information.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case [734643]” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CAPT Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHeather S. Bell\n\nRecipient Title\n\nPresident\n\nKoven Technologies, Inc.\n\n477 N. Lindbergh Blvd. Ste. 220\n\nSaint Louis, MO 63141\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 734643\nJuly 21, 2026\nDear Ms. Bell:\nDuring an inspection of your firm located in Saint Louis, MO, conducted from February 2, 2026, through February 6, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and\u002For markets the Bidop 3 Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality Management System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from Heather Bell, President, on February 27, 2026; April 17, 2026; and May 28, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include but are not limited to the following:\n1. Failure to document procedures to control design and development changes, and determine the significance of these changes to function, performance, usability, safety and regulatory requirements for the medical device and its intended use, as required by ISO 13485:2016 Clause 7.3.9.\nSpecifically, your firm failed to follow procedure 1-SOP-014, Design Control, which states, “All design changes must be identified, documented, where appropriate validated, reviewed and approved before the changes may be implemented.” Additionally, your firm failed to follow procedure 2-SOP-010, Device Registration, Submission and Notification, which requires that once a device or process is changed, (b)(4). Your firm did not document design and development changes related to expanding the indications for use of the Bidop 3 (K954397) to include a fetal application which was not cleared as an intended use. During the inspection, the Bidop 3 operations manual noted the indications for use include detection of fetal heart sounds. Your firm has not provided documentation of:\nA. The review and approval of design change documentation, including:\ni. Specific modifications made to the device (hardware, software, or performance specifications) to support fetal use.\nii. Validation data demonstrating the device's safety and effectiveness for fetal applications.\nB. An evaluation to determine whether the change in indications for use (from non-fetal to fetal application) required a new 510(k) submission.\nC. The date when distribution was initiated for the Bidop 3 as a Fetal Doppler.\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your responses mention that your firm notified customers via certified mail to suspend the use of fetal probes with Bidop 3 doppler units and that you conducted a 21 CFR 806 reportability assessment. FDA received your 806 report on 03\u002F06\u002F2026 and it is being processed under RES ID: 98556. The recall is on-going.\n2. Failure to document one or more processes for risk management in product realization and determine, as appropriate, quality objectives and requirements for the product, as required by ISO 13485:2016 Clause 7.1.\nSpecifically, your firm’s risk management analysis for your devices revealed inadequate hazard identification and risk analysis as evidenced by the two (2) fetal dopplers below:\nA. Product ES-100V3 (Bidop 3), 510(k) K954397, cleared March 29, 1996: The risk management report (Document (b)(4), dated September 3, 2025) was revised to include an indication for use as a fetal heart rate doppler, according to management. However, this report fails to evaluate risks to the fetus, despite the device being labeled for determining fetal heart rate and sounds.\nB. Product Bidop 7, 510(k) K201114, cleared January 5, 2021: The risk management report (Document (b)(4), dated February 5, 2020) contains no evaluation of risks to the fetus, despite the device's indication for use, which includes displaying bi-directional velocity waveforms, numerical data, and fetal heart rate with a heartbeat indicator.\nThe fetus is directly exposed to ultrasound energy and is the primary patient population for these devices. Failure to evaluate fetal-specific hazards (e.g., thermal effects, acoustic exposure, diagnostic accuracy affecting clinical decisions) represents inadequate risk analysis for the devices' intended use. Use of doppler ultrasound devices for fetal monitoring entails additional risks as compared to their use for blood flow monitoring. Fetal tissue is more vulnerable to prolonged or inappropriate ultrasound exposure than adult tissue. Additionally, improper use of the doppler for fetal monitoring may cause misinterpretation of maternal heartbeats or placental blood flow as fetal heartbeat, creating false reassurance. This can result in missed fetal distress signals, delayed care, and severe outcomes including fetal death. Conversely, failure to correctly detect a fetal heartbeat may cause anxiety and unnecessary clinical interventions.\nTherefore, the risk analysis of the fetal doppler ultrasound device should clearly assess these specific risks associated with use of the device for fetal monitoring as discussed above and specific hazards including fetal distress or death due to misinterpretation, and delayed care.\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm completed a review of the risk management files for the Bidop 7 to address hazards consistent with the cleared intended use. However, your firm did not provide supporting documentation.\n3. Failure to establish criteria for the evaluation and selection of suppliers, as required by ISO 13485:2016 Clause 7.4.1.\nSpecifically, your firm has not established adequate criteria for the evaluation and selection of your approved suppliers based on their ability to provide product that meets requirements, the performance of the supplier, and the effect of the purchased product on the quality of the device. For example,\nA. Your firm holds 25 510(k) clearances for devices designed and manufactured by a contract manufacturer. During the inspection the Bidop 3 Doppler was found to have indications for use that differ from those in the cleared 510(k). The indications for use were changed from non-fetal to fetal application. This design change was implemented by your contract manufacturer and your firm does not have documentation of this change nor could your firm identify when this change occurred. The quality agreement between your firm and your contract manufacturer (Section 5.5, Labeling) requires that any changes to labeling (b)(4). This undocumented change represents a failure to ensure that (b)(4) labeling changes as is established in your quality agreement. Furthermore, the quality agreement fails to (b)(4) design changes beyond labeling.\nB. Per procedure 1-SOP-020, (b)(4) supplier approval criteria include requirements that must be met such as having a quality agreement, product inspection, and site assessment. There is no documentation that a site assessment (supplier audit) has been conducted for the contract manufacturer, a (b)(4) supplier which your firm’s procedure defines as “Highest\u002FCritical Impact.”\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. We acknowledge that one of your corrective actions is that your firm amended the quality agreement with your contract manufacturer to include comprehensive design change notifications, access to change logs, and audit rights commensurate with the planned transfer of the 510(k)’s to your supplier. You mention that CAPA CA2026-3 is complete; however, it is in the effectiveness stage and your firm mentioned open corrective actions. As such, please ensure to keep the CAPA open and documented while you are completing all the steps of a CAPA.\n4. Failure to maintain records of the review, evaluation, and investigation for any complaints involving the possible failure of a device, labeling, or packaging to meet any of its specifications, as required by 21 CFR 820.35(a).\nSpecifically, your firm failed to evaluate returned devices related to device failures affecting performance and reliability as complaints. Between January 1, 2024, and December 31, 2025, approximately (b)(4) Returned Goods Authorizations (RGAs) were issued for device returns. The investigator reviewed 29 completed RGA forms coded as \"(b)(4)\" and found that 13 of these forms reported device failures but were not evaluated as complaints. Your firm did not consider these reports as complaints and did not initiate or complete a complaint form as required by your complaint procedure, SOP 4-SOP-050 (Customer Complaint). This procedure defines a complaint as \"Any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, usability, safety, or performance of a medical device that has been released from the organization's control or related to a service that affects the performance of such medical devices.” For example:\nRGA\nNumberDateDeviceCodeFailure\u002FInspection\n109236\u002F26\u002F2024Bidop 7(b)(4)The doppler memory has been cleared and when it is turned off and on, it comes up memory store #11 or memory store #1. The doppler should go straight to the LCD screen.\n110619\u002F18\u002F2024Bidop 3(b)(4)No consistent waveform with toe pressure sensor\n112111\u002F8\u002F2025Bidop 3(b)(4)Out of box failure\n115096\u002F27\u002F2025CRP-20H, cardiovascular probe(b)(4)Not picking up vascular flow\n114024\u002F22\u002F2025Aneroid Sphygmomanometer(b)(4)Doesn’t measure correctly on toe\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your corrective actions are in progress. Your firm provided the training records showing the employees trained to the updated procedures; however, you did not provide specifics on the evaluation conducted for the employees to confirm they understood the updates. Please provide this information.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Establishment Assessment Team 2, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case [734643]” when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, Ashley.Mutawakkil@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCAPT Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Koven Technologies, Inc.","koven-technologies-inc-734643-07212026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkoven-technologies-inc-734643-07212026","2026-10-26T08:09:10.23134+00:00","2026-08-04","734643","Heather S. Bell","2026-08-19T04:27:26.915+00:00","VIA Electronic Mail","2026-07-21",{"id":54,"raw":55,"subject":12,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":44,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":59,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":72,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},171,[56,57,58,59,12,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-22T04:00:00Z\">04\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Festar-technologies-ltd-716831-04222026\">Estar Technologies Ltd\u003C\u002Fa>","Center for Biologics Evaluation and Research","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-716831\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Aaron Esteron\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Estar Technologies Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15, Ha-Merkava\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holon\u003C\u002Fspan> \u003Cspan>5885111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Israel\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Aaron@estar-medical.com\"> Aaron@estar-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-716831\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Esteron:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is offering for sale the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit (hereafter, “your devices”) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), your devices are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your websites at https:\u002F\u002Fwww.tropocells.com and https:\u002F\u002Festar-medical.com\u002F (last visited April 2026), your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your introduction or delivery for introduction of your devices into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the Act, 21 U.S.C. § 331(a). Your devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce your devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a).\u003C\u002Fp>\u003Cp>Of note, the TropoCells® PRP kit was cleared under premarket notification (510(k)) submission number BK110035 with the following indication, “safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft and\u002For allograft bone prior to application to a bony defect for improving handling characteristics.” However, you include statements such as the following on your website, https:\u002F\u002Fwww.tropocells.com, regarding the uses of the Tropocells® PRP kit:\u003C\u002Fp>\u003Cp>“Tropocells® PRP is the ideal autologous technology for the healing of: musculoskeletal injuries, joint and osteoarthritis treatment, sports injuries, wound healing, ophthalmology, dentistry and oral surgery, and post-surgical recovery.”\u003C\u002Fp>\u003Cp>These represent major changes or modifications to the intended uses for this device and are changes or modifications that could significantly affect its safety or effectiveness. Therefore, premarket notification for this device is required. See 21 CFR 807.81(a)(3).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 C.F.R. § 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance for your devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Estar Technologies Ltd. should cease any activities that result in the misbranding or adulteration of the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actionsyour firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your devices are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Mr. Irving L. Wiesen, Esq\u003Cbr>US Agent\u003Cbr>Law Offices of Irving L. Wiesen PC.\u003Cbr>420 Lexington Avenue, Suite 2400\u003Cbr>New York, New York 10170\u003Cbr>lwiesen@Wiesenlaw.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-716831\n\nProduct:\n\nBiologics\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAaron Esteron\n\nRecipient Title\n\nChief Executive Officer and Founder\n\nEstar Technologies Ltd\n\n15, Ha-Merkava\n\nHolon 5885111\n\nIsrael\n\nAaron@estar-medical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nApril 22, 2026\nCBER 26-716831\nDear Mr. Esteron:\nThe United States Food and Drug Administration (FDA) has learned that your firm is offering for sale the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit (hereafter, “your devices”) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), your devices are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or any function of the body.\nBased on information and records reviewed by FDA, including your websites at https:\u002F\u002Fwww.tropocells.com and https:\u002F\u002Festar-medical.com\u002F (last visited April 2026), your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your introduction or delivery for introduction of your devices into interstate commerce, or the causing thereof is a prohibited act under section 301(a) of the Act, 21 U.S.C. § 331(a). Your devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce your devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a).\nOf note, the TropoCells® PRP kit was cleared under premarket notification (510(k)) submission number BK110035 with the following indication, “safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient point of care. The PRP is mixed with autograft and\u002For allograft bone prior to application to a bony defect for improving handling characteristics.” However, you include statements such as the following on your website, https:\u002F\u002Fwww.tropocells.com, regarding the uses of the Tropocells® PRP kit:\n“Tropocells® PRP is the ideal autologous technology for the healing of: musculoskeletal injuries, joint and osteoarthritis treatment, sports injuries, wound healing, ophthalmology, dentistry and oral surgery, and post-surgical recovery.”\nThese represent major changes or modifications to the intended uses for this device and are changes or modifications that could significantly affect its safety or effectiveness. Therefore, premarket notification for this device is required. See 21 CFR 807.81(a)(3).\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA. 21 C.F.R. § 807.81(b). The kind of information that you need to submit in order to obtain approval or clearance for your devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nEstar Technologies Ltd. should cease any activities that result in the misbranding or adulteration of the Tropocells® PRP kit, Tropocells® PRF kit, Tropocells® TRS kit, Tropocells® PRFM kit, TropoVisc™ kit, Tropokine™ kit, and Cellenis® PRP kit, such as the commercial distribution of the devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actionsyour firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your devices are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc: Mr. Irving L. Wiesen, Esq\nUS Agent\nLaw Offices of Irving L. Wiesen PC.\n420 Lexington Avenue, Suite 2400\nNew York, New York 10170\nlwiesen@Wiesenlaw.com","Estar Technologies Ltd","estar-technologies-ltd-716831-04222026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Festar-technologies-ltd-716831-04222026","2026-10-26T08:08:36.3981+00:00","2026-05-12","716831","BiologicsMedical Devices","Aaron Esteron","2026-08-19T04:42:21.534+00:00","Via UPS and EMAIL","CBER 26-716831","2026-04-22",{"id":75,"raw":76,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":90,"body_fetched_at":91,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},1095,[77,78,79,38,80,13,13,13],"\u003Ctime datetime=\"2025-01-14T14:20:00Z\">01\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-09T05:00:00Z\">12\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxoran-technologies-llc-694229-12092024\">Xoran Technologies, LLC\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert P. Bryan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO) \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Xoran Technologies, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5210 S State Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ann Arbor\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 694229\u003C\u002Fp>\u003Cp>December 9, 2024\u003C\u002Fp>\u003Cp>Dear Mr. Bryan:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Ann Arbor, MI on June 25, 2024 through July 11, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures computed tomography (CT) systems and supporting software to include (but not limited to) the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices and XoranConnect image processing software. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Mr. Zeke Church, Director of Quality &amp; Regulatory, dated July 29, 2024, August 30, 2024, and September 30, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 9.0 of your “Supplier Approval and Removal” procedure (WI 14.5; Rev. 9; 7\u002F21\u002F15) which requires your suppliers to complete the “Supplier Self-Assessment” Form F 14.5.1 to verify they can meet requirements of the Quality Management System (e.g., process validation under production and process controls, corrective action processes, control of nonconforming product, etc.) and the “Supplier Criteria and Setup Request” Form (F 14.5.9) to ensure your firm’s requirements can be met. For example, you did not ensure that your two (2) suppliers of printed circuit boards (PCBs) – Supplier A approved on or around June 3, 2022 and Supplier B approved on or around April 4, 2016 – conducted process validations for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> soldering processes used in your MiniCAT 2020 and MiniCAT IQ devices.\u003C\u002Fp>\u003Cp>The \u003Cstrong>(b)(4)\u003C\u002Fstrong> soldering processes cannot be fully verified by subsequent inspection and test in that your functional, electrical continuity testing, and visual inspections cannot detect voids in the solder joints. Of the two suppliers, Supplier B has been manufacturing 10 of your unvalidated PCBs (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in the devices for the last 8 years. Over the last 2 years, there were at least 4 confirmed complaints of PCB failures which required earlier-than-expected replacement of these boards within 2 years of installation. Recent distribution records covering the last 4 years revealed that 121 MiniCAT 2020 devices and 83 MiniCAT IQ devices were assembled with unvalidated PCBs from at least one or both of these suppliers. Moreover, there are currently 156 MiniCAT 2020 devices and 175 MiniCAT IQ devices installed in the field with unvalidated PCBs from one or both of your suppliers.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Although you opened CAPA 294 (not provided) to determine why your supplier files are incomplete; are no longer using Supplier B effective August 28, 2024; plan to obtain the required completed forms; will require component qualification on all PCBs received; and plan to establish a written agreement from Supplier A, your responses do not address reviewing all supplier files for completeness, including whether any additional process validations are required. Furthermore, you did not provide any details on whether you assessed the risk of using PCBs in existing inventory from unvalidated \u003Cstrong>(b)(4)\u003C\u002Fstrong> soldering processes as well as in the field.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate software validation, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, your firm’s XoranCAT software used to control MiniCAT diagnostic CT x-ray systems has not been adequately validated. For example, your “Testing” procedure (SOP 40; Rev. 5; Effective: 7\u002F31\u002F15) defines four levels of testing, including component testing, integration testing, system testing, and acceptance testing. The XoranCAT software release v5.17.3, dated February 19, 2024, introduced features (e.g., supporting the detector panels) and fixed anomalies (e.g., 64-bit Region of Interest (ROI) tool, which “[did] not work properly”). However, the test cases and results indicate that the software was validated at the software system level, utilizing only functional testing (i.e., black-box) techniques. The validation documentation does not include component testing and integration testing. Since January 2020, your firm has logged approximately 460 complaints which include “Software Issue &gt; XoranCAT” in the complaint categorization code. These complaints allege problems such as freezing\u002Fcrashing software, image reconstruction issues, and corrupted files.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated July 29, 2024, August 30, 2024, and September 30, 2024, and conclude that they are not adequate. Your firm’s responses state \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your responses do not yet include the documentation for our evaluation. Furthermore, your responses do not include a retrospective review of previously completed software changes to evaluate whether they have been validated adequately, in accordance with the SOP. It is unclear whether regression analysis was conducted to determine the need to re-execute unit, integration, and software-system level testing and if level of code coverage was commensurate with risk. Your response should include procedures for regression analysis and testing as well as procedures to ensure adequate code coverage during software testing, in accordance with the guidance document, \u003Cu>General Principles of Software Validation.\u003C\u002Fu>\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 9.0 of your “Complaint Management” procedure (SOP 6; Rev. 31-33; Effective: 2\u002F21\u002F19; 5\u002F30\u002F23; 12\u002F15\u002F23) to categorize customer calls as complaints instead of inquiries when they meet the definition of complaints as defined by 21 CFR 820.3(b). A cursory review of inquiries logged between January 1, 2022 and June 25, 2024 revealed that at least three (3) customer calls were incorrectly logged as inquiries instead of complaints. For example, you logged the following customer calls as inquiries and not complaints although they allege deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance:\u003C\u002Fp>\u003Cp> \u003Cu>Case ID # 00047929 (3\u002F28\u002F24):\u003C\u002Fu> “\u003Cem>Customer called due to gantry not returning to home position. I was able to zero the gantry in CTDT. This is the 2nd time this year this issue has occurred. Customer is due for PM and requests an onsite visit […]\u003C\u002Fem>”\u003Cbr> \u003Cu>Case ID # 00045482 (2\u002F14\u002F23):\u003C\u002Fu> “\u003Cem>Receiving shutter errors when attempting patient scans. ACQ must be rebooted to remove error and complete scans. Error has occured [sic] multiple times\u003C\u002Fem>.”\u003Cbr> \u003Cu>Case ID # 00045056 (12\u002F14\u002F22):\u003C\u002Fu> \u003Cem>Customer is unable to select protocol and reccived [sic] ‘unable to initialize panel’ message. Restarted ACQ, performed gain calibration message did not return and able to select protocol and continue with scan\u003C\u002Fem>”\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Although you opened CAPA 296 (not provided) to determine why your complaint procedures were inadequate; plan to create a process to ensure inquiries are evaluated prior to closure to ensure complaints are not misidentified as inquiries; and conduct retraining, there were no corrective actions identified to retrospectively review inquiries, for a reasonable time frame, to determine if any meet the definition of complaints, and there were no corrections to process the inquiries in the observation as complaints.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). \u003C\u002Fstrong>Specifically:\u003C\u002Fp>\u003Cp>(a) You failed to implement section 9.3 of your “Risk Management” procedure (SOP 39; Rev. 3 and 10; Effective: 5\u002F23\u002F11 and 12\u002F15\u002F23) which requires use of a hazard analysis to identify foreseeable hazards in both normal and fault conditions and estimate the risk for each hazard by determining the probability of occurrence of harm and severity of the possible consequences of that harm as a part of your risk analysis. For example, you have not calculated risks under normal use of your MiniCAT devices since your hazard analysis titled “Device Hazards and Harms Matrix” (01-2.5; Rev. 1; 6\u002F9\u002F11) only documents the severity of harms associated with hazards and not the probability of occurrence.\u003C\u002Fp>\u003Cp>(b) Your “FMEA Work Instruction” (WI 39.2; Rev. 8; Effective: 12\u002F15\u002F23) states that “***a post-mitigation RP [Risk Priority] of ‘B’ should always prompt consideration of further control measures***”; however, it does not define how to document this assessment. Your “MiniCAT DFMEA” includes approximately 29 line items with a post-mitigation Risk Priority of “B” with a blank under the “Recommended Action” field for which your firm was unable to provide evidence that additional control measures were considered.\u003C\u002Fp>\u003Cp>(c) You failed to implement section 9.8 of your current revision of your “Risk Management” procedure (SOP 39; Rev. 10; Effective: 12\u002F15\u002F23) which requires evaluation of the overall residual risk acceptability. For example, your firm has not re-evaluated and documented the overall residual risk acceptability of your MiniCAT devices despite the “MiniCAT DFMEA” (01-2.3) being revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> since approval of the “MiniCATTM Risk Management Report” (Rev. 2.0) on August 5, 2011 which determined that “***the benefits of the MiniCATTM CT scanner outweigh the inherent and residual risks***.”\u003C\u002Fp>\u003Cp>(d) You failed to implement section 9.10 of your “Risk Management” procedure (SOP 39; Rev. 10; Effective; 12\u002F15\u002F23) and “Production and Post-Production Information” section of your “MiniCATTM Risk Management Report” (Rev. 2.0; Approved 8\u002F5\u002F11) which require you to monitor customer complaints and other quality data sources to identify new risks and failure modes and update the risk management file. In particular, you do not assess the need to update your risk management file for your complaints unless they are investigated under a Failure Investigation Analysis (FIA) such that complaints without FIAs are excluded from this assessment. For example, a risk assessment was not conducted for Complaint # 47856 to determine whether the FMEA needed to be updated because it lacked an FIA.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. You opened CAPA 297 (not provided) to determine why risk analysis is not adequate and stated you plan to add probability of occurrence to your harms analysis; update the FMEAs with a column for risk priority justification; update your management review work instruction (WI 1.1) to require review of the risk management report at a minimum yearly to determine if an update is needed; and review and revise the current risk management report. Please provide updates on the progress of these corrective actions and corrections, including CAPA 297, and any supporting evidence. Also, please respond with how you plan to address the finding that your risk management file is not updated with complaints without FIAs.\u003C\u002Fp>\u003Cp>Our inspection also revealed that the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Specifically, the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices do not have 510(k) clearance. While a previous version of the MiniCAT device does have a 510(k) clearance (K113421) and while a previous version of the xCAT device does have a 510(k) clearance (K061834), the following design modifications – as documented in your firm’s US Regulatory Assessment of Product or Process Design Changes for 510(k) Cleared Medical Device – require the imaging performance and\u002For software to be evaluated in order to ascertain their impact to safety and effectiveness. These changes may be accepted in a Special 510(k) submission.\u003C\u002Fp>\u003Cp>The following changes could significantly affect the safety or effectiveness of these devices:\u003C\u002Fp>\u003Cp>\u003Cstrong>MiniCAT2020:\u003C\u002Fstrong>\u003Cbr> New model of Varex x-ray receptor panel: Varex 2121DXV. Technology and principle of operation of the 2121DXV are the same as current MiniCAT panels Varex 2520DX and 2520XI. The panel is just smaller in overall dimensions and cost.\u003Cbr> Changes to the position of the receptor panel in the gantry (offset) to maintain a field of view (FOV) size similar to MiniCAT\u002FIQ while scanning with the smaller size panel (21x21cm vs. 25x20cm)\u003Cbr> Removal of Beam Limiter board and corresponding revision to PLC firmware; use of fixed collimation\u003Cbr> Software changes to add support for the new receptor panel and reconstruction algorithm\u003C\u002Fp>\u003Cp>\u003Cstrong>MiniCAT IQ:\u003C\u002Fstrong>\u003Cbr> Software changes causing increased number of post-processing viewing filter levels\u003C\u002Fp>\u003Cp>\u003Cstrong>xCAT IQ:\u003C\u002Fstrong>\u003Cbr> New model of x-ray source\u003Cbr> Change in hardware components requiring new firmware and software controls\u003Cbr> New type of receptor panel mode that requires a new acquisition method\u003Cbr> New patient head holder that introduces biocompatibility concerns\u003Cbr> Revised XoranCAT software with a new construction protocol to accommodate soft tissue reconstruction, new soft tissue protocol and new receptor panel acquisition modes\u003C\u002Fp>\u003Cp>\u003Cstrong>xCAT XL:\u003C\u002Fstrong>\u003Cbr> Dimensional changes in system geometry that may affect imaging, including a reduction of the FoV\u003Cbr> Possible change in scattered radiation due to removal of gantry shields\u003Cbr> Change in filters that may affect scattered or leakage radiation\u003Cbr> Software uses new imaging protocols, the safety of which is unclear without more information\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 694229 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRobert P. Bryan\n\nRecipient Title\n\nChief Executive Officer (CEO)\n\nXoran Technologies, LLC\n\n5210 S State Rd\n\nAnn Arbor, MI 48108\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 694229\nDecember 9, 2024\nDear Mr. Bryan:\nDuring an inspection of your firm located in Ann Arbor, MI on June 25, 2024 through July 11, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures computed tomography (CT) systems and supporting software to include (but not limited to) the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices and XoranConnect image processing software. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Mr. Zeke Church, Director of Quality & Regulatory, dated July 29, 2024, August 30, 2024, and September 30, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\nSpecifically, you failed to implement section 9.0 of your “Supplier Approval and Removal” procedure (WI 14.5; Rev. 9; 7\u002F21\u002F15) which requires your suppliers to complete the “Supplier Self-Assessment” Form F 14.5.1 to verify they can meet requirements of the Quality Management System (e.g., process validation under production and process controls, corrective action processes, control of nonconforming product, etc.) and the “Supplier Criteria and Setup Request” Form (F 14.5.9) to ensure your firm’s requirements can be met. For example, you did not ensure that your two (2) suppliers of printed circuit boards (PCBs) – Supplier A approved on or around June 3, 2022 and Supplier B approved on or around April 4, 2016 – conducted process validations for the (b)(4) soldering processes used in your MiniCAT 2020 and MiniCAT IQ devices.\nThe (b)(4) soldering processes cannot be fully verified by subsequent inspection and test in that your functional, electrical continuity testing, and visual inspections cannot detect voids in the solder joints. Of the two suppliers, Supplier B has been manufacturing 10 of your unvalidated PCBs ((b)(4)) used in the devices for the last 8 years. Over the last 2 years, there were at least 4 confirmed complaints of PCB failures which required earlier-than-expected replacement of these boards within 2 years of installation. Recent distribution records covering the last 4 years revealed that 121 MiniCAT 2020 devices and 83 MiniCAT IQ devices were assembled with unvalidated PCBs from at least one or both of these suppliers. Moreover, there are currently 156 MiniCAT 2020 devices and 175 MiniCAT IQ devices installed in the field with unvalidated PCBs from one or both of your suppliers.\nWe reviewed your firm’s responses and conclude that they are not adequate. Although you opened CAPA 294 (not provided) to determine why your supplier files are incomplete; are no longer using Supplier B effective August 28, 2024; plan to obtain the required completed forms; will require component qualification on all PCBs received; and plan to establish a written agreement from Supplier A, your responses do not address reviewing all supplier files for completeness, including whether any additional process validations are required. Furthermore, you did not provide any details on whether you assessed the risk of using PCBs in existing inventory from unvalidated (b)(4) soldering processes as well as in the field.\n2. Failure to adequately establish and maintain procedures for validating the device design to include an adequate software validation, as required by 21 CFR 820.30(g).\nSpecifically, your firm’s XoranCAT software used to control MiniCAT diagnostic CT x-ray systems has not been adequately validated. For example, your “Testing” procedure (SOP 40; Rev. 5; Effective: 7\u002F31\u002F15) defines four levels of testing, including component testing, integration testing, system testing, and acceptance testing. The XoranCAT software release v5.17.3, dated February 19, 2024, introduced features (e.g., supporting the detector panels) and fixed anomalies (e.g., 64-bit Region of Interest (ROI) tool, which “[did] not work properly”). However, the test cases and results indicate that the software was validated at the software system level, utilizing only functional testing (i.e., black-box) techniques. The validation documentation does not include component testing and integration testing. Since January 2020, your firm has logged approximately 460 complaints which include “Software Issue > XoranCAT” in the complaint categorization code. These complaints allege problems such as freezing\u002Fcrashing software, image reconstruction issues, and corrupted files.\nWe reviewed your firm’s responses dated July 29, 2024, August 30, 2024, and September 30, 2024, and conclude that they are not adequate. Your firm’s responses state (b)(4). However, your responses do not yet include the documentation for our evaluation. Furthermore, your responses do not include a retrospective review of previously completed software changes to evaluate whether they have been validated adequately, in accordance with the SOP. It is unclear whether regression analysis was conducted to determine the need to re-execute unit, integration, and software-system level testing and if level of code coverage was commensurate with risk. Your response should include procedures for regression analysis and testing as well as procedures to ensure adequate code coverage during software testing, in accordance with the guidance document, General Principles of Software Validation.\n3. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit to ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a).\nSpecifically, you failed to implement section 9.0 of your “Complaint Management” procedure (SOP 6; Rev. 31-33; Effective: 2\u002F21\u002F19; 5\u002F30\u002F23; 12\u002F15\u002F23) to categorize customer calls as complaints instead of inquiries when they meet the definition of complaints as defined by 21 CFR 820.3(b). A cursory review of inquiries logged between January 1, 2022 and June 25, 2024 revealed that at least three (3) customer calls were incorrectly logged as inquiries instead of complaints. For example, you logged the following customer calls as inquiries and not complaints although they allege deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance:\n Case ID # 00047929 (3\u002F28\u002F24): “Customer called due to gantry not returning to home position. I was able to zero the gantry in CTDT. This is the 2nd time this year this issue has occurred. Customer is due for PM and requests an onsite visit […]”\n Case ID # 00045482 (2\u002F14\u002F23): “Receiving shutter errors when attempting patient scans. ACQ must be rebooted to remove error and complete scans. Error has occured [sic] multiple times.”\n Case ID # 00045056 (12\u002F14\u002F22): Customer is unable to select protocol and reccived [sic] ‘unable to initialize panel’ message. Restarted ACQ, performed gain calibration message did not return and able to select protocol and continue with scan”\nWe reviewed your firm’s responses and conclude that they are not adequate. Although you opened CAPA 296 (not provided) to determine why your complaint procedures were inadequate; plan to create a process to ensure inquiries are evaluated prior to closure to ensure complaints are not misidentified as inquiries; and conduct retraining, there were no corrective actions identified to retrospectively review inquiries, for a reasonable time frame, to determine if any meet the definition of complaints, and there were no corrections to process the inquiries in the observation as complaints.\n4. Failure to establish and maintain procedures for validating the device design to include an adequate risk analysis, as required by 21 CFR 820.30(g). Specifically:\n(a) You failed to implement section 9.3 of your “Risk Management” procedure (SOP 39; Rev. 3 and 10; Effective: 5\u002F23\u002F11 and 12\u002F15\u002F23) which requires use of a hazard analysis to identify foreseeable hazards in both normal and fault conditions and estimate the risk for each hazard by determining the probability of occurrence of harm and severity of the possible consequences of that harm as a part of your risk analysis. For example, you have not calculated risks under normal use of your MiniCAT devices since your hazard analysis titled “Device Hazards and Harms Matrix” (01-2.5; Rev. 1; 6\u002F9\u002F11) only documents the severity of harms associated with hazards and not the probability of occurrence.\n(b) Your “FMEA Work Instruction” (WI 39.2; Rev. 8; Effective: 12\u002F15\u002F23) states that “***a post-mitigation RP [Risk Priority] of ‘B’ should always prompt consideration of further control measures***”; however, it does not define how to document this assessment. Your “MiniCAT DFMEA” includes approximately 29 line items with a post-mitigation Risk Priority of “B” with a blank under the “Recommended Action” field for which your firm was unable to provide evidence that additional control measures were considered.\n(c) You failed to implement section 9.8 of your current revision of your “Risk Management” procedure (SOP 39; Rev. 10; Effective: 12\u002F15\u002F23) which requires evaluation of the overall residual risk acceptability. For example, your firm has not re-evaluated and documented the overall residual risk acceptability of your MiniCAT devices despite the “MiniCAT DFMEA” (01-2.3) being revised (b)(4) since approval of the “MiniCATTM Risk Management Report” (Rev. 2.0) on August 5, 2011 which determined that “***the benefits of the MiniCATTM CT scanner outweigh the inherent and residual risks***.”\n(d) You failed to implement section 9.10 of your “Risk Management” procedure (SOP 39; Rev. 10; Effective; 12\u002F15\u002F23) and “Production and Post-Production Information” section of your “MiniCATTM Risk Management Report” (Rev. 2.0; Approved 8\u002F5\u002F11) which require you to monitor customer complaints and other quality data sources to identify new risks and failure modes and update the risk management file. In particular, you do not assess the need to update your risk management file for your complaints unless they are investigated under a Failure Investigation Analysis (FIA) such that complaints without FIAs are excluded from this assessment. For example, a risk assessment was not conducted for Complaint # 47856 to determine whether the FMEA needed to be updated because it lacked an FIA.\nThe adequacy of your firm’s responses cannot be determined at this time. You opened CAPA 297 (not provided) to determine why risk analysis is not adequate and stated you plan to add probability of occurrence to your harms analysis; update the FMEAs with a column for risk priority justification; update your management review work instruction (WI 1.1) to require review of the risk management report at a minimum yearly to determine if an update is needed; and review and revise the current risk management report. Please provide updates on the progress of these corrective actions and corrections, including CAPA 297, and any supporting evidence. Also, please respond with how you plan to address the finding that your risk management file is not updated with complaints without FIAs.\nOur inspection also revealed that the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nSpecifically, the MiniCAT 2020, MiniCAT IQ, xCAT IQ, and xCAT XL devices do not have 510(k) clearance. While a previous version of the MiniCAT device does have a 510(k) clearance (K113421) and while a previous version of the xCAT device does have a 510(k) clearance (K061834), the following design modifications – as documented in your firm’s US Regulatory Assessment of Product or Process Design Changes for 510(k) Cleared Medical Device – require the imaging performance and\u002For software to be evaluated in order to ascertain their impact to safety and effectiveness. These changes may be accepted in a Special 510(k) submission.\nThe following changes could significantly affect the safety or effectiveness of these devices:\nMiniCAT2020:\n New model of Varex x-ray receptor panel: Varex 2121DXV. Technology and principle of operation of the 2121DXV are the same as current MiniCAT panels Varex 2520DX and 2520XI. The panel is just smaller in overall dimensions and cost.\n Changes to the position of the receptor panel in the gantry (offset) to maintain a field of view (FOV) size similar to MiniCAT\u002FIQ while scanning with the smaller size panel (21x21cm vs. 25x20cm)\n Removal of Beam Limiter board and corresponding revision to PLC firmware; use of fixed collimation\n Software changes to add support for the new receptor panel and reconstruction algorithm\nMiniCAT IQ:\n Software changes causing increased number of post-processing viewing filter levels\nxCAT IQ:\n New model of x-ray source\n Change in hardware components requiring new firmware and software controls\n New type of receptor panel mode that requires a new acquisition method\n New patient head holder that introduces biocompatibility concerns\n Revised XoranCAT software with a new construction protocol to accommodate soft tissue reconstruction, new soft tissue protocol and new receptor panel acquisition modes\nxCAT XL:\n Dimensional changes in system geometry that may affect imaging, including a reduction of the FoV\n Possible change in scattered radiation due to removal of gantry shields\n Change in filters that may affect scattered or leakage radiation\n Software uses new imaging protocols, the safety of which is unclear without more information\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 694229 when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Offer at (313) 393-8253 or sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Xoran Technologies, LLC","xoran-technologies-llc-694229-12092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fxoran-technologies-llc-694229-12092024","2026-10-26T08:10:35.182031+00:00","2025-01-14","694229","Robert P. Bryan","2026-08-19T17:05:09.872+00:00","2024-12-09",{"id":94,"raw":95,"subject":39,"body_html":100,"body_text":101,"firm_name":102,"letter_id":103,"created_at":104,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":23,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":19,"issuing_office":99,"recipient_name":109,"body_fetched_at":110,"delivery_method":111,"recipient_title":19,"reference_number":19,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},2979,[96,97,98,99,39,13,13,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-30T05:00:00Z\">11\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdental-technologies-inc-612599-11302021\">Dental Technologies Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Stephen A. Erickson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dental Technologies Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6901 N. Hamlin Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lincolnwood\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60712\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL # 612599\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 30, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Erickson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Dental Technologies Inc., FEI 1413475, at 6901 N. Hamlin Avenue, Lincolnwood, Illinois from December 7, 2020, to January 20, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Additionally, your drug product, Paroex 0.12% chlorhexidine oral rinse, is adulterated under section 501(a)(2)(A) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions, whereby it may have become contaminated with filth and rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the FD&amp;C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&amp;C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You lack adequate investigations into failing microbiological results for both finished drug products and components.\u003C\u002Fp>\n\n\u003Cp>A. In October 2020, your third-party laboratory identified \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC), specifically \u003Cem>Burkholderia lata\u003C\u002Fem> in Paroex 0.12% chlorhexidine oral rinse. Until prompted by FDA, your investigation failed to adequately evaluate excessive aerobic plate counts (including too numerous to count (TNTC)) and past BCC contamination events at your facility. Your investigation did not adequately address multiple potential root causes of the contamination. For example, we noted that your cleaning program was deficient. Notably, a lack of cleaning competency extended to multiple products made at your facility, and in one instance cleaning procedures had to be repeated two or more times to assure their efficacy.\u003C\u002Fp>\n\n\u003Cp>You failed to implement systemic corrective actions and preventive actions (CAPA) and investigate additional lots that may have been affected.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response, which includes your firm’s updated investigation, was inadequate.\u003C\u002Fp>\n\n\u003Cp>• Your investigation did not sufficiently address the TNTC levels of microorganisms in numerous Paroex batch retain samples, including the inability of the formulation to exert any meaningful inhibitory effect on microbial growth in your product.\u003C\u002Fp>\n\n\u003Cp>• Your investigation did not adequately explain the extreme variability of results within batches, including TNTC and passing results obtained from testing of multiple retain samples from the same batch. Also, you did not adequately describe how your future sampling strategy will be improved to provide better understanding of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>• You identified the chlorhexidine gluconate active pharmaceutical ingredient (API) as the most likely root cause of the Paroex contamination, but your investigation lacked justification for this assertion. For example:\u003Cbr>\n&nbsp; &nbsp; o The investigation indicated the API supplier found \u003Cem>Serratia marcescens\u003C\u002Fem> in certain lots of their chlorhexidine gluconate API, and this caused it to be the likely source of the BCC contamination. However, you noted the API supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, recalled affected lots contaminated with \u003Cem>Serratia marcescens\u003C\u002Fem> and your API lots met microbiological specifications. Further, your investigation lacks any indication that BCC had been isolated during chlorhexidine gluconate testing by either your supplier or your laboratory.\u003Cbr>\n&nbsp; &nbsp; o The investigation failed to address that, in addition to the lack of data indicating the presence of BCC in your API, BCC is very different from \u003Cem>Serratia marcescens\u003C\u002Fem> as they are in different taxonomic classes and have significantly different phenotypic and genotypic characteristics.\u003C\u002Fp>\n\n\u003Cp>• Your response states your Paroex 0.12% chlorhexidine gluconate oral rinse release testing did not detect \u003Cem>Burkholderia lata\u003C\u002Fem> because of a low level of contamination. This conclusion is flawed since you were not testing your product for BCC at the time, and your test method was inadequate to reliably detect these microorganisms.\u003C\u002Fp>\n\n\u003Cp>• Your response states shared equipment was cleaned and sanitized before use, per your procedures. However, your response lacks evidence of traceability confirming that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified as a potential cause of contamination, was adequately cleaned, and sanitized before use during manufacturing.\u003C\u002Fp>\n\n\u003Cp>• Your response acknowledges that the use of ancillary equipment is not documented in your batch records. However, you failed to include systemic corrections to your batch records and documentation systems to ensure traceability of each piece of equipment used during manufacturing, including but not limited to, their use, cleaning, sanitization, calibration, and maintenance.\u003C\u002Fp>\n\n\u003Cp>• You failed to adequately explain how you will systemically remediate your investigations program to ensure investigations are thorough, root causes are appropriately identified, scope of impacted products is appropriately evaluated, and CAPAs are prompt and effective.\u003C\u002Fp>\n\n\u003Cp>The Paroex product owner released a public announcement on December 28, 2020, detailing the receipt of a significant number of adverse events (29) associated with the product. Affected patients who received Paroex 0.12% chlorhexidine oral rinse tested positive for \u003Cem>Burkholderia lata\u003C\u002Fem>. Use of the contaminated product in patients who are immunocompromised or have pre-existing respiratory conditions, including critically ill patients and patients infected with COVID-19, is especially concerning as these patients are at increased risk for serious and life-threatening infections.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that batches of Paroex 0.12% chlorhexidine gluconate oral rinse bearing an expiration date from June 30 to September 30, 2022, were recalled on October 27, 2020. It was not until further discussions with FDA that the recall was extended to other potentially impacted batches of Paroex 0.12% chlorhexidine gluconate oral rinse products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA collected a sample of Paroex 0.12% chlorhexidine oral rinse lot C219DQ. Our testing revealed BCC contamination and failing total counts, which further demonstrated insanitary conditions (501(a)(2)(A)) at your facility.\u003C\u002Fp>\n\n\u003Cp>B. Your firm invalidated failing microbiological results obtained by your third-party laboratory during stability testing of a batch of AlphaCaine topical anesthetic gel in March 2019, without scientific justification.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> was isolated from the product sample and your laboratory retested the product. Your investigation determined your test method to be unsuitable because “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” After retesting with a method your laboratory determined suitable, you obtained passing results.\u003C\u002Fp>\n\n\u003Cp>Your investigation concluded, without adequate supporting evidence, that your third-party laboratory “may have contaminated the sample,” though they indicated no laboratory error had occurred and results were reproducible. Further, although you acknowledge your original test method for AlphaCaine topical anesthetic gel was inappropriate, your investigation determined “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate. You failed to perform a thorough evaluation of test methods used to ensure their adequacy.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your procedures describing in-process and finished product sampling and testing. Address how you will ensure samples are representative and can detect variation within a batch. Include how testing of individual samples (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) will be better leveraged to evaluate uniformity throughout the process.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive and independent assessment of your manufacturing processes to determine the current state of control as well as to determine if any process remediation and new validation studies are necessary. This assessment should include, but not be limited to, a study to extensively assess intra\u002Finter-batch uniformity for all appropriate attributes of your drug products.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your water system design, control, and maintenance. Include a description of all areas in your water system that can be stagnant.\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all batch failures, rejected batches, returned drug products, complaints, and deviations that may have been related to microbiological contamination for the last three years.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS results (including in-process, release, and stability testing) for products currently in the U.S. market and within expiry as of the date of this letter. Include a report summarizing the findings of the analysis, detailing the following for each OOS:\u003Cbr>\n&nbsp; &nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS results conclusively or inconclusively demonstrate causative laboratory error.\u003Cbr>\n&nbsp; &nbsp; o For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; &nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>\n&nbsp; &nbsp; o Quality unit oversight of laboratory investigations\u003Cbr>\n&nbsp; &nbsp; o Identification of adverse laboratory control trends\u003Cbr>\n&nbsp; &nbsp; o Resolution of causes of laboratory variation\u003Cbr>\n&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>\n&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA\u003Cbr>\n&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003Cbr>\n\u003Cbr>\n• Documentation to confirm the identity, cleaning, and sanitization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Paroex 0.12% chlorhexidine oral rinse, starting with lot C170FY. Specify the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in lot C170FY and each following lot.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your non-sterile aqueous-based drug product specifications did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem> until October 2020. In 2012, you had identified \u003Cem>Burkholderia cepacia\u003C\u002Fem> testing as a requirement for chlorhexidine in your OOS investigation #268. However, you did not update your finished product specifications to include this testing until after Paroex 0.12% chlorhexidine oral rinse manufactured at your facility was found contaminated with \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex in 2020.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You stated that the testing protocol submitted in the Paroex 0.12% chlorhexidine oral rinse drug application did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem>, and that the United States Pharmacopeia (USP) General Chapter &lt;1111&gt; lacks explicit reference to \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex.\u003C\u002Fp>\n\n\u003Cp>Your response states that you “followed the guidance outlined in” USP General Chapter &lt;1111&gt;. You add that “USP &lt;1111&gt; does not require testing these products for the absence of \u003Cem>B. cepacia\u003C\u002Fem>.”\u003C\u002Fp>\n\n\u003Cp>It should be noted that USP &lt;1111&gt; states that the list of specified microbes “is not necessarily exhaustive, and for a given preparation it may be necessary to test for other microorganisms.” Per USP, “the significance of other organisms recovered should be evaluated” considering multiple factors. Finally, USP &lt;1111&gt; is an informational chapter, and does not establish “requirements” or CGMP expectations.\u003C\u002Fp>\n\n\u003Cp>It is critical that firms establish scientifically sound and appropriate specifications for total count limits and freedom from objectionable microorganisms. Release testing under CGMP may include, but not be limited to, methods found in a drug application, those found in USP test chapters, and any additional tests as per 21 CFR 211.160. While USP methods are often incorporated into the release regimen, the methods are not necessarily batch release standards and may be insufficient to fully characterize the microbiological quality of a drug. USP chapters do not focus on identification of microbes, although this is essential to detect significant opportunistic pathogens in certain products. It is also important to note that USP acknowledges non-monograph tests and acceptance criteria may be necessary in addition to tests in the individual monograph. This is because it is manifestly impossible for each USP monograph to include all potential impurities and contaminants, including microbial contamination.\u003C\u002Fp>\n\n\u003Cp>While it may be impractical for each potentially objectionable microbe to be exhaustively listed in a specification, it is important that microbial flora found in your drug products be appropriately evaluated. This evaluation should include consideration of the full spectrum of patients who could receive your products based on their intended use. Such assessments should include input from qualified staff, such as individuals with strong microbiology and clinical expertise.\u003C\u002Fp>\n\n\u003Cp>Your firm continued to release drug products without BCC testing and did not update specifications until October 2020.\u003C\u002Fp>\n\n\u003Cp>Your drugs are often used in hospital or clinical settings in which patients may have a higher vulnerability to infection with \u003Cem>Burkholderia cepacia\u003C\u002Fem> and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system (including ensuring adequacy of testing functions performed by a third-party laboratory on your behalf).\u003C\u002Fp>\n\n\u003Cp>• A list of microbial specifications, including test methods, used to analyze each lot of your drug products before release to ensure they are appropriate for their intended use. Also include the formulas (ingredients; percent composition) for each drug product, and state whether you will be testing batches for BCC as part of release testing. Release testing specifications should be developed based, in part, on your formulation and validated manufacturing steps to ensure your aqueous drug products are free from BCC.\u003C\u002Fp>\n\n\u003Cp>• An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product with aqueous formulations distributed to the United States that are within expiry as of the date of this letter (if not already retrospectively tested). Include a summary of all results obtained from testing retain samples from each batch within expiry. You should test microbiological quality (total counts; identification of bioburden to detect objectionable microbes) of each batch. If such testing reveals an OOS result or otherwise indicates substandard quality, take rapid corrective actions, such as notifying customers and assessment for product recalls.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards and a CAPA plan that describes improvements to design and control.\u003C\u002Fp>\n\n\u003Cp>• Complete retrospective investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity,&nbsp;strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately validate the processes used to clean your non-dedicated, product-contact equipment.\u003C\u002Fp>\n\n\u003Cp>A. You observed residue on \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Although you documented the deviation, you did not identify the residue. You determined that no corrective action was necessary, and your cleaning procedures remained unchanged. You selected 0.12% chlorhexidine gluconate oral rinse for your cleaning validation study because you manufacture the drug product \u003Cstrong>(b)(4)\u003C\u002Fstrong> and claim that it represents other water-based rinses manufactured in the shared equipment.\u003C\u002Fp>\n\n\u003Cp>B. Adequate validation or verification studies are not always performed when introducing \u003Cstrong>(b)(4)\u003C\u002Fstrong> risk products (e.g., difficult to clean, low solubility) into the non-dedicated equipment. For example, you neither incorporated Oral Cleansing Gel, 1.7% hydrogen peroxide into your \u003Cstrong>(b)(4)\u003C\u002Fstrong>-based cleaning validation matrix nor performed cleaning verification to evaluate the cleanability of this new, more viscous product.\u003C\u002Fp>\n\n\u003Cp>C. A \u003Cstrong>(b)(4)\u003C\u002Fstrong> was \u003Cstrong>(b)(4)\u003C\u002Fstrong> when failing microbiological results were obtained during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Your cleaning procedures were not updated to reflect the need for this additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed during the validation.\u003C\u002Fp>\n\n\u003Cp>D. Your cleaning validation studies do not include all product-contact manufacturing equipment, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>E. Your procedures are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lack specificity to ensure repeatability, and do not require equipment to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure hard to reach areas are cleaned properly.\u003C\u002Fp>\n\n\u003Cp>Cleaning programs should be designed to ensure equipment is consistently and properly cleaned to prevent contamination. Inadequate removal of residues from product contact surfaces of non-dedicated manufacturing equipment during cleaning can lead to cross-contamination of drug products subsequently manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you updated cleaning procedures and commit to perform additional validations as needed. However, your response did not adequately assess the risk of potential cross-contamination and its effect on product quality for batches of drug product manufactured on this shared equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The\u003Cbr>\nassessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fp>\n\n\u003Cp>• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\u003C\u002Fp>\n\n\u003Cp>• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Recovery studies to ensure swab sample results are reliable and meaningful\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or new product.\u003C\u002Fp>\n\n\u003Cp>• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your manufacturing equipment is not designed and maintained appropriately.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon our request, you \u003Cstrong>(b)(4)\u003C\u002Fstrong> installed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Our investigators observed residue inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> after the equipment had been cleaned and sanitized. Also during our inspection, \u003Cem>Pseudomonas aeruginosa\u003C\u002Fem> was isolated from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located on another manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not easily cleanable (including sanitizable) and can contribute to contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>• You stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> would have been \u003Cstrong>(b)(4)\u003C\u002Fstrong> because it was outside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean hold time. However, you failed to explain why these residues were present after the equipment had already been cleaned and sanitized per your validated procedure.\u003C\u002Fp>\n\n\u003Cp>• You stated that the white residue was “most likely residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the hand sanitizer product.” However, after manufacturing the hand sanitizer, \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been cleaned, sanitized, and used to make another product, hydrogen peroxide rinse, 1.5% w\u002Fw. Your response lacks evidence to support your hypothesis regarding the identity of the residues.\u003C\u002Fp>\n\n\u003Cp>• You indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> will solve this insanitary design problem and commit to implement procedures to \u003Cstrong>(b)(4)\u003C\u002Fstrong> as part of routine cleaning. You did not provide any mitigating action until this CAPA intended to remediate the cleaning issue is implemented. You continue to manufacture and release drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Backflow Prevention Systems\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> connected to \u003Cstrong>(b)(4)\u003C\u002Fstrong> lacked an effective backflow prevention system to prevent contamination of drug product from downstream equipment. Upon request by our investigators, your firm swabbed the visibly contaminated and thoroughly \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Numerous microorganisms, including \u003Cem>Pseudomonas aeruginosa, Enterobacter cloacae\u003C\u002Fem>, and \u003Cem>Klebsiella oxytoca\u003C\u002Fem>, were recovered. You were unable to provide any evidence the insanitary \u003Cstrong>(b)(4)\u003C\u002Fstrong> had been changed since it was installed. Equipment used in pharmaceutical manufacturing operations should be maintained in sanitary condition, and it is critical for certain equipment to be designed with a backflow prevention system to protect drug products from contamination.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. The process flow diagram included in your response shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> also use the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> as \u003Cstrong>(b)(4)\u003C\u002Fstrong> without any mechanism to prevent backflow. The process flow diagram does not provide sufficient assurance of effective backflow prevention mechanisms to protect each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response does not evaluate drug products manufactured in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Production Oversight and Equipment Maintenance\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>In addition, your production management does not ensure the equipment used in the manufacture of drug products is suitable for its intended use and is properly maintained.\u003C\u002Fp>\n\n\u003Cp>Although the aforementioned \u003Cstrong>(b)(4)\u003C\u002Fstrong> was manifestly contaminated for an extended period, your production management failed to identify and remove the insanitary filter from use.\u003C\u002Fp>\n\n\u003Cp>Our investigators also observed packaging tape being used to seal the outside of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your employees explained that the packaging tape was being used so that the equipment would be able to hold a \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You stated that you repaired the kettle and commit to prevent unapproved maintenance activity in the future. However, there is no evidence that you performed a thorough evaluation of the current state of your manufacturing equipment. Also, you did not state how you were going to improve \u003Cstrong>(b)(4)\u003C\u002Fstrong> oversight of your facility and equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations management oversight of facilities and equipment. This plan should ensure, among other things, evaluating suitability of equipment for its intended use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• An independent, third-party review to evaluate objectively the sanitary design of your facilities and equipment, and to assess the adequacy of maintenance and control practices. Provide a detailed summary of their assessment and associated CAPA activities you will be undertaking.\u003C\u002Fp>\n\n\u003Cp>• Updated diagrams clearly identifying the \u003Cstrong>(b)(4)\u003C\u002Fstrong> located between the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the associated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, a nonconformance was not generated after the filling line mechanic found the \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;used on filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydral Dry Mouth Spray, Lot C164FT). The master filling\u002Fpackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The filter event was discussed in your out-of-specification investigation OOS-907 in response to the test results indicating \u003Cem>Burkholderia\u003C\u002Fem>, sp. contamination of the Hydral Dry Mouth Spray, Lot C164FT. The OOS-907 report confirmed that upon deconstruction of the filter housing that the filter was not connected to the cap and that product could have bypassed the filter. The OOS-907 states that the filter was not likely effective throughout the entire fill of the lot. Although the cause for the \u003Cem>Burkholderia\u003C\u002Fem> in the lot was attributed to contaminated product provided by the primary manufacturer and formula owner, you failed to adequately investigate the filter nonconformance.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response does not adequately address the observation. For example, your firm’s response indicates that your Out of Specification (OOS) procedure QSP 14.03 does not require \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no evaluation into the cause of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used on filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Hydral Dry Mouth Spray, Lot C164FT). Your firm’s response further states that you do not use \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the filling of any other products and that the Hydral Dry Mouth Spray will no longer be filled by DTI. The evaluation of nonconformances and the need for a timely investigation is essential to protecting against recurrence. Your firm has not established adequate OOS procedures to ensure the identification, documentation, evaluation, segregation and disposition of nonconforming product by DTI personnel.\u003C\u002Fp>\n\n\u003Cp>2. Failure to conduct, control and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70. Specifically, the Master Filling\u002FPackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> by the line mechanic \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Hydral Dry Mouth Spray, Lot C164FT. Your firm’s OOS-907 states that the filter was likely not effective throughout the entire fill of the lot.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate in that the corrective actions taken by your firm are not complete and appropriate to remedy the deficiencies identified on Observation 5 of the form FDA 483, Inspectional Observations. Your firm failed to adequately address the lack of process controls in the manufacture of Hydral Dry Mouth Spray. Your response states that the Hydral Dry Mouth Spray is the only product that uses the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your firm has discontinued manufacturing the product. The response is inadequate in that it does not address the underlying issue regarding the monitoring of controlled processes to ensure they remain in control. This affects all processes that can have an impact on product specifications for all products manufactured at your firm and is not limited to the Hydral Dry Mouth Spray filling operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development\u003C\u002Fa>, Q9 Quality Risk Management at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management\u003C\u002Fa>, and Q10 Pharmaceutical Quality System at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>B. cepacia\u003C\u002Fem> complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of 0.12% chlorhexidine oral rinse.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to resume manufacturing this drug for the U.S. market at this facility in the future. If you plan to resume manufacturing 0.12% chlorhexidine oral rinse for the U.S. market, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (612599). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Russell K. Riley, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Russell K. Riley at (630) 277-1908.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nOperations Div. 2 Central\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Stephen A. Erickson\n\nRecipient Title\n\nPresident and Co-Owner\n\nDental Technologies Inc.\n\n6901 N. Hamlin Avenue\n\nLincolnwood, IL 60712\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nWARNING LETTER\n\nWL # 612599\n\nNovember 30, 2021\n\nDear Mr. Erickson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Dental Technologies Inc., FEI 1413475, at 6901 N. Hamlin Avenue, Lincolnwood, Illinois from December 7, 2020, to January 20, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nAdditionally, your drug product, Paroex 0.12% chlorhexidine oral rinse, is adulterated under section 501(a)(2)(A) of the FD&C Act, 21 U.S.C. 351(a)(2)(A), in that a substance was prepared, packed, or held under insanitary conditions, whereby it may have become contaminated with filth and rendered injurious to health.\n\nUnder section 201(h) of the FD&C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\n\nThis inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\n\nDrug CGMP Violations\n\nWe reviewed your February 10, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou lack adequate investigations into failing microbiological results for both finished drug products and components.\n\nA. In October 2020, your third-party laboratory identified Burkholderia cepacia complex (BCC), specifically Burkholderia lata in Paroex 0.12% chlorhexidine oral rinse. Until prompted by FDA, your investigation failed to adequately evaluate excessive aerobic plate counts (including too numerous to count (TNTC)) and past BCC contamination events at your facility. Your investigation did not adequately address multiple potential root causes of the contamination. For example, we noted that your cleaning program was deficient. Notably, a lack of cleaning competency extended to multiple products made at your facility, and in one instance cleaning procedures had to be repeated two or more times to assure their efficacy.\n\nYou failed to implement systemic corrective actions and preventive actions (CAPA) and investigate additional lots that may have been affected.\n\nYour firm’s response, which includes your firm’s updated investigation, was inadequate.\n\n• Your investigation did not sufficiently address the TNTC levels of microorganisms in numerous Paroex batch retain samples, including the inability of the formulation to exert any meaningful inhibitory effect on microbial growth in your product.\n\n• Your investigation did not adequately explain the extreme variability of results within batches, including TNTC and passing results obtained from testing of multiple retain samples from the same batch. Also, you did not adequately describe how your future sampling strategy will be improved to provide better understanding of (b)(4).\n\n• You identified the chlorhexidine gluconate active pharmaceutical ingredient (API) as the most likely root cause of the Paroex contamination, but your investigation lacked justification for this assertion. For example:\n\no The investigation indicated the API supplier found Serratia marcescens in certain lots of their chlorhexidine gluconate API, and this caused it to be the likely source of the BCC contamination. However, you noted the API supplier, (b)(4), recalled affected lots contaminated with Serratia marcescens and your API lots met microbiological specifications. Further, your investigation lacks any indication that BCC had been isolated during chlorhexidine gluconate testing by either your supplier or your laboratory.\n\no The investigation failed to address that, in addition to the lack of data indicating the presence of BCC in your API, BCC is very different from Serratia marcescens as they are in different taxonomic classes and have significantly different phenotypic and genotypic characteristics.\n\n• Your response states your Paroex 0.12% chlorhexidine gluconate oral rinse release testing did not detect Burkholderia lata because of a low level of contamination. This conclusion is flawed since you were not testing your product for BCC at the time, and your test method was inadequate to reliably detect these microorganisms.\n\n• Your response states shared equipment was cleaned and sanitized before use, per your procedures. However, your response lacks evidence of traceability confirming that the (b)(4), identified as a potential cause of contamination, was adequately cleaned, and sanitized before use during manufacturing.\n\n• Your response acknowledges that the use of ancillary equipment is not documented in your batch records. However, you failed to include systemic corrections to your batch records and documentation systems to ensure traceability of each piece of equipment used during manufacturing, including but not limited to, their use, cleaning, sanitization, calibration, and maintenance.\n\n• You failed to adequately explain how you will systemically remediate your investigations program to ensure investigations are thorough, root causes are appropriately identified, scope of impacted products is appropriately evaluated, and CAPAs are prompt and effective.\n\nThe Paroex product owner released a public announcement on December 28, 2020, detailing the receipt of a significant number of adverse events (29) associated with the product. Affected patients who received Paroex 0.12% chlorhexidine oral rinse tested positive for Burkholderia lata. Use of the contaminated product in patients who are immunocompromised or have pre-existing respiratory conditions, including critically ill patients and patients infected with COVID-19, is especially concerning as these patients are at increased risk for serious and life-threatening infections.\n\nWe acknowledge that batches of Paroex 0.12% chlorhexidine gluconate oral rinse bearing an expiration date from June 30 to September 30, 2022, were recalled on October 27, 2020. It was not until further discussions with FDA that the recall was extended to other potentially impacted batches of Paroex 0.12% chlorhexidine gluconate oral rinse products, (b)(4), and (b)(4) drug products.\n\nIn addition, FDA collected a sample of Paroex 0.12% chlorhexidine oral rinse lot C219DQ. Our testing revealed BCC contamination and failing total counts, which further demonstrated insanitary conditions (501(a)(2)(A)) at your facility.\n\nB. Your firm invalidated failing microbiological results obtained by your third-party laboratory during stability testing of a batch of AlphaCaine topical anesthetic gel in March 2019, without scientific justification.\n\nPseudomonas aeruginosa was isolated from the product sample and your laboratory retested the product. Your investigation determined your test method to be unsuitable because “(b)(4).” After retesting with a method your laboratory determined suitable, you obtained passing results.\n\nYour investigation concluded, without adequate supporting evidence, that your third-party laboratory “may have contaminated the sample,” though they indicated no laboratory error had occurred and results were reproducible. Further, although you acknowledge your original test method for AlphaCaine topical anesthetic gel was inappropriate, your investigation determined “(b)(4).”\n\nYour firm’s response is inadequate. You failed to perform a thorough evaluation of test methods used to ensure their adequacy.\n\nIn response to this letter, provide:\n\n• Your procedures describing in-process and finished product sampling and testing. Address how you will ensure samples are representative and can detect variation within a batch. Include how testing of individual samples ((b)(4)) will be better leveraged to evaluate uniformity throughout the process.\n\n• A comprehensive and independent assessment of your manufacturing processes to determine the current state of control as well as to determine if any process remediation and new validation studies are necessary. This assessment should include, but not be limited to, a study to extensively assess intra\u002Finter-batch uniformity for all appropriate attributes of your drug products.\n\n• A comprehensive, independent assessment of your water system design, control, and maintenance. Include a description of all areas in your water system that can be stagnant.\n\n• A retrospective, independent review of all batch failures, rejected batches, returned drug products, complaints, and deviations that may have been related to microbiological contamination for the last three years.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A retrospective, independent review of all invalidated OOS results (including in-process, release, and stability testing) for products currently in the U.S. market and within expiry as of the date of this letter. Include a report summarizing the findings of the analysis, detailing the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS results conclusively or inconclusively demonstrate causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\n• A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\n\no Quality unit oversight of laboratory investigations\n\no Identification of adverse laboratory control trends\n\no Resolution of causes of laboratory variation\n\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\n\no Adequately scoping of each investigation and its CAPA\n\no Revised OOS investigation procedures with these and other remediations.\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\n• Documentation to confirm the identity, cleaning, and sanitization of the (b)(4) used in the manufacture of Paroex 0.12% chlorhexidine oral rinse, starting with lot C170FY. Specify the (b)(4) used in lot C170FY and each following lot.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYour non-sterile aqueous-based drug product specifications did not include Burkholderia cepacia until October 2020. In 2012, you had identified Burkholderia cepacia testing as a requirement for chlorhexidine in your OOS investigation #268. However, you did not update your finished product specifications to include this testing until after Paroex 0.12% chlorhexidine oral rinse manufactured at your facility was found contaminated with Burkholderia cepacia complex in 2020.\n\nYour response is inadequate. You stated that the testing protocol submitted in the Paroex 0.12% chlorhexidine oral rinse drug application did not include Burkholderia cepacia, and that the United States Pharmacopeia (USP) General Chapter \u003C1111> lacks explicit reference to Burkholderia cepacia complex.\n\nYour response states that you “followed the guidance outlined in” USP General Chapter \u003C1111>. You add that “USP \u003C1111> does not require testing these products for the absence of B. cepacia.”\n\nIt should be noted that USP \u003C1111> states that the list of specified microbes “is not necessarily exhaustive, and for a given preparation it may be necessary to test for other microorganisms.” Per USP, “the significance of other organisms recovered should be evaluated” considering multiple factors. Finally, USP \u003C1111> is an informational chapter, and does not establish “requirements” or CGMP expectations.\n\nIt is critical that firms establish scientifically sound and appropriate specifications for total count limits and freedom from objectionable microorganisms. Release testing under CGMP may include, but not be limited to, methods found in a drug application, those found in USP test chapters, and any additional tests as per 21 CFR 211.160. While USP methods are often incorporated into the release regimen, the methods are not necessarily batch release standards and may be insufficient to fully characterize the microbiological quality of a drug. USP chapters do not focus on identification of microbes, although this is essential to detect significant opportunistic pathogens in certain products. It is also important to note that USP acknowledges non-monograph tests and acceptance criteria may be necessary in addition to tests in the individual monograph. This is because it is manifestly impossible for each USP monograph to include all potential impurities and contaminants, including microbial contamination.\n\nWhile it may be impractical for each potentially objectionable microbe to be exhaustively listed in a specification, it is important that microbial flora found in your drug products be appropriately evaluated. This evaluation should include consideration of the full spectrum of patients who could receive your products based on their intended use. Such assessments should include input from qualified staff, such as individuals with strong microbiology and clinical expertise.\n\nYour firm continued to release drug products without BCC testing and did not update specifications until October 2020.\n\nYour drugs are often used in hospital or clinical settings in which patients may have a higher vulnerability to infection with Burkholderia cepacia and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\n\nIn response to this letter, provide:\n\n• A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system (including ensuring adequacy of testing functions performed by a third-party laboratory on your behalf).\n\n• A list of microbial specifications, including test methods, used to analyze each lot of your drug products before release to ensure they are appropriate for their intended use. Also include the formulas (ingredients; percent composition) for each drug product, and state whether you will be testing batches for BCC as part of release testing. Release testing specifications should be developed based, in part, on your formulation and validated manufacturing steps to ensure your aqueous drug products are free from BCC.\n\n• An action plan and timelines for conducting full microbiological testing of retain samples to determine the quality of all batches of drug product with aqueous formulations distributed to the United States that are within expiry as of the date of this letter (if not already retrospectively tested). Include a summary of all results obtained from testing retain samples from each batch within expiry. You should test microbiological quality (total counts; identification of bioburden to detect objectionable microbes) of each batch. If such testing reveals an OOS result or otherwise indicates substandard quality, take rapid corrective actions, such as notifying customers and assessment for product recalls.\n\n• A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards and a CAPA plan that describes improvements to design and control.\n\n• Complete retrospective investigations into all batches with potential objectionable microbial contamination or an OOS microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou did not adequately validate the processes used to clean your non-dedicated, product-contact equipment.\n\nA. You observed residue on (b)(4) during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Although you documented the deviation, you did not identify the residue. You determined that no corrective action was necessary, and your cleaning procedures remained unchanged. You selected 0.12% chlorhexidine gluconate oral rinse for your cleaning validation study because you manufacture the drug product (b)(4) and claim that it represents other water-based rinses manufactured in the shared equipment.\n\nB. Adequate validation or verification studies are not always performed when introducing (b)(4) risk products (e.g., difficult to clean, low solubility) into the non-dedicated equipment. For example, you neither incorporated Oral Cleansing Gel, 1.7% hydrogen peroxide into your (b)(4)-based cleaning validation matrix nor performed cleaning verification to evaluate the cleanability of this new, more viscous product.\n\nC. A (b)(4) was (b)(4) when failing microbiological results were obtained during the 0.12% chlorhexidine gluconate oral rinse cleaning validation. Your cleaning procedures were not updated to reflect the need for this additional (b)(4) performed during the validation.\n\nD. Your cleaning validation studies do not include all product-contact manufacturing equipment, such as (b)(4).\n\nE. Your procedures are (b)(4), lack specificity to ensure repeatability, and do not require equipment to be (b)(4) to ensure hard to reach areas are cleaned properly.\n\nCleaning programs should be designed to ensure equipment is consistently and properly cleaned to prevent contamination. Inadequate removal of residues from product contact surfaces of non-dedicated manufacturing equipment during cleaning can lead to cross-contamination of drug products subsequently manufactured on that equipment.\n\nWe acknowledge you updated cleaning procedures and commit to perform additional validations as needed. However, your response did not adequately assess the risk of potential cross-contamination and its effect on product quality for batches of drug product manufactured on this shared equipment.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drug products may have been released for distribution. The\n\nassessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\n• A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drug products and equipment; and all other needed remediations.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst-case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Recovery studies to ensure swab sample results are reliable and meaningful\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for drug products, processes, and equipment.\n\n4. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63)\n\nYour manufacturing equipment is not designed and maintained appropriately.\n\n(b)(4)\n\nUpon our request, you (b)(4) installed on (b)(4). Our investigators observed residue inside the (b)(4) after the equipment had been cleaned and sanitized. Also during our inspection, Pseudomonas aeruginosa was isolated from (b)(4) located on another manufacturing (b)(4). (b)(4) are not easily cleanable (including sanitizable) and can contribute to contamination.\n\nYour response is inadequate.\n\n• You stated that (b)(4) would have been (b)(4) because it was outside the (b)(4) clean hold time. However, you failed to explain why these residues were present after the equipment had already been cleaned and sanitized per your validated procedure.\n\n• You stated that the white residue was “most likely residual (b)(4) from the hand sanitizer product.” However, after manufacturing the hand sanitizer, (b)(4) had been cleaned, sanitized, and used to make another product, hydrogen peroxide rinse, 1.5% w\u002Fw. Your response lacks evidence to support your hypothesis regarding the identity of the residues.\n\n• You indicated that (b)(4) will solve this insanitary design problem and commit to implement procedures to (b)(4) as part of routine cleaning. You did not provide any mitigating action until this CAPA intended to remediate the cleaning issue is implemented. You continue to manufacture and release drug products.\n\nBackflow Prevention Systems\n\nYour (b)(4) connected to (b)(4) lacked an effective backflow prevention system to prevent contamination of drug product from downstream equipment. Upon request by our investigators, your firm swabbed the visibly contaminated and thoroughly (b)(4) and (b)(4). Numerous microorganisms, including Pseudomonas aeruginosa, Enterobacter cloacae, and Klebsiella oxytoca, were recovered. You were unable to provide any evidence the insanitary (b)(4) had been changed since it was installed. Equipment used in pharmaceutical manufacturing operations should be maintained in sanitary condition, and it is critical for certain equipment to be designed with a backflow prevention system to protect drug products from contamination.\n\nYour response is inadequate. The process flow diagram included in your response shows (b)(4) and (b)(4) also use the same (b)(4) as (b)(4) without any mechanism to prevent backflow. The process flow diagram does not provide sufficient assurance of effective backflow prevention mechanisms to protect each of the (b)(4) associated with the (b)(4). Your response does not evaluate drug products manufactured in (b)(4) and (b)(4).\n\nProduction Oversight and Equipment Maintenance\n\nIn addition, your production management does not ensure the equipment used in the manufacture of drug products is suitable for its intended use and is properly maintained.\n\nAlthough the aforementioned (b)(4) was manifestly contaminated for an extended period, your production management failed to identify and remove the insanitary filter from use.\n\nOur investigators also observed packaging tape being used to seal the outside of a (b)(4) on (b)(4). Your employees explained that the packaging tape was being used so that the equipment would be able to hold a (b)(4).\n\nYour response is inadequate. You stated that you repaired the kettle and commit to prevent unapproved maintenance activity in the future. However, there is no evidence that you performed a thorough evaluation of the current state of your manufacturing equipment. Also, you did not state how you were going to improve (b)(4) oversight of your facility and equipment.\n\nIn response to this letter, provide:\n\n• Your CAPA plan to implement (b)(4) operations management oversight of facilities and equipment. This plan should ensure, among other things, evaluating suitability of equipment for its intended use, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\n• An independent, third-party review to evaluate objectively the sanitary design of your facilities and equipment, and to assess the adequacy of maintenance and control practices. Provide a detailed summary of their assessment and associated CAPA activities you will be undertaking.\n\n• Updated diagrams clearly identifying the (b)(4) located between the (b)(4) and the associated (b)(4).\n\nMedical Device Quality System Violations\n\n1. Failure to establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, a nonconformance was not generated after the filling line mechanic found the (b)(4) used on filling line (b)(4) (Hydral Dry Mouth Spray, Lot C164FT). The master filling\u002Fpackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the (b)(4).\n\nThe filter event was discussed in your out-of-specification investigation OOS-907 in response to the test results indicating Burkholderia, sp. contamination of the Hydral Dry Mouth Spray, Lot C164FT. The OOS-907 report confirmed that upon deconstruction of the filter housing that the filter was not connected to the cap and that product could have bypassed the filter. The OOS-907 states that the filter was not likely effective throughout the entire fill of the lot. Although the cause for the Burkholderia in the lot was attributed to contaminated product provided by the primary manufacturer and formula owner, you failed to adequately investigate the filter nonconformance.\n\nYour firm’s response does not adequately address the observation. For example, your firm’s response indicates that your Out of Specification (OOS) procedure QSP 14.03 does not require (b)(4). There was no evaluation into the cause of the (b)(4) used on filling line (b)(4) (Hydral Dry Mouth Spray, Lot C164FT). Your firm’s response further states that you do not use (b)(4) for the filling of any other products and that the Hydral Dry Mouth Spray will no longer be filled by DTI. The evaluation of nonconformances and the need for a timely investigation is essential to protecting against recurrence. Your firm has not established adequate OOS procedures to ensure the identification, documentation, evaluation, segregation and disposition of nonconforming product by DTI personnel.\n\n2. Failure to conduct, control and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70. Specifically, the Master Filling\u002FPackaging batch record for Hydral Dry Mouth Spray, Lot C164FT section 2.2.5 requires the use of the (b)(4). The (b)(4) by the line mechanic (b)(4) for the Hydral Dry Mouth Spray, Lot C164FT. Your firm’s OOS-907 states that the filter was likely not effective throughout the entire fill of the lot.\n\nYour firm’s response is inadequate in that the corrective actions taken by your firm are not complete and appropriate to remedy the deficiencies identified on Observation 5 of the form FDA 483, Inspectional Observations. Your firm failed to adequately address the lack of process controls in the manufacture of Hydral Dry Mouth Spray. Your response states that the Hydral Dry Mouth Spray is the only product that uses the (b)(4) and that your firm has discontinued manufacturing the product. The response is inadequate in that it does not address the underlying issue regarding the monitoring of controlled processes to ensure they remain in control. This affects all processes that can have an impact on product specifications for all products manufactured at your firm and is not limited to the Hydral Dry Mouth Spray filling operations.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq8r2-pharmaceutical-development, Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq9-quality-risk-management, and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq10-pharmaceutical-quality-system.\n\nObjectionable Organisms\n\nFor further information regarding the significance of B. cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of 0.12% chlorhexidine oral rinse.\n\nIn response to this letter, clarify whether you intend to resume manufacturing this drug for the U.S. market at this facility in the future. If you plan to resume manufacturing 0.12% chlorhexidine oral rinse for the U.S. market, notify this office before resuming your operations.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with application sponsors and product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility\u002Fin connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (612599). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Russell K. Riley, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Russell K. Riley at (630) 277-1908.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nOperations Div. 2 Central","Dental Technologies Inc.","dental-technologies-inc-612599-11302021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdental-technologies-inc-612599-11302021","2026-10-26T08:08:22.930897+00:00","2021-12-14","612599","Mr. Stephen A. Erickson","2026-08-20T02:20:38.474+00:00","UPS","2021-11-30",{"id":114,"raw":115,"subject":120,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":130,"body_fetched_at":131,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},2066,[116,117,118,38,119,13,13,13],"\u003Ctime datetime=\"2023-06-06T13:20:00Z\">06\u002F06\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-05-25T04:00:00Z\">05\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Firhythm-technologies-inc-643474-05252023\">iRhythm Technologies, Inc.\u003C\u002Fa>","Medical Devices\u002FAdulterated\u002FQuality System Regulation (QSR) \u003Cbr \u002F>\r\n","Medical Devices\u002FAdulterated\u002FQuality System Regulation (QSR)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Quentin S. Blackford\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>iRhythm Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>699 8th Street, Suite 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Francisco\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:quentin.blackford@irhythmtech.com\"> quentin.blackford@irhythmtech.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643474\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMay 25, 2023\u003Cbr>\n\u003Cbr>\niRhythm Technologies, Inc.\u003Cbr>\n6550 Katella Ave\u003Cbr>\nCypress, CA 90630\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Blackford,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 6550 Katella Ave in Cypress, CA on July 25 through August 12, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Zio AT System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. As stated in the Zio AT System indications for use, the system is intended to continuously record and report patient symptomatic and asymptomatic cardiac events and continuous electrocardiogram (ECG) information. After wear, a final report of the entire ECG recording is generated. The ZEUS software system is a component of the Zio AT system and supports the capture, reporting, and analysis of arrhythmia events. The reports are provided to a reviewer to render a diagnosis. Therefore, the reports are components of the device system. Because Zio AT System (“Zio AT”) is intended for use in the diagnosis of disease, the Zio AT system, including its components, is a device within the meaning of section 201(h).\u003C\u002Fp>\n\n\u003Cp>We received responses from you dated September 2, 2022, October 13, 2022, November 04, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You currently have clearance for the Zio QX ECG Monitoring under K163512 for the following indications:\u003C\u002Fp>\n\n\u003Cp>The Zio QX ECG Monitoring System is intended to capture, analyze and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram (ECG) information for long-term monitoring. While continuously recording patient ECG, both patient-triggered and automatically detected arrhythmia events are transmitted to a monitoring center for reporting. After wear, a final report is generated based on beat-to-beat information from the entire ECG recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. The reports are provided for review by the intended user to render a diagnosis based on clinical judgment and experience. It is not intended for use on critical care patients.\u003C\u002Fp>\n\n\u003Cp>Thus, your device was cleared under K163512 for long-term monitoring of arrhythmia events for non-critical care patients where real-time monitoring is not needed as reporting timeliness is not consistent with life-threatening arrhythmias. However, your marketing materials and other documentation, such as the document titled “Zio AT Notification Criteria,” and your website (https:\u002F\u002Fwww.irhythmtech.com\u002Fproviders\u002Fzio-service\u002Fzio-monitors; last accessed February 28, 2023), state that the Zio AT Patch System is intended for “near real-time monitoring” as a “mobile cardiac telemetry monitor,” can provide notifications “immediately,” and that it is intended for “high-risk patients.” The claim that the device is intended as a mobile cardiac telemetry monitor implies this device is intended for high-risk patients and near real-time monitoring.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As explained in Section A.1.4 of the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (“510(k) Modifications Guidance”) in general, describing a new patient population “could significantly affect the safety and effectiveness…” and thus likely requires a new 510(k). Your firm’s labeling describes a new patient population, for example, by using the term “near real-time reporting” and “high-risk,” instead of non-critical care. This change could significantly affect the safety or effectiveness of the device because it suggests that the device is intended for a new patient population – high-risk patients. High risk patients need near real-time monitoring because they are more likely to have a life-threatening arrhythmia, which requires timely treatment to prevent serious injury or death. Accordingly, these changes required the submission of a new 510(k).\u003C\u002Fp>\n\n\u003Cp>Your response dated September 2, 2022, stated that your firm opened several Corrective and Preventative Actions investigations. Based on the outcome of your CAPA investigations, your firm proposed several labeling changes, such as removing the term “high-risk,” and replacing the phrase “near real-time monitoring” with “near real time cardiac event monitoring.” Your responses are inadequate because, even with your proposed changes, your labeling still represents a major change or modification in intended use requiring submission of a new 510(k) under 807.81(a)(3). “Near real time cardiac event monitoring” implies that the device provides monitoring for high-risk patients that require clinically actionable, timely notification of life-threatening arrythmias to prevent serious injury or death.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm made changes to the device without submission of a new 510(k). In response to our inspection, your firm provided more detail on the changes made to the device. Based on the information in your responses, the following changes were made to the device that require a new 510(k) submission:\u003C\u002Fp>\n\n\u003Cp>a. Your document titled “Zio AT (K163512) Design Changes, Brief Summary” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Hardware and Firmware Design Changes” identifies hardware and firmware changes that raise new risks including, but not limited to, changes in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and updating \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your device including the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Specifically, these changes can affect the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the device (i.e., device \u003Cstrong>(b)(4)\u003C\u002Fstrong> and device \u003Cstrong>(b)(4)\u003C\u002Fstrong>) that would require new testing to support your assertion that the device’s safety and effectiveness is unaffected. These changes can result in potential \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and may affect the basic safety of the device. According to Table B (technology, engineering, and performance changes) in the 510(k) Modifications Guidance, Question B5.2 should be answered “yes” because these changes raised new or significantly modified risks. Because these changes would require new \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing and could significantly affect safety or effectiveness, a new 510(k) must be submitted for this change.\u003C\u002Fp>\n\n\u003Cp>b. “Zio AT (K163512) Design Changes, Brief Summary” describes a change to your device made in September 2019, “Improve \u003Cstrong>(b)(4)\u003C\u002Fstrong>: the algorithm in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was adjusted based on available data to improve \u003Cstrong>(b)(4)\u003C\u002Fstrong> performance for \u003Cstrong>(b)(4)\u003C\u002Fstrong> events that meet \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;criteria. There were no changes to the algorithm that would significantly affect any clinical outcome.” Changes to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> algorithm can impact the accuracy of the detected arrhythmias, and testing would be needed to support that the algorithm’s performance is unaffected by the change. A change in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the algorithm could significantly impact safety or effectiveness, such as through missed or incorrect detection of events or arrhythmias, which could lead to patient injury due to lack of treatment. Question B5 in the 510(k) Modifications Guidance should have been answered “yes” because the change was to performance specifications. Subsequently, question B5.3 should have been answered “yes,” because the modification to the algorithm necessitated clinical validation data in order to ensure the performance of the device was maintained, using relevant device-specific data from patients. Therefore, a new 510(k) must be submitted.\u003C\u002Fp>\n\n\u003Cp>Your responses are inadequate because they fail to address how the above changes could not significantly affect the safety or effectiveness of the Zio AT System.\u003C\u002Fp>\n\n\u003Cp>Therefore, the Zio AT System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). Therefore, the kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>We also note that your responses identified other changes to the device. However, the level of information provided in your responses was insufficient to determine whether these changes to the device also require clearance in a new 510(k) submission. Please reach out to the FDA review team to discuss the changes identified in your previous responses. Further, please discuss with the FDA review team any other changes made to the device since K163512 not noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Labeling Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Zio AT System is also misbranded within the meaning of section 502(f)(1) of the Act, 21 U.S.C. § 352(f)(1), in that the labeling for the device fails to bear adequate directions for the purpose for which it is intended. The Zio AT System does not meet the criteria for an exemption from section 502(f)(1) of the Act under 21 CFR 801 subpart D. 21 CFR 801.109 expressly exempts a prescription device from section 501(f)(1) if the device meets certain criteria.\u003C\u002Fp>\n\n\u003Cp>As a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm implemented a transmission limit on how many times the Zio AT System transmits data. As a result, the device is only able to transmit 100 patient-triggered and 500 automatically detected arrhythmia events. Once the transmission limit is reached, the patient’s data stops being transmitted for review\u002Freporting. Thus, when the transmission limit is hit, the device can no longer be used for its intended purpose of transmitting patient ECG for reporting. Further, when the transmission limit is hit, the device can no longer provide near-real time monitoring for high-risk patients.\u003Cbr>\n\u003Cbr>\nThe Zio AT System does not meet the requirements for exemption from section 502(f)(1) of the Act under 21 CFR 801.109 because the device fails to include adequate directions for use for the physician related to the transmission limit. Specifically, the directions for use fail to include information related to the “indications…[and]…methods,…under which practitioners…can use the device safely and for the purposes for which it is intended, including all purposes for which it is advertised or represented.” See 21 CFR 801.109. During our inspection, it was revealed that the labeling does not inform the physician of the existence of a transmission limit, when the transmission limit is reached, or include any information about the action a physician should take if the device reaches the transmission limit. While your firm does provide a small alert on the report when the device is nearing, or has met, the transmission limit, there is no description of the what the alert means, or next steps the physician should take. In your response, your firm explained that, when “a wireless transmission threshold is approached, the [healthcare provider] is notified and given the option to replace the patch for the remainder of the wear period.” This is not adequate because an understanding of the transmission limitations by the healthcare provider is needed prior to transmission limit being reached to effectively use the device as intended.\u003C\u002Fp>\n\n\u003Cp>Further, there is no information provided to the patient that a transmission limit exists, no notification to the patient when the transmission limit is reached, and no information provided to the patient about what to do when the transmission limit is reached. In response, your firm proposed sending a new device directly to the patient in instances when the prescribing clinician could not be contacted. However, this proposed corrective action is inadequate to address the issue because there is still no information provided to the patient about the transmission limit, or what do with the newly acquired device. This information is needed for the patient to be able to use the device safely and for the purposes for which it is intended. See 21 CFR 801.5. Therefore, the Zio AT System is misbranded under section 502(f)(1) because its labeling fails to bear adequate directions related to the device’s transmission limit. Your response did not address this issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; A. You failed to identify the actions needed to correct and prevent recurrence of quality problems despite being aware of them for years. Specifically:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; &nbsp; i. You were aware of a negative trend or critical customer complaints since at least 2019 but failed to initiate a CAPA as provided by your CAPA procedures.\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nSection 6.3 of your firm’s Corrective and Preventive Action procedure states that a CAPA may be initiated for reasons including but not limited to, a negative trend or critical customer complaints. Within your CAPA procedures, critical is defined as “[a]ny nonconformance or noncompliance that will or already has adversely affected product performance meeting specifications, safety, therapeutic efficacy, or regulatory requirements.” Additionally, Section 6.1 states that the purpose of the CAPA procedure is to “[e]nsure nonconformity and quality problems that are systemic or critical in nature are promptly considered and addressed.”\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm knew that the device’s transmission limit, which was explained in the previous section, was resulting in data not being transmitted. Records reviewed during our inspection indicate that your firm has been aware of customer complaints related to this issue since at least 2019. Specifically, our inspection found a significant number of complaints regarding this issue, which revealed two deaths as well as significant arrythmias that were not reported to physicians. As designed, the device transmission limit should only be reached in rare cases. However, the customer complaints reviewed during the inspection reveal that the device was hitting the transmission limit more often than expected. When the transmission limit is reached more often than expected, it introduces a nonconformance. However, your firm failed to initiate a CAPA based on negative trends or critical customer complaints, to “[e]nsure nonconformity and quality problems that are systemic or critical in nature are promptly considered and addressed,” as required by your firm’s CAPA procedure.\u003C\u002Fp>\n\n\u003Cp>Your response maintains this is a design limitation and not a nonconformance, and that no visual cues will be added. As noted above, when the design limitation is reached more often than expected, it introduces a nonconformance. In response, your firm initiated a CAPA. The adequacy of your firm’s responses cannot be determined at this time because they do not provide sufficient details to fully assess the adequacy of your corrective actions. Following our inspection, your firm initiated a CAPA and submitted a correction report under 21 CFR part 806 (806 report) to the Agency. However, the CAPA your firm provided as part of the 806 report lacked sufficient detail to determine whether the CAPA has been properly conducted. In response to this letter, please provide more detail on your firm’s CAPA.\u003C\u002Fp>\n\n\u003Cp>Further, the cleared indications of your device include continuous recording of ECG information for monitoring, manual, and automatic transmission of arrhythmia events. As described above in the Unapproved Device Violations section, your current marketing materials indicate that the Zio AT System is intended for high-risk patients and near real-time monitoring. When the transmission limit is exceeded more than rarely, this introduces a nonconformance because the device is unable to transmit ECG information for monitoring and is not remotely capable of delivering near-real time monitoring for high-risk patients.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; &nbsp; ii. Your firm has known since 2017 that patient data is held inaccessible within your Zeus system, thereby not allowing it to be properly analyzed for potential corrective action and you failed to initiate a CAPA as provided by your CAPA procedures.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 6.3 of your firm’s Corrective and Preventive Action procedure states that a CAPA may be initiated for reasons including but not limited to, feedback that identifies problematic performance with process operations, or “product, process, or system nonconformance…”\u003C\u002Fp>\n\n\u003Cp>However, your firm failed to initiate a CAPA when you were aware that patient data, including significant arrythmias requiring physician notification (see Z ticket\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> records \u003Cstrong>(b)(4)\u003C\u002Fstrong> noting Atrial Fibrillation and \u003Cstrong>(b)(4)\u003C\u002Fstrong> noting Bradycardia), was being held inaccessible within your Zeus system. Specifically, your firm was aware that when the patient’s device registration is incomplete, the patient’s ECG information is still collected but cannot be read by anyone. When the patient’s data can no longer be analyzed and reported, the device can no longer be used for the purpose for which it is intended, which is a nonconformance. Since at least 2017, your firm has been aware of this issue where your clinical care team cannot access the patient’s data. Our inspection confirmed 39 examples from a list of over \u003Cstrong>(b)(4)\u003C\u002Fstrong> Z tickets where this problem occurred.\u003C\u002Fp>\n\n\u003Cp>In your initial response, you claim that this is not a nonconformance because the patient registration information is required based on IDTF requirements related to Medicare billing. This does not address the nonconformance. As noted above, when quality data is held inaccessible within the Zeus system where it cannot be analyzed and reported, the device can no longer be used for the purpose for which it is intended.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time because they do not provide sufficient details to fully assess the adequacy of your corrective actions. In your response, you noted that your firm initiated a CAPA. However, the CAPA your firm provided lacked sufficient detail to determine whether the CAPA has been properly conducted. For example, the provided CAPA investigation does not include an “identification of the actual failure (not to be confused with the reported observation),” as required by your CAPA procedure. Additionally, the provided CAPA investigation does not include distribution tracking, otherwise known as “\u003Cstrong>(b)(4)\u003C\u002Fstrong> information,” as required by your CAPA procedure. As your procedure notes, this information is necessary to capture “the known extend of the identified issue in order to contain or correct the issue.” In response to this letter, please provide more detail on your firm’s CAPA.\u003C\u002Fp>\n\n\u003Cp>We also acknowledge that based on the outcome of that CAPA, your firm has committed to a voluntary recall that would provide notification to doctors that monitoring cannot begin until the patient registration is completed. On September 1, 2022, your firm initiated this recall. Your firm submitted an 806 report to the Agency on October 5, 2022. We provided a response to your 806 report separately. Please continue to provide status updates with respect to your recall (RES 90954) to oradevices3recalls@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. You failed to conduct a health hazard evaluation (HHE) when required by your CAPA procedure.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection found that your firm did not perform an HHE when required by your CAPA procedure. When an unanticipated issue arises which affects product in the field, your firm’s procedure requires you to perform an HHE to evaluate the health hazard presented by the issue. “Unanticipated” is defined to include a new failure mode.\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform an HHE when it became aware of the error titled “Activation Time Mismatch.” During a CAPA investigation, you identified the “Activation Time Mismatch” error, in which prior patient data was not fully erased from the device prior to the device’s reuse. The CAPA investigation showed that this issue has the potential for adverse effect on product quality and is a risk that is not identified in an existing risk assessment document. As this was an unanticipated risk identified in this CAPA record, an HHE was required.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. Your response states that your firm’s process about when to escalate a CAPA to an HHE was not clear. As such, CAPA procedural updates were made, and training was performed. Specifically, you updated your CAPA to include the statement, “The issue will be assessed… [in accordance with the Health Hazard Evaluation Procedure], to determine if the criteria for an HHE has been met, and whether field action is required.” Your firm also conducted an HHE for the Activation Time Mismatch error, as required by your CAPA procedures. In addition, your firm conducted several other HHEs. It is important that the HHE be performed in accordance with your firm’s Risk Management SOP (00010) because the outcome of the HHE is used to determine some of your firm’s corrective and\u002For preventative actions.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, based on FDA’s own calculations, these HHEs do not appear to be conducted in accordance with your Risk Management SOP (SOP0010). For example, when conducting HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>, it appears your firm failed to properly calculate the probability of occurrence of the potential safety issue.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your miscalculation underestimated the likelihood of someone being injured. According to your updated CAPA procedure, the difference in the occurrence rating for HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> would have required an update to your risk documentation and the HHE shows that this was not selected. Further, when conducting HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm failed to apply the Health Risk Table in your Risk Management SOP (SOP0010).\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> This miscalculation is significant because this HHE procedure is used to assess whether or not you will initiate field action.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, per the requirements of 21 CFR 820.198.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Events meeting the definition of a complaint under 820.3(b) were not reviewed or evaluated to determine whether the complaint represents an event which for which reporting is required under 21 CFR part 803, Medical Device Reporting. Specifically, a review of your Service Monitoring Z tickets found complaints regarding deficiencies in the reliability of your device that your firm failed to review or evaluate.\u003C\u002Fp>\n\n\u003Cp>As the Zio AT System monitors a patient’s ECG, it may auto-generate tickets in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system (“Service Monitoring Z tickets”) for follow-up. You specified that Service Monitoring Z tickets are not reviewed or evaluated because they are not deemed a problem. However, some of the Service Monitoring Z tickets reviewed during the inspection meet the definition of a complaint under 820.3(b). Accordingly, they must be evaluated for potential reporting under Part 803, Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses noted at the top of this letter cannot be determined at this time because your corrective actions are still in progress. Your responses acknowledge that your firm did not review or evaluate complaints for Service Monitoring Z tickets appropriately. Your investigation found that your firm failed to evaluate the Service Monitoring Z tickets. In response, you stated that procedural updates have been made and training has been conducted. You also stated that you have made necessary updates to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and Z ticket template forms. Additionally, you committed to retrospectively review complaints per the newly established criteria and your March 2023 response estimates this may be completed by 8\u002F31\u002F2023. The verification of the effectiveness of your corrective action is also outstanding. A follow up inspection will be required to assure that your corrective actions are adequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to validate a process to a high degree of assurance per the requirements of 21 CFR 820.75.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, when Gateway PCBAs were returned, they were reused, and per procedure Zio AT Gateway PCBA Initialize and Test, the memory needs to be cleared. However, the AT Gateway \u003Cstrong>(b)(4)\u003C\u002Fstrong> process did not include a verification step to confirm that previous patient data was successfully erased. This resulted in distribution of Zio AT product with prior patient data remaining on it, which led to a complaint.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to this observation appears to be adequate. Your response acknowledges that the process validation failed to implement a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that validates the complete erasure of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and that the manufacturing work instructions did not include a step to verify this erasure. Your response further states this deficiency extends beyond design changes and is a systemic issue with process validation and \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification in general.\u003C\u002Fp>\n\n\u003Cp>We acknowledge the findings from the testing you performed on the Gateway process, and that you have determined R peak data (i.e., data used to determine potential arrythmias) from a prior patient would not be stored on the PCB, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We understand you committed to contain this issue by only using virgin Gateway PCBAs until the related corrective action is complete. As part of your CAPA, you developed and implemented a process to verify that all prior patient data is properly erased. You have updated related procedures and have revalidated this process. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Zio AT system is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to submit a report to FDA no later than 30 calendar days after the day that iRhythm Technologies, Inc., received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For example,\u003C\u002Fp>\n\n\u003Cp>a. The information included for the MDRs 3007208829‐2022‐00041 (corresponding to Complaint COMP‐2021‐6388) and 3007208829‐2022‐00055 (corresponding to Complaint COMP‐2021‐6385) describes MDR reportable events where a patient passed away while using the Zio AT system. iRhythm Technologies, Inc., became aware of each of the two events on October 25, 2021. However, FDA did not receive these MDRs until September 24, 2022, and December 3, 2022, respectively, which is beyond the required the 30‐calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>b. The information included for the MDR 3007208829‐2022‐00048 (corresponding to Complaint COMP‐2022‐2077) describes an MDR reportable event where the patient experienced ventricular tachycardia and syncope while using the Zio AT system and was hospitalized. iRhythm Technologies, Inc., became aware of the event on April 27, 2022. FDA did not receive this MDR until September 24, 2022, which is beyond the required the 30‐calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>As noted previously in this letter, based on your marketing materials, website, and other documentation, the Zio AT System is intended for “near real-time monitoring” and “high-risk patients,” even though the Zio AT System is not cleared for these indications. When used in this patient population, the Zio AT System may cause or contribute to serious injury or death because life-threatening arrhythmias may not receive timely treatment.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated September 1, 2022, October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, and they appear to be adequate. The responses indicate that your firm conducted a retrospective review of a total of 999,328 complaints received from March 1, 2019, through August 6, 2022, for reportability, resulting in the submission of 13 MDRs. Your firm’s response dated March 1, 2023, notes that your firm has completed all the planned corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to report an MDR for an event where your device has malfunctioned and is likely to cause or contribute to death or serious injury if this malfunction recurred, per the requirements of 21 CFR Part 803.50(a)(2).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, in complaints COMP-2021-1687, COMP-2021-2077 and COMP-2021-5397, similar to the complaints discussed in #1 above, the transmission limit was reached prior to occurrence of a significant arrythmia; therefore, these events were not transmitted to the prescribing physician until the final wear-period report was generated.\u003C\u002Fp>\n\n\u003Cp>The Zio AT System malfunctioned when the Zio AT System hit its transmission threshold and stopped submitting data that is used to determine potential arrythmias. This failure meets the definition of a reportable malfunction, as defined in 21 CFR 803.3. This malfunction is likely to cause or contribute to death or serious injury for the reasons discussed in #1 above. However, these complaints were coded as unreportable malfunctions and no MDR was filed.\u003C\u002Fp>\n\n\u003Cp>Each of the referenced malfunctions represents an MDR reportable event and a malfunction MDR for each complaint (COMP‐2021‐1687 and COMP‐2021‐5397) was required to be submitted within the 30‐calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated September 1, 2022, October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, and we were unable to determine the adequacy of your response. The responses indicate that your firm conducted a retrospective review of a total of 999,328 complaints received from March 1, 2019, through August 6, 2022, for reportability, resulting in the submission of 13 MDRs. However, your firm failed to submit an MDR for the following complaints: COMP‐2021‐1687 and COMP‐2021‐5397. Your firm should submit the MDRs for the previously mentioned complaints and provide a rationale for why they were missed in your retrospective review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For example, the following documents were collected during the inspection and were reviewed collectively as iRhythm Technologies, Inc.'s MDR procedure:\u003C\u002Fp>\n\n\u003Cp>• Document titled “Complaint Handling”, Document# SOP0021, Rev. 07, dated 02‐July‐2021, which applies to customer complaints regarding products provided by\u003Cbr>\niRhythm Technologies, Inc.\u003C\u002Fp>\n\n\u003Cp>• Document titled “Adverse Event Reporting”, Document# SOP0023, Rev. 10, dated 05‐July‐2022, which defines the process for global post‐market reporting of adverse events and applies to all medical device manufactured by iRhythm Technologies, Inc. placed on the market.\u003C\u002Fp>\n\n\u003Cp>After reviewing the MDR procedure, the following was noted:\u003C\u002Fp>\n\n\u003Cp>A. Your MDR procedure fails to establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\u003C\u002Fp>\n\n\u003Cp>For example, the procedure omits the definitions of the terms “serious injury” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>B. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form;\u003C\u002Fp>\n\n\u003Cp>b. A process for submitting supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\u003C\u002Fp>\n\n\u003Cp>c. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, your procedures do not indicate which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your firm’s response dated September 1, 2022, includes copies of the revised procedural documents titled “Complaint Handling”, Document# SOP0021, Rev.08, dated 29‐Aug‐2022 and “Adverse Event Reporting”, Document# SOP0023, Rev. 11, dated 26‐Aug‐2022. However, a collective review of each revised document noted the following:\u003C\u002Fp>\n\n\u003Cp>1. The revised MDR procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). The revised procedure omits the definition of the term “reasonably suggests” found in 803.20(c)(1). The exclusion of the definition for this term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>2. The revised procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\n\n\u003Cp>a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>\nb. How your firm will ensure that all information reasonably known to you is submitted for each reportable event. Specifically, your procedure does not provide instructions regarding which sections of the Form 3500A will need to be completed to include all reportable information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\u003C\u002Fp>\n\n\u003Cp>Your firm’s responses dated October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, didn’t provide any new information regarding the MDR procedural deficiencies listed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 643474 when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at\u003Cbr>\nLauren.Priest@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, M.D., Director\u003Cbr>\nOHT2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh, Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nMr. Mazi A. Kiani, Senior Vice President of Quality and Regulatory, mazi.kiani@irhythmtech.com\u003Cbr>\nMr. Mark W. Hughes, VP Manufacturing, mark.hughes@irhythmtech.com for\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Your procedures define a Z ticket as a detailed description of a customer’s feedback, problem, or question which are used to track and solve customer issues within \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> For example, Section 6.4 of your updated CAPA procedure states “If the risk is documented, to whether the analysis remains accurate. If changes are required (e.g., increase\u002Fdecrease in severity, probability of occurrence, risk index), update to risk documentation will become an action of the CAPA plan. If determined that the risk is not documented (e.g., identification of a new process failure mode, hazard, harm, cause, etc.), update to risk documentation will become an action of the CAPA plan.” Additionally, Section 9.2 of your updated HHE procedure states that [b]ased on the outcome of the HHE, the Team provides recommendations for next steps. Included with these recommendations are either rationale, or a description of the actions being recommended, as appropriate.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Your firm provided the actual calculations used to explain the probability level chosen. In “HHE-\u003Cstrong>(b)(4)\u003C\u002Fstrong> Zio AT Registration,” you state “\u003Cstrong>(b)(4)\u003C\u002Fstrong> may experience a moderate injury.” This is incorrect; \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> or to convert to a percentage: \u003Cstrong>(b)(4)\u003C\u002Fstrong>. When compared to your Risk Management procedure, using your Risk Level Matrix, your miscalculation led you to choose “Low” risk whereas the correct calculation would have led you to “Medium” risk category. More specifically, your original risk calculation was&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> 2. However, if calculated correctly, it would have been \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This would have required an update to your risk documentation per your updated procedures.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Your firm’s SOP0010 procedure includes a Health Risk Table. This includes probability levels, which are associated with a range (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> (between \u003Cstrong>(b)(4)\u003C\u002Fstrong>). In contrast, the HHE probability levels of the hazards associated with use of the product shown in the Health Risk Table only specify a single probability of occurrence level, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Furthermore, several of the levels do not correspond to those in&nbsp;SOP0010. For example, level \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the HHE is described as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, whereas \u003Cstrong>(b)(4)\u003C\u002Fstrong> in SOP0010 is&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. While \u003Cstrong>(b)(4)\u003C\u002Fstrong> is greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, this level does not adequately describe that the risk is for \u003Cem>any\u003C\u002Fem> probability that is greater than \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, the Health Risk Table defined by SOP0010 was not used in your HHE.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Quentin S. Blackford\n\nRecipient Title\n\nPresident and CEO\n\niRhythm Technologies, Inc.\n\n699 8th Street, Suite 600\n\nSan Francisco, CA 94103\n\nUnited States\n\nquentin.blackford@irhythmtech.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643474\n\nMay 25, 2023\n\niRhythm Technologies, Inc.\n\n6550 Katella Ave\n\nCypress, CA 90630\n\nDear Mr. Blackford,\n\nDuring an inspection of your firm located at 6550 Katella Ave in Cypress, CA on July 25 through August 12, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Zio AT System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. As stated in the Zio AT System indications for use, the system is intended to continuously record and report patient symptomatic and asymptomatic cardiac events and continuous electrocardiogram (ECG) information. After wear, a final report of the entire ECG recording is generated. The ZEUS software system is a component of the Zio AT system and supports the capture, reporting, and analysis of arrhythmia events. The reports are provided to a reviewer to render a diagnosis. Therefore, the reports are components of the device system. Because Zio AT System (“Zio AT”) is intended for use in the diagnosis of disease, the Zio AT system, including its components, is a device within the meaning of section 201(h).\n\nWe received responses from you dated September 2, 2022, October 13, 2022, November 04, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, concerning our investigator(s)’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\nYou currently have clearance for the Zio QX ECG Monitoring under K163512 for the following indications:\n\nThe Zio QX ECG Monitoring System is intended to capture, analyze and report symptomatic and asymptomatic cardiac events and continuous electrocardiogram (ECG) information for long-term monitoring. While continuously recording patient ECG, both patient-triggered and automatically detected arrhythmia events are transmitted to a monitoring center for reporting. After wear, a final report is generated based on beat-to-beat information from the entire ECG recording. It is indicated for use on patients 18 years or older who may be asymptomatic or who may suffer from transient symptoms such as palpitations, shortness of breath, dizziness, light-headedness, pre-syncope, syncope, fatigue, or anxiety. The reports are provided for review by the intended user to render a diagnosis based on clinical judgment and experience. It is not intended for use on critical care patients.\n\nThus, your device was cleared under K163512 for long-term monitoring of arrhythmia events for non-critical care patients where real-time monitoring is not needed as reporting timeliness is not consistent with life-threatening arrhythmias. However, your marketing materials and other documentation, such as the document titled “Zio AT Notification Criteria,” and your website (https:\u002F\u002Fwww.irhythmtech.com\u002Fproviders\u002Fzio-service\u002Fzio-monitors; last accessed February 28, 2023), state that the Zio AT Patch System is intended for “near real-time monitoring” as a “mobile cardiac telemetry monitor,” can provide notifications “immediately,” and that it is intended for “high-risk patients.” The claim that the device is intended as a mobile cardiac telemetry monitor implies this device is intended for high-risk patients and near real-time monitoring.1 As explained in Section A.1.4 of the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device2 (“510(k) Modifications Guidance”) in general, describing a new patient population “could significantly affect the safety and effectiveness…” and thus likely requires a new 510(k). Your firm’s labeling describes a new patient population, for example, by using the term “near real-time reporting” and “high-risk,” instead of non-critical care. This change could significantly affect the safety or effectiveness of the device because it suggests that the device is intended for a new patient population – high-risk patients. High risk patients need near real-time monitoring because they are more likely to have a life-threatening arrhythmia, which requires timely treatment to prevent serious injury or death. Accordingly, these changes required the submission of a new 510(k).\n\nYour response dated September 2, 2022, stated that your firm opened several Corrective and Preventative Actions investigations. Based on the outcome of your CAPA investigations, your firm proposed several labeling changes, such as removing the term “high-risk,” and replacing the phrase “near real-time monitoring” with “near real time cardiac event monitoring.” Your responses are inadequate because, even with your proposed changes, your labeling still represents a major change or modification in intended use requiring submission of a new 510(k) under 807.81(a)(3). “Near real time cardiac event monitoring” implies that the device provides monitoring for high-risk patients that require clinically actionable, timely notification of life-threatening arrythmias to prevent serious injury or death.\n\nOur inspection also revealed that your firm made changes to the device without submission of a new 510(k). In response to our inspection, your firm provided more detail on the changes made to the device. Based on the information in your responses, the following changes were made to the device that require a new 510(k) submission:\n\na. Your document titled “Zio AT (K163512) Design Changes, Brief Summary” and “(b)(4) Hardware and Firmware Design Changes” identifies hardware and firmware changes that raise new risks including, but not limited to, changes in the (b)(4), and updating (b)(4) of your device including the (b)(4). Specifically, these changes can affect the (b)(4) of the device (i.e., device (b)(4) and device (b)(4)) that would require new testing to support your assertion that the device’s safety and effectiveness is unaffected. These changes can result in potential (b)(4) and may affect the basic safety of the device. According to Table B (technology, engineering, and performance changes) in the 510(k) Modifications Guidance, Question B5.2 should be answered “yes” because these changes raised new or significantly modified risks. Because these changes would require new (b)(4) testing and could significantly affect safety or effectiveness, a new 510(k) must be submitted for this change.\n\nb. “Zio AT (K163512) Design Changes, Brief Summary” describes a change to your device made in September 2019, “Improve (b)(4): the algorithm in the (b)(4) was adjusted based on available data to improve (b)(4) performance for (b)(4) events that meet (b)(4) criteria. There were no changes to the algorithm that would significantly affect any clinical outcome.” Changes to the (b)(4) algorithm can impact the accuracy of the detected arrhythmias, and testing would be needed to support that the algorithm’s performance is unaffected by the change. A change in the (b)(4) for the algorithm could significantly impact safety or effectiveness, such as through missed or incorrect detection of events or arrhythmias, which could lead to patient injury due to lack of treatment. Question B5 in the 510(k) Modifications Guidance should have been answered “yes” because the change was to performance specifications. Subsequently, question B5.3 should have been answered “yes,” because the modification to the algorithm necessitated clinical validation data in order to ensure the performance of the device was maintained, using relevant device-specific data from patients. Therefore, a new 510(k) must be submitted.\n\nYour responses are inadequate because they fail to address how the above changes could not significantly affect the safety or effectiveness of the Zio AT System.\n\nTherefore, the Zio AT System is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). Therefore, the kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nWe also note that your responses identified other changes to the device. However, the level of information provided in your responses was insufficient to determine whether these changes to the device also require clearance in a new 510(k) submission. Please reach out to the FDA review team to discuss the changes identified in your previous responses. Further, please discuss with the FDA review team any other changes made to the device since K163512 not noted above.\n\nLabeling Violations\n\nThe Zio AT System is also misbranded within the meaning of section 502(f)(1) of the Act, 21 U.S.C. § 352(f)(1), in that the labeling for the device fails to bear adequate directions for the purpose for which it is intended. The Zio AT System does not meet the criteria for an exemption from section 502(f)(1) of the Act under 21 CFR 801 subpart D. 21 CFR 801.109 expressly exempts a prescription device from section 501(f)(1) if the device meets certain criteria.\n\nAs a (b)(4), your firm implemented a transmission limit on how many times the Zio AT System transmits data. As a result, the device is only able to transmit 100 patient-triggered and 500 automatically detected arrhythmia events. Once the transmission limit is reached, the patient’s data stops being transmitted for review\u002Freporting. Thus, when the transmission limit is hit, the device can no longer be used for its intended purpose of transmitting patient ECG for reporting. Further, when the transmission limit is hit, the device can no longer provide near-real time monitoring for high-risk patients.\n\nThe Zio AT System does not meet the requirements for exemption from section 502(f)(1) of the Act under 21 CFR 801.109 because the device fails to include adequate directions for use for the physician related to the transmission limit. Specifically, the directions for use fail to include information related to the “indications…[and]…methods,…under which practitioners…can use the device safely and for the purposes for which it is intended, including all purposes for which it is advertised or represented.” See 21 CFR 801.109. During our inspection, it was revealed that the labeling does not inform the physician of the existence of a transmission limit, when the transmission limit is reached, or include any information about the action a physician should take if the device reaches the transmission limit. While your firm does provide a small alert on the report when the device is nearing, or has met, the transmission limit, there is no description of the what the alert means, or next steps the physician should take. In your response, your firm explained that, when “a wireless transmission threshold is approached, the [healthcare provider] is notified and given the option to replace the patch for the remainder of the wear period.” This is not adequate because an understanding of the transmission limitations by the healthcare provider is needed prior to transmission limit being reached to effectively use the device as intended.\n\nFurther, there is no information provided to the patient that a transmission limit exists, no notification to the patient when the transmission limit is reached, and no information provided to the patient about what to do when the transmission limit is reached. In response, your firm proposed sending a new device directly to the patient in instances when the prescribing clinician could not be contacted. However, this proposed corrective action is inadequate to address the issue because there is still no information provided to the patient about the transmission limit, or what do with the newly acquired device. This information is needed for the patient to be able to use the device safely and for the purposes for which it is intended. See 21 CFR 801.5. Therefore, the Zio AT System is misbranded under section 502(f)(1) because its labeling fails to bear adequate directions related to the device’s transmission limit. Your response did not address this issue.\n\nQuality System Regulation (QSR) violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\n\nA. You failed to identify the actions needed to correct and prevent recurrence of quality problems despite being aware of them for years. Specifically:\n\ni. You were aware of a negative trend or critical customer complaints since at least 2019 but failed to initiate a CAPA as provided by your CAPA procedures.\n\nSection 6.3 of your firm’s Corrective and Preventive Action procedure states that a CAPA may be initiated for reasons including but not limited to, a negative trend or critical customer complaints. Within your CAPA procedures, critical is defined as “[a]ny nonconformance or noncompliance that will or already has adversely affected product performance meeting specifications, safety, therapeutic efficacy, or regulatory requirements.” Additionally, Section 6.1 states that the purpose of the CAPA procedure is to “[e]nsure nonconformity and quality problems that are systemic or critical in nature are promptly considered and addressed.”\n\nOur inspection revealed that your firm knew that the device’s transmission limit, which was explained in the previous section, was resulting in data not being transmitted. Records reviewed during our inspection indicate that your firm has been aware of customer complaints related to this issue since at least 2019. Specifically, our inspection found a significant number of complaints regarding this issue, which revealed two deaths as well as significant arrythmias that were not reported to physicians. As designed, the device transmission limit should only be reached in rare cases. However, the customer complaints reviewed during the inspection reveal that the device was hitting the transmission limit more often than expected. When the transmission limit is reached more often than expected, it introduces a nonconformance. However, your firm failed to initiate a CAPA based on negative trends or critical customer complaints, to “[e]nsure nonconformity and quality problems that are systemic or critical in nature are promptly considered and addressed,” as required by your firm’s CAPA procedure.\n\nYour response maintains this is a design limitation and not a nonconformance, and that no visual cues will be added. As noted above, when the design limitation is reached more often than expected, it introduces a nonconformance. In response, your firm initiated a CAPA. The adequacy of your firm’s responses cannot be determined at this time because they do not provide sufficient details to fully assess the adequacy of your corrective actions. Following our inspection, your firm initiated a CAPA and submitted a correction report under 21 CFR part 806 (806 report) to the Agency. However, the CAPA your firm provided as part of the 806 report lacked sufficient detail to determine whether the CAPA has been properly conducted. In response to this letter, please provide more detail on your firm’s CAPA.\n\nFurther, the cleared indications of your device include continuous recording of ECG information for monitoring, manual, and automatic transmission of arrhythmia events. As described above in the Unapproved Device Violations section, your current marketing materials indicate that the Zio AT System is intended for high-risk patients and near real-time monitoring. When the transmission limit is exceeded more than rarely, this introduces a nonconformance because the device is unable to transmit ECG information for monitoring and is not remotely capable of delivering near-real time monitoring for high-risk patients.\n\nii. Your firm has known since 2017 that patient data is held inaccessible within your Zeus system, thereby not allowing it to be properly analyzed for potential corrective action and you failed to initiate a CAPA as provided by your CAPA procedures.\n\nSection 6.3 of your firm’s Corrective and Preventive Action procedure states that a CAPA may be initiated for reasons including but not limited to, feedback that identifies problematic performance with process operations, or “product, process, or system nonconformance…”\n\nHowever, your firm failed to initiate a CAPA when you were aware that patient data, including significant arrythmias requiring physician notification (see Z ticket3 records (b)(4) noting Atrial Fibrillation and (b)(4) noting Bradycardia), was being held inaccessible within your Zeus system. Specifically, your firm was aware that when the patient’s device registration is incomplete, the patient’s ECG information is still collected but cannot be read by anyone. When the patient’s data can no longer be analyzed and reported, the device can no longer be used for the purpose for which it is intended, which is a nonconformance. Since at least 2017, your firm has been aware of this issue where your clinical care team cannot access the patient’s data. Our inspection confirmed 39 examples from a list of over (b)(4) Z tickets where this problem occurred.\n\nIn your initial response, you claim that this is not a nonconformance because the patient registration information is required based on IDTF requirements related to Medicare billing. This does not address the nonconformance. As noted above, when quality data is held inaccessible within the Zeus system where it cannot be analyzed and reported, the device can no longer be used for the purpose for which it is intended.\n\nThe adequacy of your firm’s responses cannot be determined at this time because they do not provide sufficient details to fully assess the adequacy of your corrective actions. In your response, you noted that your firm initiated a CAPA. However, the CAPA your firm provided lacked sufficient detail to determine whether the CAPA has been properly conducted. For example, the provided CAPA investigation does not include an “identification of the actual failure (not to be confused with the reported observation),” as required by your CAPA procedure. Additionally, the provided CAPA investigation does not include distribution tracking, otherwise known as “(b)(4) information,” as required by your CAPA procedure. As your procedure notes, this information is necessary to capture “the known extend of the identified issue in order to contain or correct the issue.” In response to this letter, please provide more detail on your firm’s CAPA.\n\nWe also acknowledge that based on the outcome of that CAPA, your firm has committed to a voluntary recall that would provide notification to doctors that monitoring cannot begin until the patient registration is completed. On September 1, 2022, your firm initiated this recall. Your firm submitted an 806 report to the Agency on October 5, 2022. We provided a response to your 806 report separately. Please continue to provide status updates with respect to your recall (RES 90954) to oradevices3recalls@fda.hhs.gov.\n\nB. You failed to conduct a health hazard evaluation (HHE) when required by your CAPA procedure.\n\nOur inspection found that your firm did not perform an HHE when required by your CAPA procedure. When an unanticipated issue arises which affects product in the field, your firm’s procedure requires you to perform an HHE to evaluate the health hazard presented by the issue. “Unanticipated” is defined to include a new failure mode.\n\nYour firm failed to perform an HHE when it became aware of the error titled “Activation Time Mismatch.” During a CAPA investigation, you identified the “Activation Time Mismatch” error, in which prior patient data was not fully erased from the device prior to the device’s reuse. The CAPA investigation showed that this issue has the potential for adverse effect on product quality and is a risk that is not identified in an existing risk assessment document. As this was an unanticipated risk identified in this CAPA record, an HHE was required.\n\nWe reviewed your firm’s response and concluded that it is not adequate. Your response states that your firm’s process about when to escalate a CAPA to an HHE was not clear. As such, CAPA procedural updates were made, and training was performed. Specifically, you updated your CAPA to include the statement, “The issue will be assessed… [in accordance with the Health Hazard Evaluation Procedure], to determine if the criteria for an HHE has been met, and whether field action is required.” Your firm also conducted an HHE for the Activation Time Mismatch error, as required by your CAPA procedures. In addition, your firm conducted several other HHEs. It is important that the HHE be performed in accordance with your firm’s Risk Management SOP (00010) because the outcome of the HHE is used to determine some of your firm’s corrective and\u002For preventative actions.4 However, based on FDA’s own calculations, these HHEs do not appear to be conducted in accordance with your Risk Management SOP (SOP0010). For example, when conducting HHE-(b)(4), it appears your firm failed to properly calculate the probability of occurrence of the potential safety issue.5 Your miscalculation underestimated the likelihood of someone being injured. According to your updated CAPA procedure, the difference in the occurrence rating for HHE-(b)(4) would have required an update to your risk documentation and the HHE shows that this was not selected. Further, when conducting HHE-(b)(4), your firm failed to apply the Health Risk Table in your Risk Management SOP (SOP0010).6 This miscalculation is significant because this HHE procedure is used to assess whether or not you will initiate field action.\n\n2. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, per the requirements of 21 CFR 820.198.\n\nEvents meeting the definition of a complaint under 820.3(b) were not reviewed or evaluated to determine whether the complaint represents an event which for which reporting is required under 21 CFR part 803, Medical Device Reporting. Specifically, a review of your Service Monitoring Z tickets found complaints regarding deficiencies in the reliability of your device that your firm failed to review or evaluate.\n\nAs the Zio AT System monitors a patient’s ECG, it may auto-generate tickets in your (b)(4) system (“Service Monitoring Z tickets”) for follow-up. You specified that Service Monitoring Z tickets are not reviewed or evaluated because they are not deemed a problem. However, some of the Service Monitoring Z tickets reviewed during the inspection meet the definition of a complaint under 820.3(b). Accordingly, they must be evaluated for potential reporting under Part 803, Medical Device Reporting.\n\nThe adequacy of your firm’s responses noted at the top of this letter cannot be determined at this time because your corrective actions are still in progress. Your responses acknowledge that your firm did not review or evaluate complaints for Service Monitoring Z tickets appropriately. Your investigation found that your firm failed to evaluate the Service Monitoring Z tickets. In response, you stated that procedural updates have been made and training has been conducted. You also stated that you have made necessary updates to the (b)(4) system and Z ticket template forms. Additionally, you committed to retrospectively review complaints per the newly established criteria and your March 2023 response estimates this may be completed by 8\u002F31\u002F2023. The verification of the effectiveness of your corrective action is also outstanding. A follow up inspection will be required to assure that your corrective actions are adequate.\n\n3. Failure to validate a process to a high degree of assurance per the requirements of 21 CFR 820.75.\n\nSpecifically, when Gateway PCBAs were returned, they were reused, and per procedure Zio AT Gateway PCBA Initialize and Test, the memory needs to be cleared. However, the AT Gateway (b)(4) process did not include a verification step to confirm that previous patient data was successfully erased. This resulted in distribution of Zio AT product with prior patient data remaining on it, which led to a complaint.\n\nYour firm’s response to this observation appears to be adequate. Your response acknowledges that the process validation failed to implement a (b)(4) that validates the complete erasure of the (b)(4), and that the manufacturing work instructions did not include a step to verify this erasure. Your response further states this deficiency extends beyond design changes and is a systemic issue with process validation and (b)(4) verification in general.\n\nWe acknowledge the findings from the testing you performed on the Gateway process, and that you have determined R peak data (i.e., data used to determine potential arrythmias) from a prior patient would not be stored on the PCB, (b)(4). We understand you committed to contain this issue by only using virgin Gateway PCBAs until the related corrective action is complete. As part of your CAPA, you developed and implemented a process to verify that all prior patient data is properly erased. You have updated related procedures and have revalidated this process. A follow up inspection will be required to assure that corrections and\u002For corrective actions are adequate.\n\nMedical Device Reporting (MDR) Violations\n\nOur inspection also revealed that your firm’s Zio AT system is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to submit a report to FDA no later than 30 calendar days after the day that iRhythm Technologies, Inc., received or otherwise became aware of information, from any source, that reasonably suggests that a device that it markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).\n\nFor example,\n\na. The information included for the MDRs 3007208829‐2022‐00041 (corresponding to Complaint COMP‐2021‐6388) and 3007208829‐2022‐00055 (corresponding to Complaint COMP‐2021‐6385) describes MDR reportable events where a patient passed away while using the Zio AT system. iRhythm Technologies, Inc., became aware of each of the two events on October 25, 2021. However, FDA did not receive these MDRs until September 24, 2022, and December 3, 2022, respectively, which is beyond the required the 30‐calendar day timeframe.\n\nb. The information included for the MDR 3007208829‐2022‐00048 (corresponding to Complaint COMP‐2022‐2077) describes an MDR reportable event where the patient experienced ventricular tachycardia and syncope while using the Zio AT system and was hospitalized. iRhythm Technologies, Inc., became aware of the event on April 27, 2022. FDA did not receive this MDR until September 24, 2022, which is beyond the required the 30‐calendar day timeframe.\n\nAs noted previously in this letter, based on your marketing materials, website, and other documentation, the Zio AT System is intended for “near real-time monitoring” and “high-risk patients,” even though the Zio AT System is not cleared for these indications. When used in this patient population, the Zio AT System may cause or contribute to serious injury or death because life-threatening arrhythmias may not receive timely treatment.\n\nWe reviewed your firm’s responses dated September 1, 2022, October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, and they appear to be adequate. The responses indicate that your firm conducted a retrospective review of a total of 999,328 complaints received from March 1, 2019, through August 6, 2022, for reportability, resulting in the submission of 13 MDRs. Your firm’s response dated March 1, 2023, notes that your firm has completed all the planned corrective actions.\n\n2. Failure to report an MDR for an event where your device has malfunctioned and is likely to cause or contribute to death or serious injury if this malfunction recurred, per the requirements of 21 CFR Part 803.50(a)(2).\n\nSpecifically, in complaints COMP-2021-1687, COMP-2021-2077 and COMP-2021-5397, similar to the complaints discussed in #1 above, the transmission limit was reached prior to occurrence of a significant arrythmia; therefore, these events were not transmitted to the prescribing physician until the final wear-period report was generated.\n\nThe Zio AT System malfunctioned when the Zio AT System hit its transmission threshold and stopped submitting data that is used to determine potential arrythmias. This failure meets the definition of a reportable malfunction, as defined in 21 CFR 803.3. This malfunction is likely to cause or contribute to death or serious injury for the reasons discussed in #1 above. However, these complaints were coded as unreportable malfunctions and no MDR was filed.\n\nEach of the referenced malfunctions represents an MDR reportable event and a malfunction MDR for each complaint (COMP‐2021‐1687 and COMP‐2021‐5397) was required to be submitted within the 30‐calendar day timeframe.\n\nWe reviewed your firm’s responses dated September 1, 2022, October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, and we were unable to determine the adequacy of your response. The responses indicate that your firm conducted a retrospective review of a total of 999,328 complaints received from March 1, 2019, through August 6, 2022, for reportability, resulting in the submission of 13 MDRs. However, your firm failed to submit an MDR for the following complaints: COMP‐2021‐1687 and COMP‐2021‐5397. Your firm should submit the MDRs for the previously mentioned complaints and provide a rationale for why they were missed in your retrospective review.\n\n3. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\n\nFor example, the following documents were collected during the inspection and were reviewed collectively as iRhythm Technologies, Inc.'s MDR procedure:\n\n• Document titled “Complaint Handling”, Document# SOP0021, Rev. 07, dated 02‐July‐2021, which applies to customer complaints regarding products provided by\n\niRhythm Technologies, Inc.\n\n• Document titled “Adverse Event Reporting”, Document# SOP0023, Rev. 10, dated 05‐July‐2022, which defines the process for global post‐market reporting of adverse events and applies to all medical device manufactured by iRhythm Technologies, Inc. placed on the market.\n\nAfter reviewing the MDR procedure, the following was noted:\n\nA. Your MDR procedure fails to establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\n\nFor example, the procedure omits the definitions of the terms “serious injury” from 21 CFR 803.3 and “reasonably suggests” found in 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nB. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form;\n\nb. A process for submitting supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a);\n\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, your procedures do not indicate which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\nWe reviewed your firm’s responses and conclude that they are not adequate. Your firm’s response dated September 1, 2022, includes copies of the revised procedural documents titled “Complaint Handling”, Document# SOP0021, Rev.08, dated 29‐Aug‐2022 and “Adverse Event Reporting”, Document# SOP0023, Rev. 11, dated 26‐Aug‐2022. However, a collective review of each revised document noted the following:\n\n1. The revised MDR procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). The revised procedure omits the definition of the term “reasonably suggests” found in 803.20(c)(1). The exclusion of the definition for this term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\n2. The revised procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\n\na. Instructions for how to obtain and complete the FDA 3500A form.\n\nb. How your firm will ensure that all information reasonably known to you is submitted for each reportable event. Specifically, your procedure does not provide instructions regarding which sections of the Form 3500A will need to be completed to include all reportable information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\n\nYour firm’s responses dated October 6, 2022, November 4, 2022, December 7, 2022, January 3, 2023, February 2, 2023, and March 1, 2023, didn’t provide any new information regarding the MDR procedural deficiencies listed above.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov. Refer to CMS 643474 when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at\n\nLauren.Priest@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBram Zuckerman, M.D., Director\n\nOHT2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh, Program Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nCc:\n\nMr. Mazi A. Kiani, Senior Vice President of Quality and Regulatory, mazi.kiani@irhythmtech.com\n\nMr. Mark W. Hughes, VP Manufacturing, mark.hughes@irhythmtech.com for\n\n______________________\n\n1 See e.g., (b)(4).\n\n2 https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device.\n\n3 Your procedures define a Z ticket as a detailed description of a customer’s feedback, problem, or question which are used to track and solve customer issues within (b)(4).\n\n4 For example, Section 6.4 of your updated CAPA procedure states “If the risk is documented, to whether the analysis remains accurate. If changes are required (e.g., increase\u002Fdecrease in severity, probability of occurrence, risk index), update to risk documentation will become an action of the CAPA plan. If determined that the risk is not documented (e.g., identification of a new process failure mode, hazard, harm, cause, etc.), update to risk documentation will become an action of the CAPA plan.” Additionally, Section 9.2 of your updated HHE procedure states that [b]ased on the outcome of the HHE, the Team provides recommendations for next steps. Included with these recommendations are either rationale, or a description of the actions being recommended, as appropriate.\n\n5 Your firm provided the actual calculations used to explain the probability level chosen. In “HHE-(b)(4) Zio AT Registration,” you state “(b)(4) may experience a moderate injury.” This is incorrect; (b)(4) is (b)(4) or to convert to a percentage: (b)(4). When compared to your Risk Management procedure, using your Risk Level Matrix, your miscalculation led you to choose “Low” risk whereas the correct calculation would have led you to “Medium” risk category. More specifically, your original risk calculation was (b)(4) 2. However, if calculated correctly, it would have been (b)(4). This would have required an update to your risk documentation per your updated procedures.\n\n6 Your firm’s SOP0010 procedure includes a Health Risk Table. This includes probability levels, which are associated with a range (e.g., (b)(4) (between (b)(4)). In contrast, the HHE probability levels of the hazards associated with use of the product shown in the Health Risk Table only specify a single probability of occurrence level, such as (b)(4). Furthermore, several of the levels do not correspond to those in SOP0010. For example, level (b)(4) of the HHE is described as (b)(4), whereas (b)(4) in SOP0010 is (b)(4). While (b)(4) is greater than (b)(4), this level does not adequately describe that the risk is for any probability that is greater than (b)(4). Therefore, the Health Risk Table defined by SOP0010 was not used in your HHE.","iRhythm Technologies, Inc.","irhythm-technologies-inc-643474-05252023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Firhythm-technologies-inc-643474-05252023","2026-10-26T08:09:00.926421+00:00","2023-06-06","643474","Mr. Quentin S. Blackford","2026-08-20T01:03:52.066+00:00","2023-05-25",{"id":134,"raw":135,"subject":140,"body_html":141,"body_text":142,"firm_name":143,"letter_id":144,"created_at":145,"fei_number":19,"letter_url":146,"updated_at":147,"action_type":22,"case_status":23,"posted_date":148,"marcs_cms_no":149,"product_type":150,"closeout_date":19,"issuing_office":139,"recipient_name":151,"body_fetched_at":152,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},3367,[136,137,138,139,140,13,13,13],"\u003Ctime datetime=\"2021-05-07T14:00:00Z\">05\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-06T04:00:00Z\">05\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalon-technologies-inc-614350-05062021\">Covalon Technologies Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research","Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Pedlar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Covalon Technologies Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1660 Tech Avenue, Unit 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mississauga\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L4W 5S7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bpedlar@covalon.com\"> bpedlar@covalon.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cfredric@covalon.com\"> cfredric@covalon.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; May 6, 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>TO: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Christopher Fredric, Senior Director, Regulatory Affairs\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.covaguard.com\u002F on March 24, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.instagram.com\u002Fcovaguard\u002F and https:\u002F\u002Fwww.facebook.com\u002Fcovaguard\u002F, where you direct consumers to your website,\u003C\u002Fspan> \u003Cspan>https:\u002F\u002Fwww.covaguard.com\u002F, to purchase your products.&nbsp;The FDA has observed that your website offers\u003C\u002Fspan>\u003Cspan> non-alcohol based hand sanitizer products\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> and other conditions in people. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Furthermore, these products are misbranded drugs under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> In addition, on March 13, 2020, there was a Presidential &nbsp;declaration of a national emergency in response to COVID-19.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 and other conditions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims on your websites that establish the intended use (as defined in 21 CFR 201.128) of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Does the CovaGuard™ formula kill the COVID-19 virus (SARS-CoV2)? \u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>Preliminary testing indicates that the&nbsp;CovaGuard&nbsp;formula kills 99.9% or greater of SARS-CoV2 virus (COVID-19)&nbsp;within 60 seconds of contact…\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>” [from your website\u003C\u002Fspan> \u003Cspan>https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Ffaqs]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>BAC [(benzalkonium chloride)] is highly effective at deactivating and killing a wide variety of pathogens, including coronaviruses\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>…” [from your website \u003C\u002Fspan>https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The BYU scientists who conducted the study. . . treated samples of the novel coronavirus with benzalkonium chloride, which is commonly used in alcohol-free hand sanitizers, and several other quaternary ammonium compounds regularly found in disinfectants. In most of the test cases, the compounds wiped out at least 99.9% of the virus within 15 seconds.” [from a December 1, 2020 news release titled, “Alcohol-free hand sanitizer just as effective against COVID as alcohol-based versions“ directly linked from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works via a hyperlink titled, “\u003Cu>Check it out for yourself!”\u003C\u002Fu>] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“‘Our results indicate that alcohol-free hand sanitizer works just as well, so we could, maybe even should, be using it to control COVID,’ said lead study author Benjamin Ogilvie.” [from a December 1, 2020 news release titled, “Alcohol-free hand sanitizer just as effective against COVID as alcohol-based versions“ directly linked from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works via a hyperlink titled, “\u003Cu>Check it out for yourself!”]\u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“24hr Protection” [from your products’ labels on your website https:\u002F\u002Fwww.covaguard.com\u002Fcollections\u002Fall]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“All day protection from bacteria and germs. One spray protects for 24 hours. Yup, 24 hours.” \u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>[from your \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>website https:\u002F\u002Fwww.covaguard.com\u002F\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“One spray. Protects all day.™” \u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>[from your \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>website https:\u002F\u002Fwww.covaguard.com\u002F\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Our technology not only kills germs on contact, but unlike traditional sanitizers, continues to kill bacteria and&nbsp;pathogens&nbsp;for up to 24 hours.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>” \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[from your \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“. . .With CovaGuard, you can rest easy knowing that your hands are protected for 24 hours. One spray protects all day!\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>” [from a January 28, 2021 post on your Facebook webpage at \u003C\u002Fspan>https:\u002F\u002Fwww.facebook.com\u002Fcovaguard\u002F\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“24-hr protection against germs” [from your Instagram webpage at \u003C\u002Fspan>https:\u002F\u002Fwww.instagram.com\u002Fcovaguard\u002F\u003Cspan>] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Based on the above claims, your hand sanitizer products \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer topical antiseptics\u003C\u002Fspan>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>These consumer topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your hand sanitizer drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>(\u003Cspan>Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>requirements.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>However, your consumer topical antiseptic products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003Csup> &nbsp;\u003C\u002Fsup>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Specifically, your labeling claims suggesting that your topical antiseptic products are effective in preventing infection or disease from the novel coronavirus that causes COVID-19 \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>go beyond merely describing the general intended use of a topical antiseptic as set forth in the 1994 TFM\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>. In addition, your labeling claims, suggesting th\u003Cspan>at your consumer antiseptic &nbsp;products \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>provide up to 24 hours of efficacy against serious-disease related pathogens including the novel coronavirus that causes COVID-19, \u003Cspan>\u003Cspan>do not conform to the 1994 TFM&nbsp;or any of the amendments to the TFM discussed above.\u003C\u002Fspan>\u003C\u002Fspan> Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by\u003C\u002Fspan>\u003Cspan> creating a false sense of security\u003C\u002Fspan> \u003Cspan>for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, these products may give users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who do not follow these interventions are at increased risk for contracting COVID-19 and for spreading disease if they have been exposed to the virus, thereby prolonging the pandemic and increasing its associated morbidity and mortality.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your hand sanitizers are GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your hand sanitizers are new drugs under section 201(p) of the FD&amp;C Act. In addition, there are no FDA-approved applica\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>tions in effect \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>for your hand sanitizers and, accordingly, they are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your hand sanitizers also do not \u003Cspan>conform to any temporary policy FDA has \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>implemented for alcohol-based hand sanitizer products during the public health emergency\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[5]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, these consumer topical antiseptic products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act\u003C\u002Fspan>\u003Cspan>. \u003Cb>Within 48 hours, please send an email to \u003C\u002Fb>\u003C\u002Fspan>\u003Cb>\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fb>\u003Cb> \u003C\u002Fb>\u003Cspan>describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. \u003C\u002Fspan>\u003Cspan>Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19.&nbsp;Your firm will be added to a published list on \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>FDA’s\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act.&nbsp;This list can be found at \u003C\u002Fspan>http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fspan>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Once you have taken actions\u003C\u002Fspan>\u003Cspan> to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19,\u003C\u002Fspan>\u003Cspan> and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> Your hand sanitizer drug products include “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 8oz,”&nbsp; “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 3.38oz,” “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 2.02oz,”&nbsp; “COVAGUARD MASK ANTIMICROBIAL HAND SANITIZER SPRAY 8oz,” “COVAGUARD MASK ANTIMICROBIAL HAND SANITIZER SPRAY 3.38oz,” and “COVAGUARD ANTIMICROBIAL HAND SANITIZER FOAM 3.38oz.”&nbsp; &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020., and subsequently renewed) \u003Ci>available \u003C\u002Fi>at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Ci>available\u003C\u002Fi> at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[5]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>See, e.g., \u003Ci>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fi>.&nbsp; Because your hand sanitizers are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBrian Pedlar\n\nRecipient Title\n\nCEO\n\nCovalon Technologies Inc.\n\n1660 Tech Avenue, Unit 5\n\nMississauga ON L4W 5S7\n\nCanada\n\nbpedlar@covalon.com\n\ncfredric@covalon.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWARNING LETTER\n\nDate: May 6, 2021\n\nTO: Christopher Fredric, Senior Director, Regulatory Affairs\n\nRE: Unapproved New Drug Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.covaguard.com\u002F on March 24, 2021. We also reviewed your social media websites at https:\u002F\u002Fwww.instagram.com\u002Fcovaguard\u002F and https:\u002F\u002Fwww.facebook.com\u002Fcovaguard\u002F, where you direct consumers to your website, https:\u002F\u002Fwww.covaguard.com\u002F, to purchase your products. The FDA has observed that your website offers non-alcohol based hand sanitizer products[1] for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19[2] and other conditions in people. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Furthermore, these products are misbranded drugs under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and 301(d) of the FD&C Act, 21 U.S.C. 331(a) and (d). These violations are described in more detail below.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[3] In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.[4] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 and other conditions in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 and other conditions.\n\nSome examples of the claims on your websites that establish the intended use (as defined in 21 CFR 201.128) of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 and other serious infections include, but may not be limited to, the following:\n\n“Does the CovaGuard™ formula kill the COVID-19 virus (SARS-CoV2)? Preliminary testing indicates that the CovaGuard formula kills 99.9% or greater of SARS-CoV2 virus (COVID-19) within 60 seconds of contact…” [from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Ffaqs]\n\n“BAC [(benzalkonium chloride)] is highly effective at deactivating and killing a wide variety of pathogens, including coronaviruses…” [from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works]\n\n“The BYU scientists who conducted the study. . . treated samples of the novel coronavirus with benzalkonium chloride, which is commonly used in alcohol-free hand sanitizers, and several other quaternary ammonium compounds regularly found in disinfectants. In most of the test cases, the compounds wiped out at least 99.9% of the virus within 15 seconds.” [from a December 1, 2020 news release titled, “Alcohol-free hand sanitizer just as effective against COVID as alcohol-based versions“ directly linked from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works via a hyperlink titled, “Check it out for yourself!”]\n\n“‘Our results indicate that alcohol-free hand sanitizer works just as well, so we could, maybe even should, be using it to control COVID,’ said lead study author Benjamin Ogilvie.” [from a December 1, 2020 news release titled, “Alcohol-free hand sanitizer just as effective against COVID as alcohol-based versions“ directly linked from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works via a hyperlink titled, “Check it out for yourself!”]\n\n“24hr Protection” [from your products’ labels on your website https:\u002F\u002Fwww.covaguard.com\u002Fcollections\u002Fall]\n\n“All day protection from bacteria and germs. One spray protects for 24 hours. Yup, 24 hours.” [from your website https:\u002F\u002Fwww.covaguard.com\u002F]\n\n“One spray. Protects all day.™” [from your website https:\u002F\u002Fwww.covaguard.com\u002F]\n\n“Our technology not only kills germs on contact, but unlike traditional sanitizers, continues to kill bacteria and pathogens for up to 24 hours.” [from your website https:\u002F\u002Fwww.covaguard.com\u002Fpages\u002Fhow-it-works]\n\n“. . .With CovaGuard, you can rest easy knowing that your hands are protected for 24 hours. One spray protects all day!” [from a January 28, 2021 post on your Facebook webpage at https:\u002F\u002Fwww.facebook.com\u002Fcovaguard\u002F]\n\n“24-hr protection against germs” [from your Instagram webpage at https:\u002F\u002Fwww.instagram.com\u002Fcovaguard\u002F]\n\nBased on the above claims, your hand sanitizer products are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as consumer topical antiseptics.\n\nThese consumer topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or under other exceptions not applicable here. No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your hand sanitizer drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, your consumer topical antiseptic products do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nSpecifically, your labeling claims suggesting that your topical antiseptic products are effective in preventing infection or disease from the novel coronavirus that causes COVID-19 go beyond merely describing the general intended use of a topical antiseptic as set forth in the 1994 TFM. In addition, your labeling claims, suggesting that your consumer antiseptic products provide up to 24 hours of efficacy against serious-disease related pathogens including the novel coronavirus that causes COVID-19, do not conform to the 1994 TFM or any of the amendments to the TFM discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, endanger the public health by creating a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. As a result, these products may give users the false impression that they need not rigorously adhere to interventions such as social distancing and exercising good hygienic practices that have been demonstrated to curb the spread of COVID-19. Users who do not follow these interventions are at increased risk for contracting COVID-19 and for spreading disease if they have been exposed to the virus, thereby prolonging the pandemic and increasing its associated morbidity and mortality.\n\nWe are unaware of any adequate and well-controlled clinical studies in the published literature that support a determination that your hand sanitizers are GRASE for the above-described intended uses, including the time-specific extended efficacy claims. Accordingly, your hand sanitizers are new drugs under section 201(p) of the FD&C Act. In addition, there are no FDA-approved applications in effect for your hand sanitizers and, accordingly, they are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C §§ 355(a) and 331(d). We note that your hand sanitizers also do not conform to any temporary policy FDA has implemented for alcohol-based hand sanitizer products during the public health emergency.[5]\n\nIn addition, these consumer topical antiseptic products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n[1] Your hand sanitizer drug products include “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 8oz,” “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 3.38oz,” “COVAGUARD ANTIMICROBIAL HAND SANITIZER SPRAY 2.02oz,” “COVAGUARD MASK ANTIMICROBIAL HAND SANITIZER SPRAY 8oz,” “COVAGUARD MASK ANTIMICROBIAL HAND SANITIZER SPRAY 3.38oz,” and “COVAGUARD ANTIMICROBIAL HAND SANITIZER FOAM 3.38oz.”\n\n[2] As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[3] Secretary of Health and Human Services, Determination that a Public Health Emergency Exists. (originally issued on Jan. 31, 2020., and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx).\n\n[4] Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n[5] See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because your hand sanitizers are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.","Covalon Technologies Inc.","covalon-technologies-inc-614350-05062021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalon-technologies-inc-614350-05062021","2026-10-26T08:08:18.967606+00:00","2021-05-07","614350","Drugs","Brian Pedlar","2026-08-20T03:09:09.19+00:00","2021-05-06",{"id":155,"raw":156,"subject":162,"body_html":163,"body_text":164,"firm_name":165,"letter_id":166,"created_at":44,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":23,"posted_date":169,"marcs_cms_no":170,"product_type":150,"closeout_date":19,"issuing_office":160,"recipient_name":19,"body_fetched_at":171,"delivery_method":172,"recipient_title":19,"reference_number":19,"action_taken_date":173,"medical_device_id":19,"response_letter_date":19},318,[157,158,159,160,161,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falan-health-technologies-inc-dba-alan-721814-02202026\">Alan Health Technologies Inc. dba Alan\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Alan Health Technologies Inc. dba Alan\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>249 Smith St., PMB 3008\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11231\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:legal@alanmeds.com\"> legal@alanmeds.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Alan:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.alanmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Alan” on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Alan is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2 \u003C\u002Fstrong>\u003C\u002Fem>See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nAlan Health Technologies Inc. dba Alan\n\n249 Smith St., PMB 3008\n\nBrooklyn, NY 11231\n\nUnited States\n\nlegal@alanmeds.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nAlan:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.alanmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Alan” on the pictured label, suggesting Alan is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Alan is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Alan Health Technologies Inc. dba Alan","alan-health-technologies-inc-dba-alan-721814-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Falan-health-technologies-inc-dba-alan-721814-02202026","2026-10-26T08:07:52.017192+00:00","2026-03-03","721814","2026-08-19T04:52:53.238+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-20",{"id":175,"raw":176,"subject":39,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":85,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":26,"closeout_date":19,"issuing_office":180,"recipient_name":189,"body_fetched_at":190,"delivery_method":191,"recipient_title":19,"reference_number":19,"action_taken_date":192,"medical_device_id":19,"response_letter_date":19},1356,[177,178,179,180,39,13,13,13],"\u003Ctime datetime=\"2024-07-23T13:20:00Z\">07\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-12T04:00:00Z\">07\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcriticare-technologies-inc-686915-07122024\">Criticare Technologies, Inc.\u003C\u002Fa>","Division of Medical Device and Radiological Health Operations East","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Neeraj Jha\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Criticare Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6901 TPC Drive, Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32822\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:neeraj@criticare.com\"> neeraj@criticare.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Medical Device and Radiological Health Operations East\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 686915\u003C\u002Fp>\n\n\u003Cp>July 12, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jha:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Criticare Technologies, Inc., 333 Strawberry Field Rd Ste 11, Warwick, RI, FEI 3012238587, from March 21, 2024, through May 10, 2024. During the inspection, the FDA investigator determined that your firm is a manufacturer of patient monitors including the nGenuity patient vital signs monitor. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received your response dated June 3, 2023, from John Haefele, Vice President, and General Manager. which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 10, 2024. We address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 21 CFR 820.100(a). Review of your firms Corrective and Preventive Action (CAPA) Procedure, CTI 221 rev H, revealed that it does not provide instructions in sufficient detail to; identify existing and potential causes of nonconforming product, or other quality problems; conduct investigations, identify, and take appropriate corrective or preventive actions, or verify that any such actions are effective. The below examples describe a CAPA system that does not meet the above requirements of 21 CFR.820.100(a):\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm opened CAPA 1098 on May 1, 2023, to address a nGenuity device shutting off intermittently. During the inspection, your Vice President indicated that since November 2019, your firm received 21 complaints related to these devices shutting off. One of these complaints (4932) references the device shutting off during surgery. CAPA 1098 did not include any investigation and was still open at the time of the inspection.\u003C\u002Fli>\n\t\u003Cli>Your firm opened CAPA 1033 on December 1, 2017, and CAPA 1059 on July 17, 2018, to address CO2 module issues associated with your vital sign monitors. Since January 1, 2022, your firm has received 276 complaints related to the CO2 module of the nGenuity device, including reports of check line errors, CO2 measurements not reading\u002Fdisplaying, and distorted waveforms. CAPA 1033 did not include any investigation and the investigation in CAPA 1059 was not completed. Both CAPAs were open at the time of the inspection with the last notations dated June 1, 2021.\u003C\u002Fli>\n\t\u003Cli>Your firm opened CAPA 1054 on July 17, 2018, to address SpO2 printed circuit boards assembly (PCBA) related issues with your vital sign monitors. Since January 1, 2022, your firm received 68 complaints related to the SpO2 module. CAPA 1054 did not include any investigation. This CAPA was still open at the time of the inspection with the last notation documented June 1, 2021.\u003C\u002Fli>\n\t\u003Cli>Your firm opened two CAPAs, 1046 and 1050, on August 2, 2018, to address in-process nGenuity analog printed circuit boards (PCBs) and electrocardiogram (ECG) related issues. Since January 2022, your firm received 67 complaints related to the ECG module, including false flat lines or alerts of asystole and noisy waveforms. Both CAPAs were still open at the time of the inspection, and both indicated further investigation was needed with the last notations documented June 1, 2021.\u003C\u002Fli>\n\t\u003Cli>Three CAPAs (1086, 1088, and 1090), related to purchasing, CAPAs, and acceptance activities, were all initiated on November 18, 2019, to address observations from the previous FDA inspection. All four were closed despite not having an adequate root cause investigation and no effectiveness check plan. Two CAPAs (1091 and 1094), were also opened on November 18, 2019, to address design and complaint issues from the previous inspection. Verification of the proposed corrective actions were not performed for either of these CAPAs and were still open at the time of the inspection with no activity since June 1, 2021. We observed continuing deficiencies in all these above quality systems (purchasing, CAPAs, acceptance activities, design and complaints), during our recent inspection.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>This is a repeat deficiency from our 2017 Warning Letter.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion to ensure these CAPA violations will be corrected at your facility.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, your firm has not adequately controlled and documented the design of your nGenuity devices. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm has not adequately conducted a risk analysis for your nGenuity devices, as required by 21 CFR 820.30(g). Specifically, your firm provided a Hazard Analysis &amp; Management document for your nGenuity CO2 Project, dated 2007, which was a document from the company you purchased in 2015. This did not identify risks associated with distorted displays or devices shutting down unexpectedly. Since 2016, your firm received 629 complaints related to distorted displays and at least 21 complaints related to monitors shutting down unexpectedly with your nGenuity device.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Also, the above 2007 Hazard Analysis &amp; Management document for your nGenuity CO2 Project, did not identify any hazards related to faulty internal ECG cables, which were incorporated into certain nGenuity devices after 2015. During the inspection, your Vice President &amp; General Manager stated that this section of the hazard analysis is incomplete, and a faulty internal ECG cable should be identified as another hazard.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm has not adequately performed a design verification for your nGenuity device to confirm that the design output meets design input requirements, as required by 21 CFR 820.30(f). Specifically, the SpO2 accuracy specifications, in a document dated 2006, are defined as \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Two Pulse \u003Cstrong>(b)(4)\u003C\u002Fstrong> Reports from 2000 and 2001 were provided during the inspection to support the above accuracy claims. However, these reports do not support the claims made for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, the reports did not include acceptance criteria, a rationale for the sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> participants, and traceability for the devices reviewed. Your firm has been relying on older design documents for your nGenuity device yet have not performed a sufficient design review to confirm the current design has been verified.\u003C\u002Fli>\n\t\u003Cli>Your firm has not adequately conducted design validation for your nGenuity devices as required by 21 CFR 820.30(g). Specifically, the 8100E Series \u003Cstrong>(b)(4)\u003C\u002Fstrong> provided during the inspection did not include acceptance criteria and did not document a rationale for the sample size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> collecting \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> participants. Your firm has been relying on older design documents for your nGenuity device yet have not performed a sufficient design review to confirm the current device design has been validated.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these design control violations will be corrected at your facility.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that all received product conforms to specified requirements, as required by 21 CFR 820.50. For example, your firm did not have a completed supplier evaluation form for your key supplier of nGenuity SpO2, CO2, analog, and main printed circuit boards (PCBA’s), as required by your own Purchasing Process, CTI 209, Rev E. This supplier has been providing these components to your firm since 2016 yet was listed on your approved supplier list as a probationary supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these purchasing control violations will be corrected at your facility.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including procedures to address the identification, documentation, evaluation, segregation, and disposition of nonconforming (NC) product, as required by 21 CFR 820.90(a). For example, six out of six nonconformance reports reviewed during the inspection did not include documented investigations or dispositions, as required by your procedure. These include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>NC 1797 dated August 4, 2022, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-conforming SpO2 PCBs, p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>NC 1804 dated December 28, 2022, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-conforming displays, p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>NC 1786 dated November 8, 2023, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-conforming \u003Cstrong>(b)(4)\u003C\u002Fstrong>, p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>NC 1787 dated December 3, 2023, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-conforming displays, p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>NC 1790, undated, for one damaged SpO2 analog ribbon cable, p\u002Fn \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>NC 1796, undated, for \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-conforming \u003Cstrong>(b)(4)\u003C\u002Fstrong> main PCBs covering the period 2\u002F7\u002F2022 - 7\u002F21\u002F2022.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these NC violations will be corrected at your facility.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – July 31, 2025\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – July 31, 2026, and July 31, 2027\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Emma Schaefer, Acting Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 686915 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>Cc: Mr. Vinod Ramani, Chairman\u003Cbr>\nOpto Circuits (India) Ltd.\u003Cbr>\n#83 Electronics City, Bengaluru – 560 100, Karnataka, India\u003Cbr>\nEmail: \u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nNeeraj Jha\n\nRecipient Title\n\nCEO\n\nCriticare Technologies, Inc.\n\n6901 TPC Drive, Suite 300\n\nOrlando, FL 32822\n\nUnited States\n\nneeraj@criticare.com\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations East\n\nUnited States\n\nWARNING LETTER\n\nCMS # 686915\n\nJuly 12, 2024\n\nDear Mr. Jha:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Criticare Technologies, Inc., 333 Strawberry Field Rd Ste 11, Warwick, RI, FEI 3012238587, from March 21, 2024, through May 10, 2024. During the inspection, the FDA investigator determined that your firm is a manufacturer of patient monitors including the nGenuity patient vital signs monitor. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that the above devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received your response dated June 3, 2023, from John Haefele, Vice President, and General Manager. which responded to the Form FDA 483, List of Inspectional Observations issued to your firm on May 10, 2024. We address your response below.\n\nYour significant violations are as follows:\n\n1. Failure to establish and maintain procedures for implementing corrective and preventive actions, as required by 21 CFR 820.100(a). Review of your firms Corrective and Preventive Action (CAPA) Procedure, CTI 221 rev H, revealed that it does not provide instructions in sufficient detail to; identify existing and potential causes of nonconforming product, or other quality problems; conduct investigations, identify, and take appropriate corrective or preventive actions, or verify that any such actions are effective. The below examples describe a CAPA system that does not meet the above requirements of 21 CFR.820.100(a):\n\nYour firm opened CAPA 1098 on May 1, 2023, to address a nGenuity device shutting off intermittently. During the inspection, your Vice President indicated that since November 2019, your firm received 21 complaints related to these devices shutting off. One of these complaints (4932) references the device shutting off during surgery. CAPA 1098 did not include any investigation and was still open at the time of the inspection.\n\nYour firm opened CAPA 1033 on December 1, 2017, and CAPA 1059 on July 17, 2018, to address CO2 module issues associated with your vital sign monitors. Since January 1, 2022, your firm has received 276 complaints related to the CO2 module of the nGenuity device, including reports of check line errors, CO2 measurements not reading\u002Fdisplaying, and distorted waveforms. CAPA 1033 did not include any investigation and the investigation in CAPA 1059 was not completed. Both CAPAs were open at the time of the inspection with the last notations dated June 1, 2021.\n\nYour firm opened CAPA 1054 on July 17, 2018, to address SpO2 printed circuit boards assembly (PCBA) related issues with your vital sign monitors. Since January 1, 2022, your firm received 68 complaints related to the SpO2 module. CAPA 1054 did not include any investigation. This CAPA was still open at the time of the inspection with the last notation documented June 1, 2021.\n\nYour firm opened two CAPAs, 1046 and 1050, on August 2, 2018, to address in-process nGenuity analog printed circuit boards (PCBs) and electrocardiogram (ECG) related issues. Since January 2022, your firm received 67 complaints related to the ECG module, including false flat lines or alerts of asystole and noisy waveforms. Both CAPAs were still open at the time of the inspection, and both indicated further investigation was needed with the last notations documented June 1, 2021.\n\nThree CAPAs (1086, 1088, and 1090), related to purchasing, CAPAs, and acceptance activities, were all initiated on November 18, 2019, to address observations from the previous FDA inspection. All four were closed despite not having an adequate root cause investigation and no effectiveness check plan. Two CAPAs (1091 and 1094), were also opened on November 18, 2019, to address design and complaint issues from the previous inspection. Verification of the proposed corrective actions were not performed for either of these CAPAs and were still open at the time of the inspection with no activity since June 1, 2021. We observed continuing deficiencies in all these above quality systems (purchasing, CAPAs, acceptance activities, design and complaints), during our recent inspection.\n\nThis is a repeat deficiency from our 2017 Warning Letter.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion to ensure these CAPA violations will be corrected at your facility.\n\n2. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). Specifically, your firm has not adequately controlled and documented the design of your nGenuity devices. For example:\n\nYour firm has not adequately conducted a risk analysis for your nGenuity devices, as required by 21 CFR 820.30(g). Specifically, your firm provided a Hazard Analysis & Management document for your nGenuity CO2 Project, dated 2007, which was a document from the company you purchased in 2015. This did not identify risks associated with distorted displays or devices shutting down unexpectedly. Since 2016, your firm received 629 complaints related to distorted displays and at least 21 complaints related to monitors shutting down unexpectedly with your nGenuity device.\n\nAlso, the above 2007 Hazard Analysis & Management document for your nGenuity CO2 Project, did not identify any hazards related to faulty internal ECG cables, which were incorporated into certain nGenuity devices after 2015. During the inspection, your Vice President & General Manager stated that this section of the hazard analysis is incomplete, and a faulty internal ECG cable should be identified as another hazard.\n\nYour firm has not adequately performed a design verification for your nGenuity device to confirm that the design output meets design input requirements, as required by 21 CFR 820.30(f). Specifically, the SpO2 accuracy specifications, in a document dated 2006, are defined as (b)(4) for the range of (b)(4) and (b)(4) for the range of (b)(4). Two Pulse (b)(4) Reports from 2000 and 2001 were provided during the inspection to support the above accuracy claims. However, these reports do not support the claims made for the (b)(4). For example, the reports did not include acceptance criteria, a rationale for the sample size of (b)(4) participants, and traceability for the devices reviewed. Your firm has been relying on older design documents for your nGenuity device yet have not performed a sufficient design review to confirm the current design has been verified.\n\nYour firm has not adequately conducted design validation for your nGenuity devices as required by 21 CFR 820.30(g). Specifically, the 8100E Series (b)(4) provided during the inspection did not include acceptance criteria and did not document a rationale for the sample size of (b)(4) collecting (b)(4) on (b)(4) participants. Your firm has been relying on older design documents for your nGenuity device yet have not performed a sufficient design review to confirm the current device design has been validated.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these design control violations will be corrected at your facility.\n\n3. Failure to establish and maintain procedures to ensure that all received product conforms to specified requirements, as required by 21 CFR 820.50. For example, your firm did not have a completed supplier evaluation form for your key supplier of nGenuity SpO2, CO2, analog, and main printed circuit boards (PCBA’s), as required by your own Purchasing Process, CTI 209, Rev E. This supplier has been providing these components to your firm since 2016 yet was listed on your approved supplier list as a probationary supplier.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these purchasing control violations will be corrected at your facility.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including procedures to address the identification, documentation, evaluation, segregation, and disposition of nonconforming (NC) product, as required by 21 CFR 820.90(a). For example, six out of six nonconformance reports reviewed during the inspection did not include documented investigations or dispositions, as required by your procedure. These include:\n\nNC 1797 dated August 4, 2022, for (b)(4) non-conforming SpO2 PCBs, p\u002Fn (b)(4), lots (b)(4) and (b)(4).\n\nNC 1804 dated December 28, 2022, for (b)(4) non-conforming displays, p\u002Fn (b)(4), lots (b)(4), and (b)(4).\n\nNC 1786 dated November 8, 2023, for (b)(4) non-conforming (b)(4), p\u002Fn (b)(4), lot (b)(4).\n\nNC 1787 dated December 3, 2023, for (b)(4) non-conforming displays, p\u002Fn (b)(4), lots (b)(4) and (b)(4).\n\nNC 1790, undated, for one damaged SpO2 analog ribbon cable, p\u002Fn (b)(4)\n\nNC 1796, undated, for (b)(4) non-conforming (b)(4) main PCBs covering the period 2\u002F7\u002F2022 - 7\u002F21\u002F2022.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You have not provided sufficient details regarding any corrective actions, documents, or a timeline for completion, to ensure these NC violations will be corrected at your facility.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your establishment's manufacturing and quality assurance systems relative to the requirements of the device QS regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your establishment has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – July 31, 2025\n\nSubsequent certifications – July 31, 2026, and July 31, 2027\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Emma Schaefer, Acting Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 686915 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\nCc: Mr. Vinod Ramani, Chairman\n\nOpto Circuits (India) Ltd.\n\n#83 Electronics City, Bengaluru – 560 100, Karnataka, India\n\nEmail: (b)(6)","Criticare Technologies, Inc.","criticare-technologies-inc-686915-07122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcriticare-technologies-inc-686915-07122024","2026-10-26T08:08:19.255848+00:00","2024-07-23","686915","Neeraj Jha","2026-08-19T23:56:30.744+00:00","United Parcel Service","2024-07-12",{"id":194,"raw":195,"subject":12,"body_html":199,"body_text":200,"firm_name":201,"letter_id":202,"created_at":203,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":23,"posted_date":206,"marcs_cms_no":207,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":208,"body_fetched_at":209,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":210,"medical_device_id":19,"response_letter_date":19},625,[196,197,198,38,12,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-21T04:00:00Z\">08\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fseniorlife-technologies-inc-707021-08212025\">SeniorLife Technologies, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ashok Roy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SeniorLife Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1400 112th Ave., SE, Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bellevue\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ash.roy@seniorlife.io\"> ash.roy@seniorlife.io\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #707021\u003C\u002Fp>\u003Cp>August 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Roy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in 1400 112th Ave., Bellevue, WA 98004, FEI #3027535342, from March 24, 2025, through March 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures SeniorLife.AI. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cu>Unapproved Device Violation\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Our inspection revealed that your SeniorLife.AI mobile application is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The SeniorLife.AI mobile application is also misbranded under section 502(o) of the Act, 21 U.S.C. §352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k) and 21 CFR 807.81(a)(1).\u003C\u002Fp>\u003Cp>Specifically, you registered your device under 21 CFR 890.5360 Measuring Exercise Equipment. However, the evidence indicates that SeniorLife.AI is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5360 Measuring Exercise Equipment, and that your device is outside the scope of this regulation. Measuring exercise equipment consist of manual devices intended for medical purposes, such as to redevelop muscles or restore motion to joints or for use as an adjunct treatment for obesity. Your firm is distributing SeniorLife.AI for a different intended use, namely the use of artificial intelligence-based algorithms to screen and “pre-diagnose” mobility and cognitive health conditions. Examples from the SeniorLife Technologies, Inc. website (https:\u002F\u002Fwww.seniorlife.ai\u002F) include:\u003C\u002Fp>\u003Cul>\u003Cli>“Age Smarter – AI Agents for mobility and cognitive health - built for seniors, their families and care providers.”\u003C\u002Fli>\u003Cli>“…Proven to reduced [sic] Fall [sic] by 58% in a 2-year Japanese study.”\u003C\u002Fli>\u003Cli>Mobility Health Agent – Proactively identifies fall risk, recommends interventions, and continuously tracks patient mobility over time.\u003C\u002Fli>\u003Cli>Cognitive Health Agent – Conducts a 5-minute gaze-based test on an iPad to detect early signs of Alzheimer’s — fast, non-invasive, and scalable.\u003C\u002Fli>\u003Cli>“Results — The server-based AI models analyze these input to assess risks and recommend therapies.”\u003C\u002Fli>\u003Cli>One of your FAQ responses says, “Our AI enabled computer vision software can assist a caregiver to perform these tests that provide a quick pre-diagnosis.”\u003C\u002Fli>\u003Cli>“TUG or Timed-up-Go test is an enhanced gait &amp; balance test. It’s typically used to assess frailty and risk of fall. Traditional measurement is the time taken by an older adult to get up from the chair, walk 10 ft (= 3m), and walk back to the chair. Our AI models can measure as many as 7 different parameters.”\u003C\u002Fli>\u003Cli>“Gait and balance test – This test measures several irregularities in walking, balance and even movements of head of an older adult that can be early predictors of Alzheimer’s.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Use of artificial intelligence-based algorithms to screen and diagnose mobility and cognitive health conditions, including Alzheimer’s, are diagnostic functions that are not the same as measurement of exercises. Performing proprietary analyses of patient data for the screening and diagnosis of specific conditions or disorders represents a new intended use compared to use in rehabilitation or physiotherapy to provide or facilitate exercise rehabilitation and to include exercise measurement capabilities, such as for redevelopment of muscles for restoration of motion and providing accompanying measurement of range of motion. Because there is evidence that SeniorLife.AI is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5360, it does not fall within the scope of that regulation and requires a premarket submission prior to marketing.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourD evice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that SeniorLife Technologies, Inc. cease any activities that result in the misbranding or adulteration of SeniorLife.AI, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We have not received your firm’s response concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on March 26, 2025. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a).\u003C\u002Fp>\u003Cp>For example, your firm has not established procedures for implementing corrective and preventive actions.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fp>\u003Cp>For example, your firm has not established procedures for handling complaints. The investigator reviewed your complaint files and noted that they were not adequately evaluated to determine if an investigation was needed or whether the complaints should be reported to the FDA under Part 803, Medical Device Reporting, as noted by these examples:\u003C\u002Fp>\u003Cp>a. Your firm filed Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> to change the test instructions for your software application to examine based on age, device usage, and disease conditions. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting. This complaint remains open and was unresolved during the inspection.\u003C\u002Fp>\u003Cp>b. Your firm filed Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was closed on 7\u002F10\u002F23. The complaint is about a camera orientation bug where the camera stays in portrait mode when the app is opened, and the phone is turned horizontally. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting.\u003C\u002Fp>\u003Cp>c. Your firm filed Complaint \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was closed on 7\u002F10\u002F23. The issue is regarding a request to change the application after visiting a customer to demonstrate the software application. There were changes such as analyzing Timed Up and Go (TUG) tests, creating reports, and developing specifications for saving data without being overwritten, raising concerns about the quality, reliability, and performance of the software. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting.\u003C\u002Fp>\u003Cp>These examples show that your firm has not established a procedure for handling complaints which increases the likelihood complaints will not be collected and analyzed in a manner that provides a valid quality data source and identification of potential nonconformances and compromises other activities such as corrective and preventive actions.\u003C\u002Fp>\u003Cp>3. Failure to establish procedures for quality audits, as required by 21 CFR § 820.22.\u003C\u002Fp>\u003Cp>For example, your firm has not established procedures for conducting quality audits and has not performed a quality audit since it was established in 2022, despite engaging in medical device operations.\u003C\u002Fp>\u003Cp>4. Failure to establish procedures for training and identifying training needs, as required by 21 CFR § 820.25(b).\u003C\u002Fp>\u003Cp>For example, your firm has not established training procedures and have not conducted training or kept training records to ensure employees perform their assigned responsibilities.\u003C\u002Fp>\u003Cp>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. During the inspection, Mr. Ashok Roy, President, and Ms. Shoko Hoshi, Co-Founder and Product Designer, acknowledged that your firm has not developed a written MDR procedure.\u003C\u002Fp>\u003Cp>A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\u003Cp>\u003Cu>Labeling Violation\u003C\u002Fu>\u003C\u002Fp>\u003Cp>In addition, your device is further misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), which provides that a product is misbranded when its labeling is false or misleading in any particular, because your product’s website includes false and misleading representations, as described below:\u003C\u002Fp>\u003Cul>\u003Cli>Representations on and available through your website create an impression of official approval of the device and other potential endorsement by FDA and are false and misleading. The Apple and Android store app links on your website lead to the digital marketplaces from where purchasers can download the software. The images on those digital storefronts include the FDA logo. Further, the language “FDA Approved” appears in those same places. Your product has not received premarket approval from FDA so that representation is false. Your website also contains a statement “FDA Certified,” which is both false and misleading because FDA has not “certified” your device. The display of the FDA logo near images of and information about the products, as well as statements of FDA approval or certification, are misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA. In addition to those implications, the use of the logo is in violation of FDA’s logo policy, which can be found on our website: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-name-and-logo-policy.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 707021” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko, via email at charles.chacko@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAshok Roy\n\nRecipient Title\n\nPresident\n\nSeniorLife Technologies, Inc.\n\n1400 112th Ave., SE, Ste 100\n\nBellevue, WA 98004\n\nUnited States\n\nash.roy@seniorlife.io\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #707021\nAugust 21, 2025\nDear Mr. Roy:\nDuring an inspection of your firm located in 1400 112th Ave., Bellevue, WA 98004, FEI #3027535342, from March 24, 2025, through March 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures SeniorLife.AI. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violation\nOur inspection revealed that your SeniorLife.AI mobile application is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The SeniorLife.AI mobile application is also misbranded under section 502(o) of the Act, 21 U.S.C. §352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k) and 21 CFR 807.81(a)(1).\nSpecifically, you registered your device under 21 CFR 890.5360 Measuring Exercise Equipment. However, the evidence indicates that SeniorLife.AI is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5360 Measuring Exercise Equipment, and that your device is outside the scope of this regulation. Measuring exercise equipment consist of manual devices intended for medical purposes, such as to redevelop muscles or restore motion to joints or for use as an adjunct treatment for obesity. Your firm is distributing SeniorLife.AI for a different intended use, namely the use of artificial intelligence-based algorithms to screen and “pre-diagnose” mobility and cognitive health conditions. Examples from the SeniorLife Technologies, Inc. website (https:\u002F\u002Fwww.seniorlife.ai\u002F) include:\n“Age Smarter – AI Agents for mobility and cognitive health - built for seniors, their families and care providers.”\n“…Proven to reduced [sic] Fall [sic] by 58% in a 2-year Japanese study.”\nMobility Health Agent – Proactively identifies fall risk, recommends interventions, and continuously tracks patient mobility over time.\nCognitive Health Agent – Conducts a 5-minute gaze-based test on an iPad to detect early signs of Alzheimer’s — fast, non-invasive, and scalable.\n“Results — The server-based AI models analyze these input to assess risks and recommend therapies.”\nOne of your FAQ responses says, “Our AI enabled computer vision software can assist a caregiver to perform these tests that provide a quick pre-diagnosis.”\n“TUG or Timed-up-Go test is an enhanced gait & balance test. It’s typically used to assess frailty and risk of fall. Traditional measurement is the time taken by an older adult to get up from the chair, walk 10 ft (= 3m), and walk back to the chair. Our AI models can measure as many as 7 different parameters.”\n“Gait and balance test – This test measures several irregularities in walking, balance and even movements of head of an older adult that can be early predictors of Alzheimer’s.”\nUse of artificial intelligence-based algorithms to screen and diagnose mobility and cognitive health conditions, including Alzheimer’s, are diagnostic functions that are not the same as measurement of exercises. Performing proprietary analyses of patient data for the screening and diagnosis of specific conditions or disorders represents a new intended use compared to use in rehabilitation or physiotherapy to provide or facilitate exercise rehabilitation and to include exercise measurement capabilities, such as for redevelopment of muscles for restoration of motion and providing accompanying measurement of range of motion. Because there is evidence that SeniorLife.AI is intended for uses that are different from those of legally marketed devices classified under 21 CFR 890.5360, it does not fall within the scope of that regulation and requires a premarket submission prior to marketing.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourD evice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that SeniorLife Technologies, Inc. cease any activities that result in the misbranding or adulteration of SeniorLife.AI, such as the commercial distribution of the device for the uses discussed above.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe have not received your firm’s response concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on March 26, 2025. These violations include but are not limited to the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR § 820.100(a).\nFor example, your firm has not established procedures for implementing corrective and preventive actions.\n2. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\nFor example, your firm has not established procedures for handling complaints. The investigator reviewed your complaint files and noted that they were not adequately evaluated to determine if an investigation was needed or whether the complaints should be reported to the FDA under Part 803, Medical Device Reporting, as noted by these examples:\na. Your firm filed Complaint (b)(4) on (b)(4) to change the test instructions for your software application to examine based on age, device usage, and disease conditions. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting. This complaint remains open and was unresolved during the inspection.\nb. Your firm filed Complaint (b)(4) on (b)(4), which was closed on 7\u002F10\u002F23. The complaint is about a camera orientation bug where the camera stays in portrait mode when the app is opened, and the phone is turned horizontally. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting.\nc. Your firm filed Complaint (b)(4) on (b)(4), which was closed on 7\u002F10\u002F23. The issue is regarding a request to change the application after visiting a customer to demonstrate the software application. There were changes such as analyzing Timed Up and Go (TUG) tests, creating reports, and developing specifications for saving data without being overwritten, raising concerns about the quality, reliability, and performance of the software. It is unclear if a proper investigation was conducted to determine the root cause(s) and if it was evaluated for MDR reporting.\nThese examples show that your firm has not established a procedure for handling complaints which increases the likelihood complaints will not be collected and analyzed in a manner that provides a valid quality data source and identification of potential nonconformances and compromises other activities such as corrective and preventive actions.\n3. Failure to establish procedures for quality audits, as required by 21 CFR § 820.22.\nFor example, your firm has not established procedures for conducting quality audits and has not performed a quality audit since it was established in 2022, despite engaging in medical device operations.\n4. Failure to establish procedures for training and identifying training needs, as required by 21 CFR § 820.25(b).\nFor example, your firm has not established training procedures and have not conducted training or kept training records to ensure employees perform their assigned responsibilities.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. During the inspection, Mr. Ashok Roy, President, and Ms. Shoko Hoshi, Co-Founder and Product Designer, acknowledged that your firm has not developed a written MDR procedure.\nA device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\nLabeling Violation\nIn addition, your device is further misbranded within the meaning of section 502(a) of the Act, 21 U.S.C. § 352(a), which provides that a product is misbranded when its labeling is false or misleading in any particular, because your product’s website includes false and misleading representations, as described below:\nRepresentations on and available through your website create an impression of official approval of the device and other potential endorsement by FDA and are false and misleading. The Apple and Android store app links on your website lead to the digital marketplaces from where purchasers can download the software. The images on those digital storefronts include the FDA logo. Further, the language “FDA Approved” appears in those same places. Your product has not received premarket approval from FDA so that representation is false. Your website also contains a statement “FDA Certified,” which is both false and misleading because FDA has not “certified” your device. The display of the FDA logo near images of and information about the products, as well as statements of FDA approval or certification, are misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA. In addition to those implications, the use of the logo is in violation of FDA’s logo policy, which can be found on our website: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-name-and-logo-policy.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 707021” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Charles J. Chacko, via email at charles.chacko@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","SeniorLife Technologies, Inc.","seniorlife-technologies-inc-707021-08212025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fseniorlife-technologies-inc-707021-08212025","2026-10-26T08:09:55.526654+00:00","2025-09-16","707021","Ashok Roy","2026-08-19T16:24:30.618+00:00","2025-08-21",{"id":212,"raw":213,"subject":162,"body_html":215,"body_text":216,"firm_name":217,"letter_id":218,"created_at":44,"fei_number":19,"letter_url":219,"updated_at":220,"action_type":22,"case_status":23,"posted_date":169,"marcs_cms_no":221,"product_type":150,"closeout_date":19,"issuing_office":160,"recipient_name":19,"body_fetched_at":222,"delivery_method":172,"recipient_title":19,"reference_number":19,"action_taken_date":173,"medical_device_id":19,"response_letter_date":19},312,[157,158,214,160,161,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaxlife-technologies-inc-dba-maxlife-721453-02202026\">MaxLife Technologies Inc. dba Maxlife \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>MaxLife Technologies Inc. dba Maxlife \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>220 Technology Dr Ste. 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hq@maxlife.com\"> hq@maxlife.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Maxlife:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fmaxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Maxlife is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“generic compounded medication”\u003C\u002Fli>\u003Cli>“With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.”\u003C\u002Fli>\u003Cli>“With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.”\u003C\u002Fli>\u003Cli>“FDA Approved”\u003C\u002Fli>\u003Cli>“Active ingredients in Ozempic® &amp; Wegovy®”\u003C\u002Fli>\u003Cli>“Active ingredients in Mounjaro® &amp; Zepbound®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMaxLife Technologies Inc. dba Maxlife\n\n220 Technology Dr Ste. 215\n\nIrvine, CA 92618\n\nUnited States\n\nhq@maxlife.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nMaxlife:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fmaxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Maxlife is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“generic compounded medication”\n“With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.”\n“With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.”\n“FDA Approved”\n“Active ingredients in Ozempic® & Wegovy®”\n“Active ingredients in Mounjaro® & Zepbound®”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","MaxLife Technologies Inc. dba Maxlife","maxlife-technologies-inc-dba-maxlife-721453-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmaxlife-technologies-inc-dba-maxlife-721453-02202026","2026-10-26T08:09:21.894493+00:00","721453","2026-08-19T04:55:07.096+00:00",{"id":224,"raw":225,"subject":230,"body_html":231,"body_text":232,"firm_name":233,"letter_id":234,"created_at":18,"fei_number":19,"letter_url":235,"updated_at":236,"action_type":22,"case_status":23,"posted_date":237,"marcs_cms_no":238,"product_type":150,"closeout_date":19,"issuing_office":229,"recipient_name":239,"body_fetched_at":240,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":241,"medical_device_id":19,"response_letter_date":19},1608,[226,227,228,229,230,13,13,13],"\u003Ctime datetime=\"2024-02-13T14:20:00Z\">02\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-06T05:00:00Z\">02\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-life-technologies-corp-674279-02062024\">Global Life Technologies Corp.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John Willimann\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Life Technologies Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4608 N. Park Avenue, 2nd floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chevy Chase\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20815\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:john@nozin.com\"> john@nozin.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 6, 2024\u003Cbr>\n\u003Cbr>\nRE: 3007588545\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Willimann:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the over-the-counter (OTC) drug product Nozin® Nasal Sanitizer®. The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nozin.com\u002F on October 19 and October 20, 2023. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FNozinNasalSanitizer\u002Fwall\u002F and https:\u002F\u002Ftwitter.com\u002Fnozin; these websites direct consumers to your website https:\u002F\u002Fwww.nozin.com\u002F to purchase your products.\u003C\u002Fp>\n\n\u003Cp>Nozin® Nasal Sanitizer® is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food &amp; Cosmetic Act (FD&amp;C Act,) 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Nozin® Nasal Sanitizer® is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as both a consumer and a health care topical antiseptic drug.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Nozin® Nasal Sanitizer® labeling from your website and the social media websites listed above that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003Cbr>\n“Nozin Nasal Sanitizer is an antiseptic that is used to kill pathogenic bacteria that are carried in the anterior nares (nasal vestibule). The vestibule is the single most abundant reservoir of antibiotic resistant and susceptible \u003Cem>Staph aureus\u003C\u002Fem> (MRSA &amp; MSSA) on the body and also harbors other microbial pathogens. The use of the Nasal Sanitizer® antiseptic also contributes to good nasal hygiene.” [from your website under Consumer FAQs https:\u002F\u002Fwww.nozin.com\u002Fconsumer-faq\u002F]\u003C\u002Fp>\n\n\u003Cp>“Nozin® Nasal Sanitizer® Nozaseptin® formula combines ethanol with antioxidant rich natural emollients. This provides a highly effective antiseptic for the nose in a pleasant and moisturizing application. No prescription needed.” “Helps reduce risk of infection.” [from your website under Buy Nozin https:\u002F\u002Fwww.nozin.com\u002Fproduct\u002Fnozin-nasal-sanitizer-12ml-bottle\u002F]\u003C\u002Fp>\n\n\u003Cp>“…Universal sustained nasal decolonization is now possible without some of the familiar constraints of antibiotics and iodine. Nozin® Infection Prevention Program helps safeguard your most vulnerable patients from the risks of MRSA colonization.” [from your website under product comparison https:\u002F\u002Fwww.nozin.com\u002Fnozin-nasal-sanitizer\u002F]\u003C\u002Fp>\n\n\u003Cp>“Nozin® Nasal Sanitizer® is specially formulated to effectively address nasal carriage of bacteria:\u003Cbr>\nEffective - kills 99.99% of germs and is clinically proven to decrease nasal bacteria carriage Safe, fast acting - the active ingredient is ethyl alcohol, a well-established, trusted, broad spectrum antiseptic 12-hour duration - soothing solution is well tolerated, safe for regular use and Nasal Sanitizer® effect lasts 12 hours” [from your website under How It Works https:\u002F\u002Fwww.nozin.com\u002Fhow-it-works\u002F]\u003C\u002Fp>\n\n\u003Cp>“The staff were very open to the idea of using Nozin, it meant we could quit using Mupirocin ointment. Patients could get swabbed for MRSA and did not have to stay a couple of hours for the MRSA results.” [from a testimonial on your website https:\u002F\u002Fwww.nozin.com\u002Fcustomer-testimonials\u002F]\u003C\u002Fp>\n\n\u003Cp>“We began the Nozin program right before COVID hit, it has been a game changer for us on saving on PPE, availability of patient rooms, and the patients have been better satisfied as they are not in isolation” [from a testimonial on your website https:\u002F\u002Fwww.nozin.com\u002Fcustomer-testimonials\u002F]\u003C\u002Fp>\n\n\u003Cp>“Now is the time to keep abreast of innovations in patient care to ensue optimal reduction of not only COVID-19 risk, but also HAI risk. With the support of hospital leadership, IP departments have long been early adopter of innovative products and practices in the interest of patient safety. Universal nasal and skin decolonization is an innovative approach with many advantages designed to reduce the transmission of MRSA and MSSA and associated infection risk in the interest of patient safety and cost containment.” [from a White Paper downloaded from your website under Healthcare Pros https:\u002F\u002Fwww.nozin.com\u002F: “Increased Risk of HAIs and the Case for Patient Decolonization in the COVID-19 Era for Healthcare Professionals”]\u003C\u002Fp>\n\n\u003Cp>“Independently conducted research studies of programs using Nozin Nasal Sanitizer antiseptic for nasal decolonization” led to a “100% reduction in total hip and total knee surgical site infections.” [from a post on your Facebook webpage, dated 9\u002F02\u002F2020, at https:\u002F\u002Fwww.facebook.com\u002FNozinNasalSanitizer\u002Fwall\u002F]\u003C\u002Fp>\n\n\u003Cp>“Road trip time. Consider packing Nozin Nasal Sanitizer antiseptic, #1 hospital-trusted product for daily nasal decolonization, contains alcohol which kills 99.99% of germs and keeps working for up to 12 hours.” [from a repost by you on your X (formerly Twitter) webpage, dated 7\u002F29\u002F2020, at https:\u002F\u002Ftwitter.com\u002Fnozin]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, Nozin® Nasal Sanitizer® is intended for use as a consumer and a health care topical antiseptic product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&amp;C Act or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product identified above.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>We note that OTC topical antiseptic products had been the subject of a rulemaking under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Health care topical antiseptics were addressed in the 1994 TFM, as further amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (Health Care Antiseptics Proposed Rule), and “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 82 FR 60474 (December 20, 2017) (Health Care Antiseptics Final Rule). Over the course of these rulemakings, six active ingredients (benzalkonium chloride, benzethonium chloride, chloroxylenol, ethyl alcohol, isopropyl alcohol, and povidone-iodine) were classified as Category III for use in health care antiseptic products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as health care antiseptics, including patient antiseptic skin preparations.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, your Nozin® Nasal Sanitizer® product does not conform to the 1994 TFM, nor any other TFM, proposed rule, or final rule and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>Specifically, your labeling claims, suggesting that Nozin® Nasal Sanitizer® is effective in preventing infection or disease from the novel coronavirus that causes COVID-19 and other pathogenic organisms, such as Staphylococcus aureus that is either Methicillin-resistant (MRSA) or Methicillin-susceptible (MSSA), go beyond merely describing the general intended use of an antiseptic as set forth in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, your labeling claims, suggesting that Nozin® Nasal Sanitizer® provides up to 12 hours of efficacy against serious-disease related pathogens, are not permitted under the 1994 TFM or any of the amendments to the TFM, as discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, may lead to a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. This labeled intended use goes beyond merely describing the general intended use of topical antiseptics as set forth in the 1994 TFM and the amendments to the TFM, as discussed above.\u003C\u002Fp>\n\n\u003Cp>In addition, according to the product labeling, Nozin® Nasal Sanitizer® is intended to be applied inside the nostrils. Consumer and health care antiseptic products intended for administration inside the nostrils are not permitted under the 1994 TFM, as further amended by the Consumer Antiseptic Rubs Proposed Rule and the Health Care Antiseptics Proposed Rule.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Nozin® Nasal Sanitizer® is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nOffice Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your Nozin® Nasal Sanitizer® drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that can potentially cause disease and health care and consumer antiseptics that are indicated to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as inside the nose are not permitted. Under the 1994 TFM, as amended by the 2015 Health Care Antiseptics Proposed Rule and 2017 Health Care Antiseptics Final Rule, certain health care topical antiseptic products intended for use without water, including patient antiseptic skin preparations, are permitted. Health care antiseptic products intended for use inside the nose are not permitted because the inside of the nose is a mucous membrane.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn Willimann\n\nRecipient Title\n\nPresident\n\nGlobal Life Technologies Corp.\n\n4608 N. Park Avenue, 2nd floor\n\nChevy Chase, MD 20815\n\nUnited States\n\njohn@nozin.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nFebruary 6, 2024\n\nRE: 3007588545\n\nDear Mr. Willimann:\n\nThis letter concerns your firm’s distribution of the over-the-counter (OTC) drug product Nozin® Nasal Sanitizer®. The U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.nozin.com\u002F on October 19 and October 20, 2023. We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FNozinNasalSanitizer\u002Fwall\u002F and https:\u002F\u002Ftwitter.com\u002Fnozin; these websites direct consumers to your website https:\u002F\u002Fwww.nozin.com\u002F to purchase your products.\n\nNozin® Nasal Sanitizer® is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food & Cosmetic Act (FD&C Act,) 21 U.S.C. 355(a) and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nNozin® Nasal Sanitizer® is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as both a consumer and a health care topical antiseptic drug.\n\nExamples of claims observed on the Nozin® Nasal Sanitizer® labeling from your website and the social media websites listed above that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“Nozin Nasal Sanitizer is an antiseptic that is used to kill pathogenic bacteria that are carried in the anterior nares (nasal vestibule). The vestibule is the single most abundant reservoir of antibiotic resistant and susceptible Staph aureus (MRSA & MSSA) on the body and also harbors other microbial pathogens. The use of the Nasal Sanitizer® antiseptic also contributes to good nasal hygiene.” [from your website under Consumer FAQs https:\u002F\u002Fwww.nozin.com\u002Fconsumer-faq\u002F]\n\n“Nozin® Nasal Sanitizer® Nozaseptin® formula combines ethanol with antioxidant rich natural emollients. This provides a highly effective antiseptic for the nose in a pleasant and moisturizing application. No prescription needed.” “Helps reduce risk of infection.” [from your website under Buy Nozin https:\u002F\u002Fwww.nozin.com\u002Fproduct\u002Fnozin-nasal-sanitizer-12ml-bottle\u002F]\n\n“…Universal sustained nasal decolonization is now possible without some of the familiar constraints of antibiotics and iodine. Nozin® Infection Prevention Program helps safeguard your most vulnerable patients from the risks of MRSA colonization.” [from your website under product comparison https:\u002F\u002Fwww.nozin.com\u002Fnozin-nasal-sanitizer\u002F]\n\n“Nozin® Nasal Sanitizer® is specially formulated to effectively address nasal carriage of bacteria:\n\nEffective - kills 99.99% of germs and is clinically proven to decrease nasal bacteria carriage Safe, fast acting - the active ingredient is ethyl alcohol, a well-established, trusted, broad spectrum antiseptic 12-hour duration - soothing solution is well tolerated, safe for regular use and Nasal Sanitizer® effect lasts 12 hours” [from your website under How It Works https:\u002F\u002Fwww.nozin.com\u002Fhow-it-works\u002F]\n\n“The staff were very open to the idea of using Nozin, it meant we could quit using Mupirocin ointment. Patients could get swabbed for MRSA and did not have to stay a couple of hours for the MRSA results.” [from a testimonial on your website https:\u002F\u002Fwww.nozin.com\u002Fcustomer-testimonials\u002F]\n\n“We began the Nozin program right before COVID hit, it has been a game changer for us on saving on PPE, availability of patient rooms, and the patients have been better satisfied as they are not in isolation” [from a testimonial on your website https:\u002F\u002Fwww.nozin.com\u002Fcustomer-testimonials\u002F]\n\n“Now is the time to keep abreast of innovations in patient care to ensue optimal reduction of not only COVID-19 risk, but also HAI risk. With the support of hospital leadership, IP departments have long been early adopter of innovative products and practices in the interest of patient safety. Universal nasal and skin decolonization is an innovative approach with many advantages designed to reduce the transmission of MRSA and MSSA and associated infection risk in the interest of patient safety and cost containment.” [from a White Paper downloaded from your website under Healthcare Pros https:\u002F\u002Fwww.nozin.com\u002F: “Increased Risk of HAIs and the Case for Patient Decolonization in the COVID-19 Era for Healthcare Professionals”]\n\n“Independently conducted research studies of programs using Nozin Nasal Sanitizer antiseptic for nasal decolonization” led to a “100% reduction in total hip and total knee surgical site infections.” [from a post on your Facebook webpage, dated 9\u002F02\u002F2020, at https:\u002F\u002Fwww.facebook.com\u002FNozinNasalSanitizer\u002Fwall\u002F]\n\n“Road trip time. Consider packing Nozin Nasal Sanitizer antiseptic, #1 hospital-trusted product for daily nasal decolonization, contains alcohol which kills 99.99% of germs and keeps working for up to 12 hours.” [from a repost by you on your X (formerly Twitter) webpage, dated 7\u002F29\u002F2020, at https:\u002F\u002Ftwitter.com\u002Fnozin]\n\nBased on the above labeling claims, Nozin® Nasal Sanitizer® is intended for use as a consumer and a health care topical antiseptic product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless it is lawfully marketed under section 505G of the FD&C Act or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product identified above.1\n\nWe note that OTC topical antiseptic products had been the subject of a rulemaking under the Agency’s OTC Drug Review. In particular, consumer topical antiseptics were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub. Health care topical antiseptics were addressed in the 1994 TFM, as further amended by “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (Health Care Antiseptics Proposed Rule), and “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Final Rule, 82 FR 60474 (December 20, 2017) (Health Care Antiseptics Final Rule). Over the course of these rulemakings, six active ingredients (benzalkonium chloride, benzethonium chloride, chloroxylenol, ethyl alcohol, isopropyl alcohol, and povidone-iodine) were classified as Category III for use in health care antiseptic products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as health care antiseptics, including patient antiseptic skin preparations.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM and comply with all other applicable requirements.\n\nHowever, your Nozin® Nasal Sanitizer® product does not conform to the 1994 TFM, nor any other TFM, proposed rule, or final rule and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nSpecifically, your labeling claims, suggesting that Nozin® Nasal Sanitizer® is effective in preventing infection or disease from the novel coronavirus that causes COVID-19 and other pathogenic organisms, such as Staphylococcus aureus that is either Methicillin-resistant (MRSA) or Methicillin-susceptible (MSSA), go beyond merely describing the general intended use of an antiseptic as set forth in the 1994 TFM.2 In addition, your labeling claims, suggesting that Nozin® Nasal Sanitizer® provides up to 12 hours of efficacy against serious-disease related pathogens, are not permitted under the 1994 TFM or any of the amendments to the TFM, as discussed above. Time-specific extended efficacy claims, especially when related to serious-disease related pathogens, may lead to a false sense of security for the general public that may result in infrequent hand washing or the substitution of these products for protective gloves and clothing, which are the principal methods for protecting against the spread of diseases caused by pathogenic microorganisms. This labeled intended use goes beyond merely describing the general intended use of topical antiseptics as set forth in the 1994 TFM and the amendments to the TFM, as discussed above.\n\nIn addition, according to the product labeling, Nozin® Nasal Sanitizer® is intended to be applied inside the nostrils. Consumer and health care antiseptic products intended for administration inside the nostrils are not permitted under the 1994 TFM, as further amended by the Consumer Antiseptic Rubs Proposed Rule and the Health Care Antiseptics Proposed Rule.3\n\nMisbranded Drug Violations\n\nNozin® Nasal Sanitizer® is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action including, without limitation, seizure and injunction.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nOffice Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n___________________\n\n1 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your Nozin® Nasal Sanitizer® drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling.\n\n2 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that can potentially cause disease and health care and consumer antiseptics that are indicated to decrease bacteria on the skin. 59 FR at 31443.\n\n3 The 2016 Consumer Antiseptic Rubs Proposed Rule covered consumer antiseptic products intended for use without water. Under the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, only consumer topical antiseptic products intended for use on the hands without water are permitted. Products intended for other areas of the body such as inside the nose are not permitted. Under the 1994 TFM, as amended by the 2015 Health Care Antiseptics Proposed Rule and 2017 Health Care Antiseptics Final Rule, certain health care topical antiseptic products intended for use without water, including patient antiseptic skin preparations, are permitted. Health care antiseptic products intended for use inside the nose are not permitted because the inside of the nose is a mucous membrane.","Global Life Technologies Corp.","global-life-technologies-corp-674279-02062024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-life-technologies-corp-674279-02062024","2026-10-26T08:08:46.581551+00:00","2024-02-13","674279","John Willimann","2026-08-20T00:18:09.319+00:00","2024-02-06",{"id":243,"raw":244,"subject":249,"body_html":250,"body_text":251,"firm_name":252,"letter_id":253,"created_at":125,"fei_number":19,"letter_url":254,"updated_at":255,"action_type":22,"case_status":23,"posted_date":256,"marcs_cms_no":257,"product_type":150,"closeout_date":19,"issuing_office":258,"recipient_name":259,"body_fetched_at":260,"delivery_method":261,"recipient_title":19,"reference_number":19,"action_taken_date":262,"medical_device_id":19,"response_letter_date":19},2144,[245,246,247,248,249,13,13,13],"\u003Ctime datetime=\"2023-03-28T13:20:00Z\">03\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-13T04:00:00Z\">03\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnugeneration-technologies-llc-645821-03132023\">NuGeneration Technologies LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Donato B. Polignone\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u002FFounder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NuGeneration Technologies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1155 Park Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Emeryville\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dpolignone@nugentec.com\"> dpolignone@nugentec.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Polignone:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, NuGeneration Technologies LLC., FEI 3004943112, at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 12, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to conduct adequate release testing of your NuRinse Hand Sanitizer drug product\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. You only conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing prior to release. Full release testing, which includes strength and identity testing of the active ingredient (e.g., ethanol), and appropriate impurity and microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to test incoming active pharmaceutical ingredients (API) (e.g., ethanol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for Purified Water and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>\u003Cem>Inadequate API Testing\u003C\u002Fem>\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm relied on the COA from unqualified suppliers of ethanol. This component is used as an active ingredient in the manufacture of your NuRinse Hand Sanitizer drug product. CGMP requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals. You also failed to appropriately test your incoming ethanol, used as an active ingredient, for methanol.\u003C\u002Fp>\n\n\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ethanol at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Inadequate Component Water\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP Purified Water monograph and appropriate microbials limits. Your firm lacked sufficient testing of your DI water system. For example, you failed to appropriately test for total organic carbon or microbial organisms, and you failed to ensure that your conductivity results are accurate and recorded.\u003C\u002Fp>\n\n\u003Cp>Without routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked stability data to support the expiration dates for your NuRinse Hand Sanitizer drug product currently in distribution. Without an adequate stability program, you cannot confirm that your drug product will meet established specifications and all pre-determined quality criteria throughout their shelf life.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; Stability-indicating methods\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o&nbsp; An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; Detailed definition of the specific attributes to be tested at each station(timepoint)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to validate the manufacturing process for NuRinse Hand Sanitizer drug product currently in distribution.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>Timelines for completed process performance qualification for marketed drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier \u003Cstrong>645821\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any further questions, please contact Compliance Officer Nayan J. Patel by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>____________________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). Because NuGeneration Technologies LLC.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDonato B. Polignone\n\nRecipient Title\n\nChief Executive Officer\u002FFounder\n\nNuGeneration Technologies LLC\n\n1155 Park Avenue\n\nEmeryville, CA 94608\n\nUnited States\n\ndpolignone@nugentec.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMarch 13, 2023\n\nDear Mr. Polignone:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, NuGeneration Technologies LLC., FEI 3004943112, at 1155 Park Avenue in Emeryville, California from September 14 to September 22, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your October 12, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm failed to conduct adequate release testing of your NuRinse Hand Sanitizer drug product1. You only conducted (b)(4), and (b)(4) testing prior to release. Full release testing, which includes strength and identity testing of the active ingredient (e.g., ethanol), and appropriate impurity and microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and211.84(d)(2)).\n\nYour firm failed to test incoming active pharmaceutical ingredients (API) (e.g., ethanol) and other components (e.g., deionized (DI) water) used to manufacture over-the-counter drug products to determine their identity, purity, strength, and other appropriate quality attributes. Additionally, you have not shown that your water system can consistently produce water suitable for drug manufacturing, and, at a minimum, meets the USP monograph for Purified Water and appropriate microbial limits.\n\nInadequate API Testing\n\nYour firm relied on the COA from unqualified suppliers of ethanol. This component is used as an active ingredient in the manufacture of your NuRinse Hand Sanitizer drug product. CGMP requires identity testing for each component lot used in drug product manufacturing, and you can only rely on the COA for other component attributes by appropriately validating the supplier’s test results at appropriate intervals. You also failed to appropriately test your incoming ethanol, used as an active ingredient, for methanol.\n\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) to help you meet the CGMP requirements when manufacturing drugs containing ethanol at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nInadequate Component Water\n\nYour firm has not shown that your DI water is suitable for aqueous-based dosage form drug product manufacturing, and, at a minimum, meets the USP Purified Water monograph and appropriate microbials limits. Your firm lacked sufficient testing of your DI water system. For example, you failed to appropriately test for total organic carbon or microbial organisms, and you failed to ensure that your conductivity results are accurate and recorded.\n\nWithout routine water monitoring of an appropriately designed system, you cannot ensure that your water meets minimum microbiological and chemical standards suitable for the manufacture of your drug products.\n\nIn response to this letter, provide:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\n\nRegarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm lacked stability data to support the expiration dates for your NuRinse Hand Sanitizer drug product currently in distribution. Without an adequate stability program, you cannot confirm that your drug product will meet established specifications and all pre-determined quality criteria throughout their shelf life.\n\nIn response to this letter, provide:\n\nA comprehensive, independent assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\nA comprehensive, independent assessment of your water system design, control, and maintenance.\n\no Detailed definition of the specific attributes to be tested at each station(timepoint)\n\nAll procedures that describe these and other elements of your remediated stability program.\n\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to validate the manufacturing process for NuRinse Hand Sanitizer drug product currently in distribution.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nIn response to this letter, provide:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling, and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nTimelines for completed process performance qualification for marketed drug products.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facility. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your response with unique identifier 645821.\n\nIf you have any further questions, please contact Compliance Officer Nayan J. Patel by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV\n\n____________________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because NuGeneration Technologies LLC.’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","NuGeneration Technologies LLC","nugeneration-technologies-llc-645821-03132023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnugeneration-technologies-llc-645821-03132023","2026-10-26T08:09:35.725918+00:00","2023-03-28","645821","Division of Pharmaceutical Quality Operations IV","Donato B. Polignone","2026-08-20T01:10:36.39+00:00","Via Email","2023-03-13",{"id":264,"raw":265,"subject":270,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":275,"fei_number":19,"letter_url":276,"updated_at":277,"action_type":22,"case_status":23,"posted_date":278,"marcs_cms_no":279,"product_type":280,"closeout_date":19,"issuing_office":269,"recipient_name":281,"body_fetched_at":282,"delivery_method":283,"recipient_title":19,"reference_number":19,"action_taken_date":278,"medical_device_id":19,"response_letter_date":19},3544,[266,267,268,269,270,13,13,13],"\u003Ctime datetime=\"2021-02-12T14:00:00Z\">02\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-12T05:00:00Z\">02\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-vapor-technologies-llc-613229-02122021\">Premium Vapor Technologies LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Travis Pinkerton and Candace Almaguer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Premium Vapor Technologies LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>300 Brushy Creek Road Ste 304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cedar Park\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78613\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vaportec.austin@gmail.com\"> vaportec.austin@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@vapevta.com\"> support@vapevta.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:vtawholesale@vapevta.com\"> vtawholesale@vapevta.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>February 12, 2021\u003C\u002Fspan>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Dear Travis Pinkerton and Candace Almaguer:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Fvapevta.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1.&nbsp; Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Cu>\u003Cspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect.&nbsp; A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Our review of https:\u002F\u002Fvapevta.com revealed that you manufacture and offer for sale or distribution\u003Cb> \u003C\u002Fb>to customers in the United States e-liquid products\u003Cb> \u003C\u002Fb>without a marketing authorization order including: Odin’s Mead and Asgard.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 140 products listed with FDA.&nbsp; It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.&nbsp; Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.&nbsp; You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, RW2101495, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301)&nbsp;796-9235 \u003Cspan>or via email at\u003C\u002Fspan> \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp;&nbsp;&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>VIA UPS and Electronic Mail\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cc:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Premium Vapor Technologies LLC\u003Cbr>\nAttn: Travis Pinkerton and Candace Almaguer\u003Cbr>\n100 East Whitestone Blvd Ste 148\u003Cbr>\n#343\u003Cbr>\nCedar Park, TX&nbsp; 78613\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GoDaddy.com, LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@godaddy.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Shopify, Inc. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@shopify.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTravis Pinkerton and Candace Almaguer\n\nPremium Vapor Technologies LLC\n\n300 Brushy Creek Road Ste 304\n\nCedar Park, TX 78613\n\nUnited States\n\nvaportec.austin@gmail.com\n\nsupport@vapevta.com\n\nvtawholesale@vapevta.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 12, 2021\n\nWARNING LETTER\n\nDear Travis Pinkerton and Candace Almaguer:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed https:\u002F\u002Fvapevta.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of https:\u002F\u002Fvapevta.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Odin’s Mead and Asgard.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 140 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101495, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nPremium Vapor Technologies LLC\n\nAttn: Travis Pinkerton and Candace Almaguer\n\n100 East Whitestone Blvd Ste 148\n\n#343\n\nCedar Park, TX 78613\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Premium Vapor Technologies LLC","premium-vapor-technologies-llc-613229-02122021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpremium-vapor-technologies-llc-613229-02122021","2026-10-26T08:09:43.721663+00:00","2021-02-12","613229","Tobacco","Travis Pinkerton and Candace Almaguer","2026-08-20T03:23:22.913+00:00","VIA UPS and Electronic Mail",{"id":285,"raw":286,"subject":292,"body_html":293,"body_text":294,"firm_name":295,"letter_id":296,"created_at":85,"fei_number":19,"letter_url":297,"updated_at":298,"action_type":22,"case_status":23,"posted_date":299,"marcs_cms_no":300,"product_type":301,"closeout_date":19,"issuing_office":290,"recipient_name":302,"body_fetched_at":303,"delivery_method":304,"recipient_title":19,"reference_number":305,"action_taken_date":306,"medical_device_id":19,"response_letter_date":19},1204,[287,288,289,290,291,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-01T04:00:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024\">Amnio Technology, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-646460\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Merrill B. Stromer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amnio Technology, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>22510 N. 18th Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85027-1363\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 1, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER 24-646460\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nDear Dr. Stromer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your products are intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\u003C\u002Fp>\n\n\u003Cp>As a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Because PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>For example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\n\n\u003Cp>PalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>PalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&amp;C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\u003C\u002Fp>\n\n\u003Cp>Neither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&amp;C Act. Since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Amnio Technology, LLC \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® Flow® and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. \u003C\u002Fstrong>Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and did not include tests for sterility.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\u003C\u002Fp>\n\n\u003Cp>Your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We also have concerns regarding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&amp;C Act or a device under section 201(h) of the FD&amp;C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You manufacture an amniotic membrane derived product for private label customers using \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process used for Palingen Flow under product names including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen InovoFlo.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER 24-646460\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMerrill B. Stromer\n\nRecipient Title\n\nChairman\n\nAmnio Technology, LLC\n\n22510 N. 18th Drive\n\nPhoenix, AZ 85027-1363\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nOctober 1, 2024\n\nCBER 24-646460\n\nDear Dr. Stromer:\n\nDuring an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at (b)(4), conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.1 Your products are intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, (b)(4), reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\n\nAs a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nBecause PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nFor example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed (b)(4) to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\n\nPalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).2\n\nPalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval.\n\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\n\nNeither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&C Act. Since (b)(4), Amnio Technology, LLC (b)(4) However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further, (b)(4) PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately (b)(4) units of PalinGen® Flow® and approximately (b)(4) units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\n\n2. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed (b)(4) and (b)(4) and did not include tests for sterility.\n\n3. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\n\nWe acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\n\nYour response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\n\nYour response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\n\nNeither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe also have concerns regarding your (b)(4) sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&C Act or a device under section 201(h) of the FD&C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nCc:\n\n(b)(4)\n\n_________________________\n\n1 You manufacture an amniotic membrane derived product for private label customers using (b)(4) manufacturing process used for Palingen Flow under product names including (b)(4), ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and (b)(4). The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name (b)(4). The instructions for use are the same as those for PalinGen InovoFlo.\n\n2 Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).","Amnio Technology, LLC","amnio-technology-llc-646460-10012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024","2026-10-26T08:07:55.44972+00:00","2024-10-22","646460","Biologics","Merrill B. Stromer","2026-08-19T21:55:18.541+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","CBER 24-646460","2024-10-01",{"id":308,"raw":309,"subject":39,"body_html":315,"body_text":316,"firm_name":317,"letter_id":318,"created_at":145,"fei_number":19,"letter_url":319,"updated_at":320,"action_type":22,"case_status":321,"posted_date":322,"marcs_cms_no":323,"product_type":26,"closeout_date":324,"issuing_office":313,"recipient_name":325,"body_fetched_at":326,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":327,"medical_device_id":19,"response_letter_date":19},3079,[310,311,312,313,39,13,314,13],"\u003Ctime datetime=\"2021-10-19T13:20:00Z\">10\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-17T04:00:00Z\">09\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021\">Magnolia Medical Technologies, Inc.\u003C\u002Fa>","Office of Medical Devices and Radiological Health, Division 3","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-05042022\">\u003Ctime datetime=\"2022-05-18T04:00:00Z\">05\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gregory J. Bullington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Magnolia Medical Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>200 W. Mercer Street, Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seattle\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98119\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Greg.bullington@magnolia-medical.com\"> Greg.bullington@magnolia-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health, Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 617922\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 17, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Bullington:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\u003C\u002Fp>\n\n\u003Cp>b. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) \u003Cstrong>(b)(4)\u003C\u002Fstrong>, 2) application of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); however, your firm did not investigate or document your evaluation of the other potential causes.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\u003C\u002Fp>\n\n\u003Cp>Additionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\u003C\u002Fp>\n\n\u003Cp>c. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>d. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\u003C\u002Fp>\n\n\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Additionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at \u003Cstrong>ORADevices3 FirmResponse@fda.hhs.gov\u003C\u002Fstrong>. Please identify your response with FEI 3009976527.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological\u003Cbr>\nHealth, Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGregory J. Bullington\n\nRecipient Title\n\nCEO\n\nMagnolia Medical Technologies, Inc.\n\n200 W. Mercer Street, Suite 500\n\nSeattle, WA 98119\n\nUnited States\n\nGreg.bullington@magnolia-medical.com\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health, Division 3\n\nUnited States\n\nWARNING LETTER\n\nCMS 617922\n\nSeptember 17, 2021\n\nDear Mr. Bullington:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\n\na. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\n\nWe have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\n\nb. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) (b)(4), 2) application of (b)(4) sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause ((b)(4)); however, your firm did not investigate or document your evaluation of the other potential causes.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\n\nAdditionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\n\nc. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts (b)(4) (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product ((b)(4) and (b)(4)) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\n\nd. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\n\n2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\n\nSpecifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\n\nWe have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the (b)(4) inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\n\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\n\nSpecifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\n\nWe have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nAdditionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at ORADevices3 FirmResponse@fda.hhs.gov. Please identify your response with FEI 3009976527.\n\nIf you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological\n\nHealth, Division 3","Magnolia Medical Technologies, Inc.","magnolia-medical-technologies-inc-617922-09172021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021","2026-10-26T08:09:18.447816+00:00","Closed Out","2021-10-19","617922","2022-05-18","Gregory J. Bullington","2026-08-20T02:31:05.728+00:00","2021-09-17",{"id":329,"raw":330,"subject":270,"body_html":334,"body_text":335,"firm_name":336,"letter_id":337,"created_at":104,"fei_number":19,"letter_url":338,"updated_at":339,"action_type":22,"case_status":23,"posted_date":340,"marcs_cms_no":341,"product_type":280,"closeout_date":19,"issuing_office":269,"recipient_name":342,"body_fetched_at":343,"delivery_method":283,"recipient_title":19,"reference_number":19,"action_taken_date":344,"medical_device_id":19,"response_letter_date":19},2904,[331,332,333,269,270,13,13,13],"\u003Ctime datetime=\"2022-01-25T14:20:00Z\">01\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-21T05:00:00Z\">01\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsas-technologies-inc-dba-save-smoker-625483-01212022\">SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Erick Slaick\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4074 S US Hwy 231F Suite B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ozark\u003C\u002Fspan>, \u003Cspan>AL\u003C\u002Fspan> \u003Cspan>36360\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@saveasmoker.com\"> info@saveasmoker.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 21, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Erick Slaick:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.saveasmoker.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.saveasmoker.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Save A Smoker– Buttery Waffle and Save A Smoker – Vanilla Cinnamon Roll.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 5,900 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001270 on September 8, 2020. However, FDA issued a negative action for PMTA STN PM0001270 in the form of a Refuse to Accept determination on May 24, 2021, which covers 1,662 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001270 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201727, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Save a Smoker\u003Cbr>\nAttn: Eric Slaick\u003Cbr>\n1809 Berkshire Drive\u003Cbr>\nDothan, AL 36303\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nsaveasmoker.com@domainsbyproxy.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Google LLC\u003Cbr>\ngoogle-cloud-compliance@google.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nErick Slaick\n\nSAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker\n\n4074 S US Hwy 231F Suite B\n\nOzark, AL 36360\n\nUnited States\n\ninfo@saveasmoker.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 21, 2022\n\nWARNING LETTER\n\nDear Erick Slaick:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.saveasmoker.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.saveasmoker.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Save A Smoker– Buttery Waffle and Save A Smoker – Vanilla Cinnamon Roll.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 5,900 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001270 on September 8, 2020. However, FDA issued a negative action for PMTA STN PM0001270 in the form of a Refuse to Accept determination on May 24, 2021, which covers 1,662 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001270 that resulted in a Refuse to Accept determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201727, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nSave a Smoker\n\nAttn: Eric Slaick\n\n1809 Berkshire Drive\n\nDothan, AL 36303\n\nDomains By Proxy, LLC\n\nsaveasmoker.com@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nGoogle LLC\n\ngoogle-cloud-compliance@google.com","SAS Technologies, Inc d\u002Fb\u002Fa Save A Smoker","sas-technologies-inc-dba-save-smoker-625483-01212022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsas-technologies-inc-dba-save-smoker-625483-01212022","2026-10-26T08:09:54.121663+00:00","2022-01-25","625483","Erick Slaick","2026-08-20T02:14:57.419+00:00","2022-01-21",{"id":346,"raw":347,"subject":351,"body_html":352,"body_text":353,"firm_name":354,"letter_id":355,"created_at":145,"fei_number":19,"letter_url":356,"updated_at":357,"action_type":22,"case_status":23,"posted_date":358,"marcs_cms_no":359,"product_type":26,"closeout_date":19,"issuing_office":38,"recipient_name":360,"body_fetched_at":361,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":362,"medical_device_id":19,"response_letter_date":19},3184,[348,349,350,38,351,13,13,13],"\u003Ctime datetime=\"2021-08-26T17:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-24T04:00:00Z\">08\u002F24\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvisi-smart-technologies-uk-ltd-614512-08242021\">Invisi Smart Technologies UK LTD\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Saba Yussouf\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Invisi Smart Technologies UK LTD\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>112 Cumberland House\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>80 Scrubs Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>London\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>NW10 6RF\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 24, 2021\u003C\u002Fp>\n\n\u003Cp>Re: Invisi Smart Mask\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Saba Yussouf:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at https:\u002F\u002Fwww.invisismart.com\u002F, https:\u002F\u002Fshop.invisismart.com\u002F, and https:\u002F\u002Ftwitter.com\u002FInvisiSmart on, June 21, 2021. The FDA has observed that your websites offer the ISM5 Invisi Smart Mask, ISM5 Invisi Smart Mask (Black Edition) and the ISM30 Invisi Smart Mask for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your websites revealed the following statements that establish that the masks are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“\u003Cstrong>ISM30 Invisi Smart Mask\u003C\u002Fstrong>, Invisi Smart technology has been tested against the SARSCoV-2 virus’s spike protein by the University of Cambridge.”\u003C\u002Fli>\n\t\u003Cli>“Invisi Smart Mask™ has been tested against human coronavirus and not a weaker strain from the feline coronavirus subfamily.”\u003C\u002Fli>\n\t\u003Cli>“Invisi Smart Mask™ kills viruses and bacteria as they come into contact with the mask allowing you to wear your mask with confidence all day… and for the next 30 days!”\u003C\u002Fli>\n\t\u003Cli>“Our self–disinfecting technology allows you to safely wear the Invisi Smart Mask™ without the need to wash it.”\u003C\u002Fli>\n\t\u003Cli>“Our main ingredient, titanium dioxide, … is generally recognized as safe (GRAS) by the FDA, with up to 1% allowance in food products without having to add it to the ingredients label.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your websites are offering for sale in the United States the above mentioned mask models without marketing approval, clearance, or authorization from the FDA. Accordingly, your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of your intent to introduce them into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>FDA contacted your firm on October 8, 2020, and informed you that you must submit a premarket notification submission before marketing these devices in the U.S. On October 14, 2020, FDA contacted your firm again and discussed certain claims that remained on your website. FDA further reiterated that you must submit a premarket notification submission prior to distributing devices of this type in the U.S. FDA asked your firm to provide your plan regarding these masks to FDA by October 19, 2020. FDA had another teleconference meeting with your chief scientific officer per your request to discuss FDA regulations on October 15, 2020. On October 22, 2020, FDA sent an email in response to your written feedback request regarding FDA regulations and again asked your firm to provide a plan for premarket notification submission. FDA did not receive a response from you to this email.\u003C\u002Fp>\n\n\u003Cp>A review of your websites on June 21, 2021, shows that your products are still being marketed without FDA approval, clearance, or authorization. To date, FDA has not cleared, approved, or authorized the three mask models cited above.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>If you believe that your devices meet the requirements for Emergency Use Authorization (EUA) under section 564 of the FD&amp;C Act for claims associated with use of your devices for COVID-19, please submit an email to CDRH-NonDiagnosticEUA-Templates@fda.hhs.gov. Guidance regarding the applicable criteria and the information to include in an EUA submission is available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97321\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Our office requests that your firm immediately cease activities that result in the misbranding or adulteration of these devices, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the product(s) or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing the product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, authorized by FDA and that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken corrective actions and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66, Rm 3657\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the identification number CMS #614512 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Cynthia J. Chang, Ph.D. at 301-796-6891.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical and Infection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> COVID-19 is the official name for the disease that is causing the 2019 novel coronavirus outbreak, first identified in Wuhan, China.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergencyconcerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSaba Yussouf\n\nRecipient Title\n\nCEO\n\nInvisi Smart Technologies UK LTD\n\n112 Cumberland House\n\n80 Scrubs Lane\n\nLondon\n\nNW10 6RF\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nAugust 24, 2021\n\nRe: Invisi Smart Mask\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019\n\nDear Ms. Saba Yussouf:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at https:\u002F\u002Fwww.invisismart.com\u002F, https:\u002F\u002Fshop.invisismart.com\u002F, and https:\u002F\u002Ftwitter.com\u002FInvisiSmart on, June 21, 2021. The FDA has observed that your websites offer the ISM5 Invisi Smart Mask, ISM5 Invisi Smart Mask (Black Edition) and the ISM30 Invisi Smart Mask for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your websites revealed the following statements that establish that the masks are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including but not limited to:\n\n“ISM30 Invisi Smart Mask, Invisi Smart technology has been tested against the SARSCoV-2 virus’s spike protein by the University of Cambridge.”\n\n“Invisi Smart Mask™ has been tested against human coronavirus and not a weaker strain from the feline coronavirus subfamily.”\n\n“Invisi Smart Mask™ kills viruses and bacteria as they come into contact with the mask allowing you to wear your mask with confidence all day… and for the next 30 days!”\n\n“Our self–disinfecting technology allows you to safely wear the Invisi Smart Mask™ without the need to wash it.”\n\n“Our main ingredient, titanium dioxide, … is generally recognized as safe (GRAS) by the FDA, with up to 1% allowance in food products without having to add it to the ingredients label.”\n\nBased on our review, your websites are offering for sale in the United States the above mentioned mask models without marketing approval, clearance, or authorization from the FDA. Accordingly, your devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of your intent to introduce them into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nFDA contacted your firm on October 8, 2020, and informed you that you must submit a premarket notification submission before marketing these devices in the U.S. On October 14, 2020, FDA contacted your firm again and discussed certain claims that remained on your website. FDA further reiterated that you must submit a premarket notification submission prior to distributing devices of this type in the U.S. FDA asked your firm to provide your plan regarding these masks to FDA by October 19, 2020. FDA had another teleconference meeting with your chief scientific officer per your request to discuss FDA regulations on October 15, 2020. On October 22, 2020, FDA sent an email in response to your written feedback request regarding FDA regulations and again asked your firm to provide a plan for premarket notification submission. FDA did not receive a response from you to this email.\n\nA review of your websites on June 21, 2021, shows that your products are still being marketed without FDA approval, clearance, or authorization. To date, FDA has not cleared, approved, or authorized the three mask models cited above.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nIf you believe that your devices meet the requirements for Emergency Use Authorization (EUA) under section 564 of the FD&C Act for claims associated with use of your devices for COVID-19, please submit an email to CDRH-NonDiagnosticEUA-Templates@fda.hhs.gov. Guidance regarding the applicable criteria and the information to include in an EUA submission is available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97321\u002Fdownload.\n\nOur office requests that your firm immediately cease activities that result in the misbranding or adulteration of these devices, such as the commercial distribution of the devices for the uses discussed above.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the product(s) or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing the product(s) as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, authorized by FDA and that you do not make representations that misbrand the product(s) in violation of the Act.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken corrective actions and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66, Rm 3657\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the identification number CMS #614512 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Cynthia J. Chang, Ph.D. at 301-796-6891.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT4: Office of Surgical and Infection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n______________________\n\n1 COVID-19 is the official name for the disease that is causing the 2019 novel coronavirus outbreak, first identified in Wuhan, China.\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergencyconcerning-novel-coronavirus-disease-covid-19-outbreak\u002F","Invisi Smart Technologies UK LTD","invisi-smart-technologies-uk-ltd-614512-08242021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finvisi-smart-technologies-uk-ltd-614512-08242021","2026-10-26T08:09:00.601879+00:00","2021-08-26","614512","Saba Yussouf","2026-08-20T02:39:52.943+00:00","2021-08-24",{"id":364,"raw":365,"subject":249,"body_html":370,"body_text":371,"firm_name":372,"letter_id":373,"created_at":145,"fei_number":19,"letter_url":374,"updated_at":375,"action_type":22,"case_status":23,"posted_date":376,"marcs_cms_no":377,"product_type":150,"closeout_date":19,"issuing_office":369,"recipient_name":378,"body_fetched_at":379,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":380,"medical_device_id":19,"response_letter_date":19},3215,[366,367,368,369,249,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-27T04:00:00Z\">07\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanit-technologies-llc-dba-durisan-614278-07272021\">Sanit Technologies, LLC dba Durisan\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Wetzer\u002FDr. Joseph Antoun\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u002FChief Scientific Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sanit Technologies, LLC dba Durisan\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7810 25th Court East Unit 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sarasota\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>34243-2841\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 27, 2021\u003C\u002Fp>\n\n\u003Cp>Case: 614278\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nMr. Wetzer and Dr. Antoun:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sanit Technologies LLC., dba Durisan, FEI 3014538924, at 7810 25th Court East Unit 6, Sarasota, Florida, from March 1 to 5, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of quality control over batch release\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You manufactured and distributed over the counter (OTC) drug products labeled as Durisan Hand Sanitizer, Alcohol-Free. Your quality unit (QU) approved and released Durisan Hand Sanitizer, Alcohol-Free into the market that failed its finished product\u003Cbr>\n\u003Cbr>\nspecifications for total aerobic microbial count for bacteria (TAMC) and yeast\u002Fmolds (Y\u002FM) from at least March through December 2020. Furthermore, your firm identified \u003Cem>Burkholderia cepacia\u003C\u002Fem>, an opportunistic pathogen, in the drug product Hand Sanitizer Kidney lot# DHS030920A1-S, Hand Sanitizer lot # DHS030920A2-S and Sanitizer Wipes lot# DHS031020A4-S. You released these lots for distribution in April, July, and December of 2020.\u003C\u002Fp>\n\n\u003Cp>In the affidavit dated March 5, 2021, and signed by you, the Chief Executive Officer, you stated that products manufactured from March 1 to June 30, 2020 were shipped in “contaminated form.”\u003C\u002Fp>\n\n\u003Cp>These topical products could be applied to broken skin or used by vulnerable populations. Objectionable microbiological contamination of these products can pose a serious hazard to consumers. Moreover, you stated to our investigator that one of your top three customers is a school system that includes infant, toddler, and pre-k programs.\u003C\u002Fp>\n\n\u003Cp>Related to the release of drug products with microbiological contamination, your QU failed to execute its duties and oversight related to the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Opening and thoroughly investigating out-of-specification results (OOS) for your finished drug products when they failed their finished product specifications for microorganisms. You also failed to open deviations and thoroughly investigate failures in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system, which produces a component of your drugs, including findings of too numerous to count (TNTC) for microorganisms in water samples. (21 CFR 211.192)\u003C\u002Fli>\n\t\u003Cli>Ensuring your water system, used to manufacture your OTC drug products was suitable for use. The water system produced water contaminated with microorganisms recorded at a level of TNTC on March 23, 2020. Despite these findings, your QU did not exercise its authority to reject drug components made from this system and instead your firm continued to manufacture and release OTC drug products with objectionable microbiological contamination. (21 CFR 211.63)\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Deficiencies related to your water system are not new. FDA conducted a regulatory meeting with your firm on October 29, 2019 and discussed the status of your firm’s water system. You stated during the regulatory meeting that you were planning to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA further discussed the inadequate monitoring of the water system and you stated your reasoning for not adequately monitoring was because of limited manufacturing. FDA provided information regarding the number of recalls initiated because of microbiological contamination incidents in the industry that are associated with non-sterile drug products and objectionable organisms. You stated that if you received an OOS result for the water, you would quarantine product, open an investigation, and determine if a recall was necessary. However, your QU failed to follow through with your commitments made during the regulatory meeting and knowingly released contaminated water for use in manufacturing and distributed drug product contaminated with dangerous levels of microorganisms recorded as TNTC.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Procedures and Responsibility for Finished Product Specifications and the Stability Program\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your QU failed to exercise its duties and oversight related to the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Establish finished product drug specifications for your active pharmaceutical ingredient benzalkonium chloride. You changed your specifications numerous times for your finished product assay and stated that you were still in the process of “optimizing” and performing a justification for the specification. (21 CFR 211.160(b))\u003C\u002Fli>\n\t\u003Cli>Establish a stability program that ensures that the drug product retains its quality attributes throughout its expiry. (21 CFR 211.166(a))\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response you stated that because of “high demand from consumers; the decision was taken by prior leadership to fill and ship product on the premise that it was acceptable. Subsequent finished goods testing, which at times was shown to be positive for bacteria, was largely disregarded and deemed unreliable as results were inconsistent with no obvious correlation to why they were positive.” Although you stated that the previous management made these release decisions, your current management released and distributed at least 23 shipments of contaminated drug product containing high levels of microorganisms.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide details for how you will ensure your quality unit provides the necessary oversight for your drug manufacturing processes to ensure a safe and effective drug product is released to the market. For example, your response inadequately details how your quality unit will determine the suitability of all batches of drug product, which is an essential element of your quality unit responsibility. Additionally, your firm cannot solely rely on microbiological testing for justification to release drug product batches. Contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Acknowledge your responsibility in writing, for all products that remain in the market and are within expiry.\u003C\u002Fli>\n\t\u003Cli>Indicate how you will maintain quality assessments, including ongoing review of adverse events and customer complaints for drugs remaining in distribution.\u003C\u002Fli>\n\t\u003Cli>A full reconciliation for all drug products that you have not recalled remaining in the market and within expiry.\u003C\u002Fli>\n\t\u003Cli>A full reconciliation for all drug products that you have received because of your recall and any drug product that remained in inventory.\u003C\u002Fli>\n\t\u003Cli>For any drug products that you disposed of, provide documentation that clearly indicates how you inventoried, reconciled, and disposed of the product.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed plan for the dissolution of your business which includes contact information, documentation demonstrating dissolution and that you have de-registered your firm as a drug manufacturer with FDA. Indicate in this plan how you have dispositioned the equipment and property.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Burkholderia cepacia\u003C\u002Fem> complex poses a risk of contamination in non-sterile, water- based drug products. For Further information regarding the significance of \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex contamination in drug products, see FDA’s July 7, 2021, advisory, at \u003Cstrong>FDA advises drug manufacturers that \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex poses a contamination risk in non-sterile, water-based drug products | FDA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Cessation of Manufacturing at the Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your decision to cease all production and distribution of drug products from the site as of June 30, 2021.\u003C\u002Fp>\n\n\u003Cp>Note that remediating these CGMP violations will be necessary if you, a successor, or an acquirer resumes drug manufacturing operations at this site for the U.S. market. If you plan to resume drug manufacturing operations, at this, or at another location, contact the agency before resuming your operations and include written confirmation of full remediation, including detailed supporting documents, of the related CGMP violations cited.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3014538924. Send your electronic reply to Dr. Shawn Larson – Compliance Officer at Shawn.Larson@fda.hhs.gov and ORAPHARM2_Responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Dr. Larson at 214-253-5216.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR John W. Diehl, M.S.\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Osman Lambiro\u003Cbr>\nQuality Manager\u003Cbr>\nSanit Technologies LLC., dba Durisan\u003Cbr>\n7810 25th Court East Unit 106\u003Cbr>\nSarasota, FL 34243-2841\u003C\u002Fp>\n\n\u003Cp>CC: Guy Gabriel\u003Cbr>\nOperations Manager\u003Cbr>\nSanit Technologies LLC., dba Durisan\u003Cbr>\n7810 25th Court East Unit 106\u003Cbr>\nSarasota, FL 34243-2841\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Wetzer\u002FDr. Joseph Antoun\n\nRecipient Title\n\nChief Executive Officer\u002FChief Scientific Officer\n\nSanit Technologies, LLC dba Durisan\n\n7810 25th Court East Unit 106\n\nSarasota, FL 34243-2841\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nJuly 27, 2021\n\nCase: 614278\n\nWARNING LETTER\n\nMr. Wetzer and Dr. Antoun:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sanit Technologies LLC., dba Durisan, FEI 3014538924, at 7810 25th Court East Unit 6, Sarasota, Florida, from March 1 to 5, 2021.\n\nThis warning letter summarizes significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nYour firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nLack of quality control over batch release\n\nYou manufactured and distributed over the counter (OTC) drug products labeled as Durisan Hand Sanitizer, Alcohol-Free. Your quality unit (QU) approved and released Durisan Hand Sanitizer, Alcohol-Free into the market that failed its finished product\n\nspecifications for total aerobic microbial count for bacteria (TAMC) and yeast\u002Fmolds (Y\u002FM) from at least March through December 2020. Furthermore, your firm identified Burkholderia cepacia, an opportunistic pathogen, in the drug product Hand Sanitizer Kidney lot# DHS030920A1-S, Hand Sanitizer lot # DHS030920A2-S and Sanitizer Wipes lot# DHS031020A4-S. You released these lots for distribution in April, July, and December of 2020.\n\nIn the affidavit dated March 5, 2021, and signed by you, the Chief Executive Officer, you stated that products manufactured from March 1 to June 30, 2020 were shipped in “contaminated form.”\n\nThese topical products could be applied to broken skin or used by vulnerable populations. Objectionable microbiological contamination of these products can pose a serious hazard to consumers. Moreover, you stated to our investigator that one of your top three customers is a school system that includes infant, toddler, and pre-k programs.\n\nRelated to the release of drug products with microbiological contamination, your QU failed to execute its duties and oversight related to the following:\n\nOpening and thoroughly investigating out-of-specification results (OOS) for your finished drug products when they failed their finished product specifications for microorganisms. You also failed to open deviations and thoroughly investigate failures in your (b)(4) water system, which produces a component of your drugs, including findings of too numerous to count (TNTC) for microorganisms in water samples. (21 CFR 211.192)\n\nEnsuring your water system, used to manufacture your OTC drug products was suitable for use. The water system produced water contaminated with microorganisms recorded at a level of TNTC on March 23, 2020. Despite these findings, your QU did not exercise its authority to reject drug components made from this system and instead your firm continued to manufacture and release OTC drug products with objectionable microbiological contamination. (21 CFR 211.63)\n\nDeficiencies related to your water system are not new. FDA conducted a regulatory meeting with your firm on October 29, 2019 and discussed the status of your firm’s water system. You stated during the regulatory meeting that you were planning to (b)(4). FDA further discussed the inadequate monitoring of the water system and you stated your reasoning for not adequately monitoring was because of limited manufacturing. FDA provided information regarding the number of recalls initiated because of microbiological contamination incidents in the industry that are associated with non-sterile drug products and objectionable organisms. You stated that if you received an OOS result for the water, you would quarantine product, open an investigation, and determine if a recall was necessary. However, your QU failed to follow through with your commitments made during the regulatory meeting and knowingly released contaminated water for use in manufacturing and distributed drug product contaminated with dangerous levels of microorganisms recorded as TNTC.\n\nLack of Procedures and Responsibility for Finished Product Specifications and the Stability Program\n\nYour QU failed to exercise its duties and oversight related to the following:\n\nEstablish finished product drug specifications for your active pharmaceutical ingredient benzalkonium chloride. You changed your specifications numerous times for your finished product assay and stated that you were still in the process of “optimizing” and performing a justification for the specification. (21 CFR 211.160(b))\n\nEstablish a stability program that ensures that the drug product retains its quality attributes throughout its expiry. (21 CFR 211.166(a))\n\nIn your response you stated that because of “high demand from consumers; the decision was taken by prior leadership to fill and ship product on the premise that it was acceptable. Subsequent finished goods testing, which at times was shown to be positive for bacteria, was largely disregarded and deemed unreliable as results were inconsistent with no obvious correlation to why they were positive.” Although you stated that the previous management made these release decisions, your current management released and distributed at least 23 shipments of contaminated drug product containing high levels of microorganisms.\n\nYour response is inadequate. You did not provide details for how you will ensure your quality unit provides the necessary oversight for your drug manufacturing processes to ensure a safe and effective drug product is released to the market. For example, your response inadequately details how your quality unit will determine the suitability of all batches of drug product, which is an essential element of your quality unit responsibility. Additionally, your firm cannot solely rely on microbiological testing for justification to release drug product batches. Contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\n\nIn response to this letter, provide the following:\n\nAcknowledge your responsibility in writing, for all products that remain in the market and are within expiry.\n\nIndicate how you will maintain quality assessments, including ongoing review of adverse events and customer complaints for drugs remaining in distribution.\n\nA full reconciliation for all drug products that you have not recalled remaining in the market and within expiry.\n\nA full reconciliation for all drug products that you have received because of your recall and any drug product that remained in inventory.\n\nFor any drug products that you disposed of, provide documentation that clearly indicates how you inventoried, reconciled, and disposed of the product.\n\nProvide a detailed plan for the dissolution of your business which includes contact information, documentation demonstrating dissolution and that you have de-registered your firm as a drug manufacturer with FDA. Indicate in this plan how you have dispositioned the equipment and property.\n\nObjectionable Organisms\n\nBurkholderia cepacia complex poses a risk of contamination in non-sterile, water- based drug products. For Further information regarding the significance of Burkholderia cepacia complex contamination in drug products, see FDA’s July 7, 2021, advisory, at FDA advises drug manufacturers that Burkholderia cepacia complex poses a contamination risk in non-sterile, water-based drug products | FDA\n\nCessation of Manufacturing at the Facility\n\nWe acknowledge your decision to cease all production and distribution of drug products from the site as of June 30, 2021.\n\nNote that remediating these CGMP violations will be necessary if you, a successor, or an acquirer resumes drug manufacturing operations at this site for the U.S. market. If you plan to resume drug manufacturing operations, at this, or at another location, contact the agency before resuming your operations and include written confirmation of full remediation, including detailed supporting documents, of the related CGMP violations cited.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with FEI 3014538924. Send your electronic reply to Dr. Shawn Larson – Compliance Officer at Shawn.Larson@fda.hhs.gov and ORAPHARM2_Responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, please contact Dr. Larson at 214-253-5216.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR John W. Diehl, M.S.\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nCC: Osman Lambiro\n\nQuality Manager\n\nSanit Technologies LLC., dba Durisan\n\n7810 25th Court East Unit 106\n\nSarasota, FL 34243-2841\n\nCC: Guy Gabriel\n\nOperations Manager\n\nSanit Technologies LLC., dba Durisan\n\n7810 25th Court East Unit 106\n\nSarasota, FL 34243-2841","Sanit Technologies, LLC dba Durisan","sanit-technologies-llc-dba-durisan-614278-07272021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsanit-technologies-llc-dba-durisan-614278-07272021","2026-10-26T08:09:53.563649+00:00","2021-08-10","614278","Mr. Michael Wetzer\u002FDr. Joseph Antoun","2026-08-20T02:43:01.779+00:00","2021-07-27",{"id":382,"raw":383,"subject":39,"body_html":388,"body_text":389,"firm_name":390,"letter_id":391,"created_at":125,"fei_number":19,"letter_url":392,"updated_at":393,"action_type":22,"case_status":321,"posted_date":394,"marcs_cms_no":395,"product_type":26,"closeout_date":396,"issuing_office":38,"recipient_name":397,"body_fetched_at":398,"delivery_method":304,"recipient_title":19,"reference_number":19,"action_taken_date":399,"medical_device_id":19,"response_letter_date":19},2051,[384,385,386,38,39,13,387,13],"\u003Ctime datetime=\"2023-06-20T13:20:00Z\">06\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-12T04:00:00Z\">06\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023\">Vitang Technology LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-07232024\">\u003Ctime datetime=\"2024-07-31T04:00:00Z\">07\u002F31\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Jiang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vitang Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14662 Franklin Ave Ste H\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tustin\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92780-7224\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ron@vitangtechnology.com\"> ron@vitangtechnology.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS # 653455\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jiang:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\u003C\u002Fp>\n\n\u003Cp>Therefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure,\u003Cem> Customer complaints and refinements\u003C\u002Fem>, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your \u003Cem>Validation of Process\u003C\u002Fem> procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, the Equipment Calibration List in your firm’s \u003Cem>Control of Monitoring and Measuring Equipment’s\u003C\u002Fem> procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\u003Cbr>\n\u003Cbr>\nSpecifically, you firm has no record of management reviews. Your \u003Cem>Quality Manual and Management Responsibility\u003C\u002Fem> documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address this observation.\u003C\u002Fp>\n\n\u003Cp>8. Failure to document personnel training as required by 21 CFR 820.25(b).\u003C\u002Fp>\n\n\u003Cp>Your firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\u003C\u002Fp>\n\n\u003Cp>However, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Representations that Create an Impression of FDA Approval\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRonald Jiang\n\nRecipient Title\n\nOwner & CEO\n\nVitang Technology LLC\n\n14662 Franklin Ave Ste H\n\nTustin, CA 92780-7224\n\nUnited States\n\nron@vitangtechnology.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 653455\n\nJune 12, 2023\n\nDear Mr. Jiang:\n\nDuring an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nMisbranded and\u002For Unapproved Device Violations\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\n\nOur inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\n\nTherefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nOur inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\n\nSpecifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure, Customer complaints and refinements, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\n\nWe reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\n\n2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\n\nSpecifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\n\n3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\n\nSpecifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\n\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\n\nSpecifically, your Validation of Process procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\n\nWe reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\n\n5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nSpecifically, the Equipment Calibration List in your firm’s Control of Monitoring and Measuring Equipment’s procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\n\n6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\n\nSpecifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\n\n7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\n\nSpecifically, you firm has no record of management reviews. Your Quality Manual and Management Responsibility documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\n\nYour firm’s response is inadequate because it does not address this observation.\n\n8. Failure to document personnel training as required by 21 CFR 820.25(b).\n\nYour firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\n\nHowever, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\n\nYour firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\n\nRepresentations that Create an Impression of FDA Approval\n\nThe UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nIn addition, we offer the following comment:\n\nWe note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest","Vitang Technology LLC","vitang-technology-llc-653455-06122023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023","2026-10-26T08:10:28.614825+00:00","2023-06-20","653455","2024-07-31","Ronald Jiang","2026-08-20T01:02:45.663+00:00","2023-06-12",28,{"510k":402,"classification":403,"enforcement":404,"event":405,"event_backfill":406,"pma":407,"warning_letter":408},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]